

INDEX

Page numbers followed by “f” indicate figures, and those followed by “t” indicate tables.

- ABCB11* gene. *See* *BSEP* gene
- ABO incompatibility
- bilirubin production and, 279
 - liver transplantation and, 981
- abscesses
- from *Entamoeba histolytica*, 880–881, 881f
 - pyogenic, 871–873, 872f
- acalculous cholecystitis, 349–350
- clinical features of, 349–350, 350f
 - etiology and pathogenesis of, 349, 349t
 - other acalculous entities of, 351
- acalculous gallbladder disease, 347
- acanthosis nigricans, in nonalcoholic fatty liver disease, 831
- accumulation theory of liver injury in α 1-antitrypsin deficiency, 556
- acetaminophen
- N*-acetylcysteine (NAC) therapy for, 90
 - in acute liver failure, 80f
 - acute liver failure and, 74
 - and acute liver failure in children, 485
 - and alcohol, 486
 - elimination half-life of, 486
 - in Gilbert’s syndrome, 290–291
 - hepatotoxicity and metabolism of, 484–487, 485f
 - outcomes for overdose, 91
 - and tumor risk, 944
- N*-acetyl glutamate synthetase (NAGS), 862
- N*-acetyl-L-cysteine, for veno-occlusive disease, 903
- N*-acetyl-p-aminophenol (APAP). *See* acetaminophen
- N*-acetyl-p-benzoquinoneimine (NAPQI), in acetaminophen metabolism, 485–486
- N*-acetyl transferase 2 (NAT2), 19
- N*-acetylcysteine (NAC), 90
- in acetaminophen toxicity, 484–486
 - and fulminant hepatic failure, 977
 - in tyrosinemia, 707
- acetylsalicylic acid (aspirin). *See* aspirin
- acid α -glucosidase (GAA), 725
- acid-base disturbances, 87, 89
- acid ceramidase (ASAH), 720
- acid sphingomyelinase deficiency, 719f, 719–720
- acquired immunodeficiency syndrome (AIDS), 240–241
- Actinomyces israeli*, 877–878
- actinomycosis, 877–878
- acute fatty liver of pregnancy (AFLP), 781
- acute liver failure and, 78
 - vs. HELLP syndrome, 781–782
 - and maternal liver disease and LCHAD deficiency, 782t, 782–783
 - metabolites in, 816
- acute intermittent porphyria (AIP), 682–684. *See also* porphyria(s)
- classification of, 680, 680t
 - clinical features of, 682–683
 - diagnosis of, 683–684
 - drugs that may be harmful in, 682, 683t
 - homozygous dominant, 684t, 684–685
 - treatment of, 684
- acute liver failure (ALF) in children, 71–92
- complications of, 82–89
 - aplastic anemia, 86
 - ascites, 87
 - cardiovascular and pulmonary, 88
 - cerebral edema, 84–85
 - coagulopathy and hemorrhage, 85–86
 - electrolyte and acid-base disturbances, 87
 - encephalopathy, 82–84, 83t
 - hypoglycemia, 86
 - pancreatitis, 87
 - renal dysfunction, 87
 - secondary infections, 88–89
- definition of, 71
 - etiology of, 72t, 72–79, 73t
 - autoimmune hepatitis, 76, 77f
 - drug and toxin related, 72–75, 485
 - hepatitis viruses, 75–76
 - indeterminate causes, 78f, 78–79
 - infectious diseases, 75
 - inherited and metabolic, 77
 - ischemia and abnormal perfusion, 77–78
 - malignancy and infiltrative disorders, 78
 - miscellaneous diseases, 78
 - non-hepatitis viruses, 76
 - nonviral hepatitis, 76
 - frequency of, 71
 - immunologic disturbances and, 514
 - management of, 89–91
 - general measures, 89–90
 - therapies, 90–91
 - outcomes and prognosis, 91–92
 - causes of death, 91
 - indicators of outcome, 91
 - model for, 91–92
 - and onset of complications, 91
 - from PALF study, 73t, 91
 - overview of, 71
 - pathogenesis of, 80–82
 - exposure, 80–81
 - hepatocyte injury, 81
 - potentiation, 81–82
 - regeneration, 82
 - pathology and biochemistry of, 79–80
 - aminotransferase levels, 79–80, 80f
 - bilirubin levels, 80
 - biopsy, 79, 79f, 80f, 81f
 - presentation of, 82
 - acute phase response (APR), and liver infection, 31
 - acute phase response to infection, 897

996 ■ INDEX

- acute vanishing bile duct syndrome, 985–986
- acyclovir, 236, 428, 986–987
- acyl-CoA oxidase deficiency, 850
- acylcarnitine. *See also* carnitine
fatty acid oxidation and, 538–539
laboratory assessment of, 785, 786*t*, 788*f*
- adefovir dipivoxil, 238
adverse effects of, 403
duration of therapy, 403
and hepatitis B treatment, 402*t*, 402–403, 520
for HIV hepatitis coinfection, 520
resistance to, 403
therapy for transplant patients, 404–405
use in children, 403
- adenosine, and blood flow regulation, 899
- adenosine deaminase (ADA) deficiency, 518
- adiponectin, in nonalcoholic fatty liver syndrome, 833
- adolase enzymes and fructose metabolism, 603–604
- ADPKD. *See* autosomal dominant polycystic kidney disease
- adrenal disorders, 907
- Adriamycin (doxorubicin)
hepatotoxicity of, 487–488
for tumor chemotherapy, 965–966
- adult type polycystic disease. *See* autosomal dominant polycystic kidney disease
- aflatoxin
as cause of kwashiorkor, 908
in Indian childhood cirrhosis, 649
- AFP. *See* alpha-fetoprotein
- agenesis of extrahepatic bile ducts, 58–59
aberrant and accessory, 58, 256
anomylies of, 59
congenital bronchobiliary fistula, 58–59
duplication, 58
hypoplasia, 59
spontaneous perforation, 59
- agenesis of the gallbladder, 346
- aggresome formation, 558
- AGS. *See* Alagille syndrome
- AhR. *See* aryl hydrocarbon receptor
- Aicardi-Goutieres syndrome, 241–242
- AIDS. *See* acquired immunodeficiency syndrome
- AIRE1 gene, 451
- ALA-dehydratase porphyria (ADP), 681–682. *See also* porphyria(s)
classification of, 680, 680*t*
clinical features of, 681–682
diagnosis of, 682
drugs that may be harmful in, 682, 683*t*
treatment of, 682
- Alagille syndrome (AGS), 45–46, 326–342
abnormalities associated with, 339
bile duct paucity in, 326–327, 327*t*
definitions in, 327*f*, 327*t*, 327–328
histopathology of, 328, 328*f*
- bile duct-to-portal tract (BD/PT) ratio
in, 45, 327
- clinical features and complications of, 327*f*, 329–339
cardiac, 332*f*, 332–333, 333*f*
facial, 334–335, 335*f*
growth disorders and, 338
hepatic, 330–331
hepatic features in infancy, 331–332
musculoskeletal, 335–336, 336*f*, 337*f*
neurologic, 338
ocular, 333–334, 334*f*
pancreatic, 338–339, 339*f*
renal, 333, 334*f*
vascular, 336–338, 338*f*
diagnosis of, 328–329, 329*t*, 330*t*
etiology of, 45–46
genes in, 186
genetics of, 340–342
gene identification and mutation analysis, 340
genotype/phenotype correlations, 341
Notch signaling pathway, 340–341
testing of, 341–342
hypercholesteremia in, 203
liver transplantation in, 331
morbidity and mortality rates and outcome of, 339
naming of, 326–327
and neoplasia, 947*f*
and partial biliary diversion for pruritis, 201
pathogenesis of, 46
prognosis for, 46
therapy for, 339–340
ursodeoxycholic acid, effect on, 194, 201, 339
- alanine aminotransferase (ALT)
and adefovir dipivoxil treatment, 402
in cirrhosis and chronic liver failure, 107
half-life of, 899
in hepatic drug reaction, 482
in hepatitis B infection, 385
in hepatitis C infection, 410
treatment for persons with normal levels, 423
in hepatitis E infection, 430
and lamivudine treatment, 401–402
and liver function tests, 164–165
in myopathy mimicking liver disease, 907
and peginterferon treatment, 404
in sclerosing cholangitis, 461*t*, 464
ursodeoxycholic acid therapy, 469
- albendazole
for ascariasis, 883
for capillariasis, 883
for *Entamoeba histolytica*, 882
for toxocarasis, 883
- albumin
as carrier for bilirubin, 272, 273*f*, 282
hemofiltration of, 90
- infusions and paracentesis, 113
as liver specific marker, 3
tests for, 107, 168
- aldose reductase inhibitors, in galactosemia treatment, 599
- aldosterone
in patients with cirrhosis and ascites, 109
- alemtuzumab, for liver transplantation, 983
- ALF. *See* acute liver failure
- Alimentum, 205–208
- alkaline phosphatase (AP), 165–166
in cystic fibrosis diagnosis, 585
in sclerosing cholangitis, 461*t*, 464
post-transplantation, 471
ursodeoxycholic acid therapy, 469
- allografts. *See* liver transplantation
- Alpers' disease, 812–814, 813*f*, 824*t*
acute liver failure and, 74, 77
- alpha-1,4 glucan-6-glycosyl transferase deficiency. *See* glycogen storage disease, type IV
- 5 α -cholestan-3 β -ol (cholestanol). *See* cerebrotendinous xanthomatosis
- alpha-fetoprotein (AFP)
and Beckwith–Wiedemann syndrome, 944, 946*f*
as indicator of regeneration, 91
as liver specific marker, 3
for tumors
diagnosis of, 948–949, 950*t*
prognosis for, 964
therapy for, 967
in tyrosinemia
with carcinoma, 699, 700*f*
with chronic liver disease, 698
- 12 α -hydroxylase deficiency, 750
- α -L-fucosidase protein and gene, 723
- α -mannosidosis, 716*t*, 723–724
- alpha tocopherol. *See* vitamin E
- α 1-antitrypsin deficiency, 545–564
cellular adaptive mechanisms to α 1-ATZ mutations, in ER, 553–555, 554*f*
clinical manifestations of
liver disease in, 545–547, 546*t*, 561*f*
lung disease in, 547
in cystic fibrosis, 579
diagnosis of, 560
differential diagnosis of, 546
hepatic regeneration and carcinogenesis in, 559–560
pathogenesis of liver injury in, 555–558, 557*f*
pathology of, 557*f*, 560–561
pathophysiology of, 547–553
biosynthesis of α 1-antitrypsin, 551–552
clearance and distribution of
 α 1-antitrypsin, 552
deficiency of α 1-antitrypsin, 549–550

- mechanism for deficiency, 548*f*, 552–553
 structure of α 1-antitrypsin, 547–549, 548*f*, 549*f*, 550*t*, 551*t*
 prevention of, 563–564
 prognostic factors for, 546
 treatment of, 561–563
 alternative strategies for, 563
 emphysema, 562–563
 gene replacement therapy, 563
 orthotopic liver transplantation, 562
 pharmacologic, 562
 shunt surgery, 562
 α -methylacyl-CoA racemase, 844–845, 850–851
 ALT. *See* alanine aminotransferase
 aluminum, 217
Amanita phalloides, 81
 American Indian cholestasis, 321–322
 amino acid metabolism, in fetus and neonate, 17
 disorders in, 532*t*, 534*t*, 540–541
 maple syrup urine disease, 540–541
 nonketotic hyperglycinemia, 541
 enzymes for, 16–17
 of glutamine, 16–17
 organic acidurias and, 533–534, 535*t*
 transport of, 16
 transulfuration pathway and, 16
 amino acids
 branched-chain
 in encephalopathy, 118
 metabolism and peroxisomes, 843*f*, 845–846
 and neurotransmitters, 118
 as test for hereditary fructose intolerance, 606
 and test for lactic acidemias, 534–537, 536*t*
 as test for liver disease, 173
 5'-aminolevulinate (ALA)
 in acute intermittent porphyria, 683
 in ALA-dehydratase porphyria, 682
 urinary tests for, 681
 5'-aminolevulinate (ALA) dehydratase, in heme biosynthesis, 678, 678*f*, 679*t*
 5'-aminolevulinate (ALA) synthase, in heme biosynthesis, 677–678, 678*f*, 679*t*
 δ -aminolevulinic acid, in tyrosinemia neurologic crises, 706–707
 aminophospholipid transporter, 314
 aminotransferases
 in acetaminophen toxicity, 484
 in acute liver failure, 79–80, 80*f*
 AST:ALT ratio, 164–165
 and autoimmune hepatitis treatment, 454
 in cystic fibrosis, 580
 and hepatitis B infection, 391
 and liver function tests, 164–165
 normal concentrations of, 164
 in sclerosing cholangitis, 464
 and screening for liver damage, 494
 and screening for nonalcoholic fatty liver disease, 830–831, 832, 832*t*
 in Wilson's disease, 642
 amiodarone
 acute liver failure and, 74
 hepatotoxicity of, 487, 487*f*
 ammonia. *See also* urea cycle disorders
 conversion of, 858, 859*t*
 in hepatic encephalopathy, 84, 114–115
 and lactulose therapy, 117
 laboratory assessments, 171–172, 862
 ammonium tetrathiomolybdate, for Wilson's disease, 644*t*, 645–646
 Ammonul, 864, 865*t*
 amoxicillin, for lyme disease, 879
 amphotericin B
 for aspergillosis, 889
 for *Candida* infection, 887
 for *Coccidioides immitis*, 888
 for *Cryptococcus neoformans*, 888
 for histoplasmosis, 888
 for leishmaniasis, 886
 for *Penicillium marneffe*, 887
 ampicillin
 in bacterial cholangitis, 874
 for listeriosis, 876
 ampicillin-clavulanic acid, and acute liver failure, 74
 amylo-1,6-glucosidase deficiency. *See* glycogen storage disease, type III
 amyloidosis, 905, 913
 amylopectinosis. *See* glycogen storage disease, type IV
 Andersen's disease. *See* glycogen storage disease, type IV
 anti-liver kidney microsomal antibody type 1 (anti-LKM-1)
 in autoimmune hepatitis (type 2), 447, 448–449, 450*t*
 anti-mitochondrial antibody (AMA), 448
 anti-neoplastic drugs, 487–488, 965–966
 and liver transplantation, 977, 978*t*
 toxicity of, 966–967
 anti-neutrophil cytoplasmic antibody (ANCA)
 in autoimmune hepatitis, 449
 in sclerosing cholangitis, 465
 anti-nuclear antibody (ANA)
 in autoimmune hepatitis (type 1), 447–449, 450*t*
 in autoimmune sclerosing cholangitis, 455, 462, 462*f*
 anti-smooth muscle antibody (ASMA)
 in autoimmune hepatitis (type 1), 447–449, 450*t*
 in autoimmune sclerosing cholangitis, 455, 462, 462*f*
 anticonvulsants and γ -glutamyltransferase, 167
 antioxidants. *See also specific antioxidants*
 in cystic fibrosis
 and CFTR function, 579
 as future therapy for, 589
 and pathogenesis of injury in, 578
 as future therapy for, 586
 and malnutrition, 908
 for nonalcoholic fatty liver disease treatment, 835, 836*t*
 for respiratory chain disorders, 820*t*, 821–823, 822*t*
 in total parenteral nutrition associated liver disease, 912
 for Wilson's disease, 646
 antithrombin III, coagulation inhibitor, 119
 antithymocyte globulin, for graft-versus-host diseases, 904
 AP. *See* alkaline phosphatase
 APC gene, 944, 960
 APECED. *See* autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy
 aplastic anemia, in acute liver failure, 86
 APOLT. *See* auxiliary partial orthotopic transplantation
 APR. *See* acute phase response
 Apt testing, 279–280
 Aqua-E, 213
 Aquamephyton, 215
 arachidonic acid, 207
 arginase deficiency, 861–862
 arginine, for urea cycle disorders, 864–865, 865*t*
 argininosuccinic acid lyase deficiency, biopsy in, 859
 argininosuccinic acid synthase (ASS), 859*f*, 862
 Arias' syndrome, 281, 291. *See also* Crigler–Najjar syndrome
 ARPKD. *See* autosomal recessive polycystic kidney disease
 arrhythmias, in acute liver failure, 88
 arterial chemo-embolization, 967
 “arthritis-dermatitis” in hepatitis B infection, 389
 arthrogyposis multiplex congenital and renal dysfunction in cholestasis, 321
 aryl hydrocarbon receptor (AhR), 18
 ASAH. *See* acid ceramidase
 ascariasis, 882–883, 883*f*
Ascaris lumbricoides, 882–883, 883*f*
 and pigment gallstone formation, 355
 ascites. *See also* portal hypertension
 in acute liver failure, 87
 in cirrhosis and chronic liver failure, 108–114
 β -blockers, 113
 diuretics, 112–113
 “overflow” hypothesis, 109, 110*f*

998 ■ INDEX

- ascites (*cont.*)
 overview of, 108–109
 paracentesis, 113
 peripheral arterial vasodilation
 hypothesis, 109–110, 110*f*
 peritoneovenous shunts, 114
 presentation of, 110–111
 testing for, 111–112, 112*f*
 transjugular intrahepatic
 portasystemic shunts, 113–114
 treatment of, 112
 “underfilling” hypothesis, 109, 110*f*
 in portal hypertension, 144
 and portal vein pressure, 108–109
 and sodium levels, 109
 and spontaneous bacterial peritonitis,
 121
- ascitic fluid, 122*t*
- aspartate aminotransferase (AST), 107
 half-life of, 899
 and liver function tests, 164–165
 in myopathy mimicking liver disease,
 907
 in sclerosing cholangitis, 461*t*, 464
 ursodeoxycholic acid therapy, 469
 and screening for nonalcoholic fatty liver
 disease, 831–832
- aspergillosis (and *Aspergillus* spp.), 888–889
Aspergillus flavus, and Indian childhood
 cirrhosis, 649
- aspirin (acetylsalicylic acid), 816–817
 hepatotoxicity of, 488–489
 in juvenile rheumatoid arthritis, 904–905
 in total parenteral nutrition associated
 liver disease, 913
 and variceal hemorrhage, 143
- ASS. *See* argininosuccinic acid synthase
- AST. *See* aspartate aminotransferase
- atherosclerosis, 203
- ATP-Binding Cassette (ABC), in Dubin–
 Johnson syndrome, 293–294
- ATP7B gene
 mutations in, 631
 pathogenesis of Wilson’s disease, 631
 role in copper absorption and
 metabolism, 627*f*, 627–628
 in Wilson’s disease, 638–639, 817–818
- autoimmune hepatitis (AIH), 447–456
 acute liver failure and, 76, 77*f*
 after liver transplantation
 de-novo, 456
 recurrence, 456
 vs. autoimmune polyendocrinopathy-
 candidiasis-ectodermal dystrophy,
 450–451
 clinical features of, 447
 definition of, 447
 diagnosis of, 448, 448*f*
 autoantibodies, 448–449
 type 1 vs. type 2, 449, 450*t*
 differential diagnosis of, 449–450
 history and epidemiology of, 447
 laboratory assessment of, 448–449
 management of, 454
 pathogenesis of, 451–454
 in animal models, 453–454
 autoreactive T cells, 452–453
 defective immunoregulation, 451–452
 genetics of, 451
 mechanisms of liver autoimmune
 attack, 451, 452*f*
 vs. propylthiouracil hepatotoxicity, 496–497
 and sclerosing cholangitis, 462, 462*f*
 and sclerosing cholangitis overlap
 syndrome, 450*t*, 454–456, 455*f*, 455*t*
- autoimmune hepatitis/primary sclerosing
 cholangitis overlap disorder. *See*
 autoimmune sclerosing cholangitis
 (ASC)
- autoimmune polyendocrinopathy-
 candidiasis-ectodermal dystrophy
 (APECED), 450–451
- autoimmune sclerosing cholangitis (ASC),
 450*t*, 454–456
 clinical presentation of, 455, 455*f*, 455*t*,
 462, 462*f*
 prevalence of, 454–455
 treatment of, 455–456
- autophagy, in $\alpha 1$ -antitrypsin deficiency,
 553–554, 558
- autosomal dominant polycystic hepatic
 disease. *See* isolated polycystic liver
 disease
- autosomal dominant polycystic kidney
 disease (ADPKD), 52*f*, 52–54,
 934–936
 cysts, renal and hepatic, 53*f*, 53–54, 929
 diagnostic evaluation of, 935
 genetics of, 935–936
 incidence of, 52, 934
 pathogenesis and animal models in,
 937*t*, 937–939, 939*f*
 PKD genes, 53
 and polycystic liver disease, 936*f*,
 936–937
 polycystin proteins, 53
 presentation of, 52–53, 934–935, 935*f*
- autosomal recessive polycystic kidney
 disease (ARPKD), 47–48, 931–933.
See also Caroli’s disease
 vs. Caroli’s disease, 931
 congenital hepatic fibrosis in, 48–49.
See also congenital hepatic fibrosis
- cysts, renal and hepatic, 929
 etiology of, 47
 incidence of, 47, 931
 and MODY5, 49–50
 pathogenesis and animal models in,
 937*t*, 937–939
 presentation and genetics of, 47–48, 48*f*,
 931–933, 932*f*, 933*f*
 prognosis for, 48, 933
 treatment of, 933
 von Meyenburg complexes and, 51–52
- auxiliary partial orthotopic transplantation
 (APOLT), 977. *See also* liver
 transplantation
- Axenfeld anomaly, 334
- azathioprine
 for autoimmune hepatitis, 454, 456
 for autoimmune sclerosing cholangitis,
 455–456
 hepatotoxicity of, 489
 for liver transplantation, 983
 for sclerosing cholangitis, 469*t*, 470
- azithromycin dihydrate
 for cat scratch disease, 874–875
 for mycobacterium avium complex, 877
- BA. *See* biliary atresia
- Bacillus cereus*, 818
- bacterial infections of liver, 871–880.
*See also specific bacterial infections
 and agents*
 actinomycosis, 877–878
 brucellosis, 875–876
 cat scratch disease, 874*f*, 874–875, 875*f*
 cholangitis, 873*f*, 873–874
 ehrlichioses, 878
 hyperbilirubinemia with sepsis, 871, 872*f*
 leptospirosis, 879*f*, 879–880
 listeriosis, 876
 lyme disease, 878–879
 mycobacterium avium complex, 877
 perihepatitis, 875
 pyogenic liver abscess, 871–873, 872*f*
 Q fever, 880
 Rocky Mountain Spotted Fever, 880
Streptococcus infection, 876
 syphilis, 878
 toxic shock syndrome, 876
 tuberculosis, 876–877, 877*f*
 tularemia, 876
 typhoid hepatitis, 875
- Bacteroides* spp.
 in bacterial cholangitis, 873
 total parenteral nutrition associated
 infection with, 911
- band ligation. *See* ligation therapy
- Baraitser–Reardon syndrome, 241–242
- barbiturates and encephalopathy, 115–118,
 117*f*
- Bartonella henselae*, 874*f*, 874–875, 875*f*
- basiliximab, for liver transplantation, 983
- basolateral sodium taurocholate cotrans-
 porting polypeptide (Ntcp), 23
- BCS1L gene, 810
- Beckwith–Wiedemann syndrome (BWS)
 and tumor risk, 944, 946*f*
- benign recurrent intrahepatic cholestasis
 (BRIC). *See also* progressive familial
 intrahepatic cholestasis
 clinical features of, 311–312

- γ -glutamyltransferase levels and, 167, 312
- genetics of, 313
- history of, 310
- in progressive familial intrahepatic cholestasis, Type 2, 315
- treatment of, 316–317
 - enterohepatic circulation, interruption of, 316–317
 - liver transplantation, 317
 - nutrition in, 316
 - pharmacologic, 317
 - pruritis management, 316
 - surgical therapies, 317
- benzoate (Ammonul, Ucyclyd Pharma), 864, 865*t*
- benzodiazepines
 - antagonists for encephalopathy in cirrhosis, 118
 - and encephalopathy, 115–118, 117*f*
 - for porphyria, 684
- β blockers
 - and ascite treatment, 113
 - and portal hypertension, 148
- β -carotene, for erythropoietic protoporphyria, 690
- β -catenin gene, 960–963, 963*f*, 964
- β -galactosidase gene (*GLB1*), 720, 724
- β -glucosidase (GBA), in Gaucher's disease, 714, 718
- 3 β -hydroxy-C27-steroid
 - dehydrogenase/isomerase deficiency, 745*f*, 746–747, 747*f*
- β -ketothiolase deficiency, 781
- β -glucuronidase, 276–277
- D-bifunctional protein (DBP), 842
 - deficiency in, 846, 849–850
- bile
 - and copper secretion, 627*f*, 628
 - formation of, 574
 - malabsorption from reduced delivery of, 204–218
 - pigment excretion
 - adults vs. neonates, 274*f*, 276
 - in neonates, 275*f*
 - normal vs. disorders, 290*f*
 - secretion of, 575
- bile acid coenzyme A: amino acid *N*-acyltransferase (BAAT'), 322
- bile acid synthesis, 736–756
 - from cholesterol, 736–744, 737*f*
 - allo-bile acid formation by 5 α reduction and, 742–743
 - alternative pathways for, via
 - 27-hydroxylation, 740–742, 741*f*
 - cholic acid synthesis (hydroxylation pathway), 742
 - conjugation of, 737*f*, 743–744
 - cytochrome P450 hydroxylations, 743
 - formation of secondary bile acids, 744
 - 27-hydroxylated 3-oxo- Δ 4-sterol intermediates, 742
 - 7 α -hydroxylation (neutral pathway), 736, 738*f*
 - 21-hydroxylation pathway, 742
 - involving steroid side-chain, 739–740
 - nuclear reactions in, 737–739, 740*f*
 - rate limiting step for (cholesterol 7 α -hydroxylase), 736–737
 - Yamasaki pathway, 742
 - defects in, causing metabolic liver disease and fat-soluble vitamin malabsorption, 744–756, 745*f*
 - in alternate 25-hydroxylation pathway, 752
 - bile acid-CoA conjugation, 745*f*, 754*f*, 754–755
 - cerebrotendinous xanthomatosis, 750–752, 751*f*
 - cholesterol 7 α -hydroxylase deficiency, 750
 - 3 β -hydroxy-C27-steroid
 - dehydrogenase/isomerase deficiency, 745*f*, 746–747, 747*f*
 - 12 α -hydroxylase deficiency, 750
 - involving reactions leading to side-chain modification, 750, 750*f*
 - involving reactions to steroid nucleus, 745*f*, 745–746
 - 2-methylacyl Co-A racemase deficiency, 745*f*, 752*f*, 752–753
 - other disorders affecting, 755*t*, 755–756
 - Δ 4-3-oxosteroid 5 β -reductase deficiency, 745*f*, 747–748, 749*f*
 - oxysterol 7 α -hydroxylase deficiency, 745*f*, 748–750, 749*f*
 - peroxisomal, 745*f*, 753–754
 - overview of, 736
 - in peroxisomes, 844
- bile acids
 - accumulation of, 911
 - in biliary atresia, 43
 - cellular mechanisms of formation, 22–24
 - anion transporters, 23
 - intracellular transport of, 23
 - multidrug resistance protein and, 23
 - Na⁺-K⁺ ATPase, 22
 - nuclear receptors, 23–24
 - salt excretory pump, 23
 - transport across basolateral plasma membrane, 22–23
 - transport across canalicular plasma membrane, 23
 - clinical implications of, 24
 - composition of, 29–30
 - concentration of, 20, 30, 32
 - in cystic fibrosis, 577–578
 - effect of retention on hepatocytes, 30, 32*f*
 - excretion of, 20*t*, 20–21, 21*f*
 - flow of bile, 21–22, 28, 29*f*, 911
 - formation of, 28–29, 574
 - functions of, 28
 - and gallbladder role, 22
 - hepatotoxicity of, 190–193
 - hydrophilic bile acid toxicity, 819
 - ion flux and, 29
 - and pathogenesis of injury in cystic fibrosis, 577–578
 - in PFIC1, 312
 - secretion of, 21, 575
 - and solubilization of dietary fats, 204, 204*f*
 - solutes in, 28–29
 - synthesis defects, treatment, 195
 - synthesis of, 20
 - tests for, 165–168, 171
 - transport of organic anions, 21
 - and vasodilation in portal hypertension, 142
- bile canaliculi, appearance of, 38
- bile duct cells. *See* cholangiocytes
- bile duct hypoplasia, 59
- bile duct-to-portal tract (BD/PT) ratio, 38
 - in paucity of interlobular bile ducts, 44
 - nonsyndromic PILBD, 46
 - syndromic (Alagille syndrome), 45
 - syndromic (Alagille syndrome), 327
- bile ducts
 - atresia of. *See* biliary atresia
 - classification of cysts in, 262*t*
 - extrahepatic
 - in biliary atresia, 249
 - intrahepatic. *See* intrahepatic bile ducts
 - morphogenesis defects and biliary atresia, 249*f*, 251
 - obstruction and gallstones, 358*f*, 358–359
 - paucity of. *See* paucity of interlobular bile ducts
 - proliferation of in PFIC3, 318
 - in sclerosing cholangitis, 466
 - spontaneous perforation of, 263–264, 264*f*
- bile formation
 - and bile flow, 28, 29*f*, 251
 - composition of, 29–30
 - concentration of, 30, 32
 - formation of, 28–29
 - functions of, 28
 - ion flux and, 29
 - overview of, 32–33
 - physiology of, 28–29
 - solutes in, 28–29
- bile salt export pump (BSEP)
 - activation of, 24
 - bile transport and, 28, 29*f*
 - cellular mechanisms of, 23
 - and cyclosporine, 490
 - γ -glutamyltransferase levels and, 167

1000 ■ INDEX

- bile salt export pump (BSEP) (*cont.*)
 gene in PFIC2, 315–316
 in progressive familial intrahepatic cholestasis, 314
- bile salts
 in biliary atresia, 43
 in Byler's disease, 313–314
 and cholesterol gallstone formation, 356, 356*f*
 excretion of, 275
 and nuclear receptors, 23–24
 in progressive familial intrahepatic cholestasis, Type 2, 316
 in progressive familial intrahepatic cholestasis, Type 3, 320
 ursodeoxycholic acid, effect on, 193
- biliary ascariasis. *See* ascariasis
- biliary atresia (BA), 40–44, 247–261
 bile duct hypoplasia and, 59
 and cholangiopathy of extrahepatic bile ducts, 58
 and cholestasis, 183, 242, 247–248
 classic
 histologic alterations to, 40
 clinical features of, 248–249
 clinical forms of, 248, 248*t*
 definition of, 40
 diagnosis of
 biopsy role, 253–254, 254*f*, 255*f*
 evaluation of, 252*t*, 252–253
 surgical exploration role, 254–255
 early severe, 41–42
 embryonic/fetal form, 43–44
 genetics of, 43
 etiology and pathogenesis of, 43, 249*f*, 249–252
 disordered immunologic mechanisms, 251–252
 environmental toxic exposure, 252
 morphogenesis defect, 251
 vascular abnormalities, 252
 viral, 250–251
 future directions in, 261
 incidence of, 248
 liver lesions and portoenterostomy, 42–43
 liver transplantation, 259–261, 260*f*
 outcome of, 261
 as primary therapy for, 260–261, 975–976
 management of, 255–258
 anatomical variants of, 256
 hepatportoenterostomy, 256–258, 257*f*
 surgical, 256
 and manganese, 216
 outcome, 258–259
 pathology of
 extrahepatic bile ducts, 40
 liver and intrahepatic bile ducts, 40–41, 41*f*
 paucity of interlobular bile ducts with, 46–47
 perinatal or acquired forms of, 44
 and portal hypertension, 145–146
 prognosis, 258–259
 ursodeoxycholic acid, effect on, 195
- biliary cirrhosis
 histologic findings in, 97, 99*f*
 and neoplasia, 947*f*
- biliary colic, 351
- biliary diversion
 in Alagille syndrome, 339
 partial and pruritis, 201–202
- biliary epithelial cells (BEC), in sclerosing cholangitis, 467
- biliary microhamartomas. *See* von Meyenburg complex
- biliary tree
 branching of, 39
 development of, 928
- bilirubin. *See also* jaundice; neonatal jaundice
 in acute liver failure, 80
 binding agents for, 292
 and cholestasis, 180–183
 conjugated, 170
 daily production rates of, 270
 delta, 170, 275–276
 and dental hygiene, 218
 fractionation test, 290
 glucuronides, 170
 increased production of, 279–280
 and liver transplantation, 979
 measurement of in neonates, 278, 280*f*
 metabolism of. *See* bilirubin metabolism
 production of, 170
 decreased, 280–282
 increased, 279–280
 in sclerosing cholangitis, 464
 structure/properties of, 271–272, 273*f*
 tests for, 107, 170–171
 unconjugated, 170, 171
 in pigment gallstones, 353
- bilirubin metabolism, 270–277. *See also* jaundice; neonatal jaundice
 conjugation of, 272–274, 274*f*
 disorders of, 273*f*, 287*t*, 287–294, 288*t*
 Gilbert's syndrome, 287–291
 enterohepatic circulation, 273*f*, 274*f*, 275*f*, 276*f*, 276–277
 and hepatocyte uptake, 272, 273*f*
 production and circulation, 270–272, 271*f*, 273*f*
 secretion of conjugates, 274–276
- bilirubin oxidase, 277, 286
- bilirubin UDP-glucuronosyltransferase (BUGT), 272
 and bilirubin production, 286
 in Crigler–Najjar syndrome, 288*t*, 291
 in Gilbert's syndrome, 289
- bilirubinostasis, in biliary atresia, 40–41
- biopsy
 in acute liver failure, 74, 79, 79*f*, 81*f*
 after hepatic portoenterostomy, 42, 42*f*
 allograft, post liver transplantation, 985
 in α -mannosidosis, 724
 in α_1 -antitrypsin deficiency, 561*f*
 in autoimmune hepatitis, 76, 448, 448*f*
 in biliary atresia, 41, 42*f*
 in biliary atresia diagnosis, 253–254, 254*f*, 255*f*
 in cholestasis, 187
 in cystic fibrosis, 585
 in erythropoietic protoporphyria, 689*f*
 in fucosidosis, 723
 for hepatic fibrosis in cirrhosis, 100–101
 in hepatitis, neonatal, 233*f*, 234
 in human immunodeficiency virus patients, 241
 in hyperbilirubinemia with sepsis, 871, 872*f*
 in juvenile rheumatoid arthritis, 494
 in Niemann–Pick disease, 722
 in nonalcoholic fatty liver disease, 833–834
 in paucity of interlobular bile ducts, 44
 in paucity of intrahepatic bile ducts, 328
 in primary hyperoxaluria type 1, 850
 in progressive familial intrahepatic cholestasis, 312*f*
 in sarcoidosis, 913
 in sclerosing cholangitis, 462*f*, 465, 465*f*
 in secondary iron overload treatment, 669
 timing of, 106
 transjugular, 91
 of tumors
 misinterpretation of, 957
 and treatment of, 965
 in urea cycle disorders, 859
 valproic acid hepatotoxicity vs. Reye's syndrome, 498*f*
 in Wilson's disease, 638
- biotransformation, in fetus and neonate, 19, 20. *See also* drug-induced liver disease; hepatotoxins
 and cytochrome P450 enzymes, role of, 18*f*
 regulation of gene expression for, 18
 stages of, 15*t*, 17–18
 phase one, 18–19
 phase three, 20
 phase two, 19–20
 variables that influence, 17
- bithionol, for *Fasciola hepatica*, 885
- black liver, in Dubin–Johnson syndrome, 293
- blood flow
 altered systemic circulation of, 898–899
 in portal vein, 138
- BMPs. *See* bone morphogenetic proteins

- BMT. *See* bone marrow transplantation
- body fat measurements in cholestasis, 205
- bone marrow transplantation (BMT), 902–904
- in Farber's disease, 720
- in glycogen storage disease type II (Pompe disease), 726
- hepatocytes differentiated from bone marrow, 9
- in mucopolysaccharidoses, 728
- and veno-occlusive disease, 900, 900*t*
- bone morphogenetic proteins (BMPs), 5
- and Gata4 transcription factor, 5
- and Hex expression, 7
- Borrelia burgdorferi*, 878–879
- Borrelia recurrentis*, 879
- brainstem auditory evoked potentials (BAEP), 282–283
- branched chain amino acids (BCAA), 207
- breast-feeding. *See also* formula
- in α 1-antitrypsin deficiency, 561–562
- and β -glucuronidase, 277
- and decreased bilirubin production, 281
- and fructose intolerance, hereditary, 604, 606
- and hepatitis C infection, 409
- in human immunodeficiency virus infected infants, 519
- and Indian childhood cirrhosis, 648
- of infants with HBsAg positive mother, 394
- and kernicterus, 278
- maternal ingestion and liver injury, 909
- in neonatal hepatitis, 237, 238
- in neonatal jaundice, 183, 278, 281, 286
- and steatorrhea, 205–207
- with tyrosinemia, 705–706
- bromsulphophthalein (BSP) clearance tests, 294
- brucellosis, 875–876
- BSEP. *See* bile salt excretory pump
- BSEP gene, mutations in PFIC2, 315–316
- Budd–Chiari syndrome, 899–901
- cardiac cirrhosis and, 98
- classification of, 900, 900*t*
- clinical presentation of, 900
- definition of, 899
- diagnostic evaluation of, 899–900
- and estrogens (oral contraceptives), 491
- etiology of, 900
- obstructions leading to, 140
- treatment of, 900–901
- bumetanides, 113
- Buphenyl, 865
- Burkitt's lymphoma, 902
- butterfly vertebrae, in Alagille syndrome, 329, 335–336, 336*f*
- BWRIA gene, 960
- Byler's disease (progressive familial intrahepatic cholestasis), 241
- bile acid tests for, 171
- and bile duct damage, 46
- γ -glutamyltransferase levels and, 167
- genes in, 180, 186
- genetics of, 313
- history of, 310
- and partial biliary diversion for pruritis, 201
- pathophysiology of, 313–314
- ursodeoxycholic acid, effect on, 194
- Cacchi–Ricci disease *vs.* Caroli's disease, 47
- CACT. *See* carnitine-acylcarnitine translocase (CACT) deficiency
- caffeine
- in liver function test, 107
- metabolism of, 481
- calciferol, ergocalciferol, cholecalciferol. *See* vitamin D
- calcineurin inhibitors (CNIs). *See* cyclosporine; tacrolimus
- calcium bilirubinates. *See* pigment gallstones
- calcium carbonate
- in pigment gallstones, 353–354
- black, 354
- calcium in cholestasis, 210*t*, 215–217
- calcium phosphate
- in pigment gallstones, 353–354
- black, 354
- Calciviridae family, 429
- canalicular membrane
- and bile salt export pump mutations, 315–316
- and secretion of bilirubin conjugates, 274–275
- canalicular multispecific organic anion transporter (cMOAT)
- in Dubin–Johnson syndrome, 293–294
- and secretion of bilirubin conjugates, 275
- cancer, in α 1-antitrypsin deficiency, 546
- Candida* infection, 886–887, 986
- Capillaria hepatica*, 883
- capillaritis, 883
- CAR. *See* constitutive androstane receptor
- carbamazepine
- acute liver failure and, 74–75
- hepatotoxicity of, 489
- and isoniazid hepatotoxicity, 493
- and phenobarbital, 495–496
- and phenytoin hepatotoxicity, 496
- for pruritis, 199–202
- carbamylphosphate synthetase (CPS), 540, 859*f*, 861
- carbohydrate loading, 684
- carbohydrate metabolism
- in fetus and neonate, 16
- enzymes for, 16
- galactose, role in, 15
- glucose-6-phosphatase and, 15
- glucose metabolism, 14
- glycogen synthesis, 15
- infant *vs.* adult, 16
- lactate and gluconeogenesis, 15
- urea synthesis and, 16
- inborn errors of, 595–618
- fructose metabolism, 602–607, 603*f*, 605*f*, 606*t*
- galactosemia, 595–602, 596*f*, 600*t*
- glycogen storage disease, 607*t*, 607–618, 608*f*, 609*f*, 610*f*
- carcinogenesis, in α 1-antitrypsin deficiency, 559–560
- carcinoma(s)
- in α 1-antitrypsin deficiency, 559–560
- in choledochal cysts, 263
- in sclerosing cholangitis, 471
- in tyrosinemia, 698–699, 699*t*, 700*f*
- cardiac cirrhosis, 97–98
- cardiac mesoderm, 4
- cardiovascular disorders
- as acute liver failure complication, 88
- arrhythmias, 88
- hypotension, 88
- in Alagille syndrome, 332–333
- in cirrhosis, 104
- in cystic fibrosis, 580
- in glycogen storage disease, type IV, 616
- systemic disorders affecting the liver, 899
- in tyrosinemia, 705
- in Wilson's disease, 636
- carnitine
- cycle, disorders of, 776–777
- carnitine-acylcarnitine translocase (CACT) deficiency, 777
- carnitine palmitoyl transferase (CPT) I deficiency, 776–777
- carnitine palmitoyl transferase (CPT) II deficiency, 775*f*, 777
- and fatty acid oxidation disorders, 538–539, 768, 769*f*
- supplementation in, 791, 816
- laboratory assessment of, 785, 786*t*
- for respiratory chain disorders, 822–823
- in total parenteral nutrition associated liver disease, 912
- uptake/transported defect, 776
- and valproic acid hepatotoxicity, 500
- carnitine-acylcarnitine translocase (CACT), 768, 769*f*
- deficiency in, 777
- carnitine palmitoyltransferase (CPT), 768, 769*f*
- animal models for, 793
- deficiency in, 776–777
- as site of fatty acid regulation, 769
- Caroli's disease, 50–51, 933. *See also* autosomal recessive polycystic kidney disease (ARPKD)
- vs.* Cacchi–Ricci disease, 47
- choledochal cyst, association with, 51, 933

1002 ■ INDEX

- Caroli's disease (*cont.*)
 definition of, 50
 etiology of, 50
 incidence of, 50
 pathogenesis of, 51, 933
 presentation of, 50–51, 51*f*, 933, 934*f*
 tests for, 106
 treatment of, 933
- Caroli's syndrome, 933. *See also* Caroli's disease
 vs. autosomal dominant polycystic kidney disease, 54, 931
 definition of, 50
 etiology of, 50
 pathogenesis of, 51, 933
 presentation of, 50–51, 933, 933*f*, 934*f*
 treatment of, 933
- caspofungin acetate, for aspergillosis, 889
- castanospermine (CST), 562
- cat scratch disease (CSD), 874*f*, 874–875, 875*f*
- catalase, 843*f*, 846
- cataracts. *See also* Kayser–Fleischer rings;
 ocular features
 in galactosemia, 597, 598
 in Wilson's disease, 633
- caudal bud. *See* caudal pars cystica
- caudal pars cystica, 35
- cefalosporin (cefotaxime), in bacterial cholangitis, 874
- ceftriaxone, 234, 281
 as bilirubin displacer, 283
 for lyme disease, 879
 and pigment gallstone formation, 355
- Celiac disease, 908
 acute liver failure and, 78
 and alanine aminotransferase, 165
- central nervous system (CNS)
 and bilirubin production, 282–283
 in cirrhosis, 105, 105*t*
 and encephalopathy, 115
 and manganese, 216
- CEP. *See* congenital erythropoietic porphyria
- cerebral edema
 in acute liver failure, 84–85, 91
 in urea cycle disorders, 858–859
- cerebrotendinous xanthomatosis (CTX), 750–752, 751*f*
 clinical presentation of, 750–751
 diagnosis of, 745*f*, 751–752
 treatment of, 752
- ceruloplasmin, 628, 631
 in Wilson's disease diagnosis, 637*t*, 637–638
- CESD. *See* cholesteryl ester storage disease
- CGT. *See* chronic granulomatous disease
- chaparral leaf, 492
- characteristic facies of Alagille syndrome, 334–335, 335*f*
- chemo-embolization, arterial, 967
- chemotherapy. *See* anti-neoplastic drugs
- chenodeoxycholic acid
 for 3 β -hydroxy-C27-steroid dehydrogenase/isomerase deficiency, 747, 747*f*
 for cerebrotendinous xanthomatosis, 752
 for cholesterol gallstone treatment, 360
 for peroxisomal disorders, 851–852
 serum concentrates of conjugates of, 21*f*
 for Zellweger syndrome, 848
- CHF. *See* congenital hepatic fibrosis
- CHFC. *See* ciliated hepatic foregut cyst
- Chlamydia trachomatis*
 in perihepatitis, 875
 in sclerosing cholangitis, 468
- chloramphenicol
 for lyme disease, 879
 for Rocky Mountain Spotted Fever, 880
- chloroquine, 686
- chloroquine phosphate for malaria, 886
- cholangiocarcinoma (CCA)
 in Caroli's disease and syndrome, 933
 and neoplasia, 947*f*
 in sclerosing cholangitis, 471
 in von Meyenburg complexes, 936
- cholangiocytes
 “bile duct plugging” theory in cystic fibrosis, 576–577, 577*f*, 582, 582*f*
 and bile formation, 573*f*, 574, 574*f*
 in biliary atresia, 43
 from bone marrow cells differentiated, 9
 branching of, 39
 and CFTR expression, 574
 development of, 8
 Notch signaling and, 8
 formation of, 39
 injury in, leading to cholangitis, 320
 injury to and cystic fibrosis, 577, 577*f*
 and parathyroid hormone related peptide expression, 38
 secretion and cystic fibrosis, 574*f*, 575
- cholangiogenesis, 39
- cholangiography
 and Alagille syndrome, 331–332
 in bacterial cholangitis, 874
 in sclerosing cholangitis, 464*f*, 464–465, 471
- cholangiopathies
 extrahepatic bile ducts, 58–59
 fibrocystic, 47–58
 intrahepatic bile ducts, range
 biliary atresia, 40–44
 and opportunistic infections in HIV, 519–520, 520*t*
- cholangitis, bacterial, 873*f*, 873–874.
See also primary sclerosing cholangitis; sclerosing cholangitis
- cholecalciferol in galactosemia therapy, 602
- cholecystectomy
 for gallstone treatment, 359–360
 contraindications to, 359–360
 laparoscopic, 360, 361
- cholecystocholangiography, 186
- cholecystokinin (CCK)
 in cholestasis, 196
 and pigment gallstone formation, 355
 in total parenteral nutrition associated liver disease, 913
- choledochal cyst, 261–263. *See also* congenital bile duct cysts
 classification of, 261, 262*f*, 262*t*
 clinical features of, 262
 complications and outcome, 263
 diagnosis of, 262*f*, 262–263
 malignancy in, 263
 pathogenesis of, 262
 spontaneous perforation of, 262
 treatment of, 263, 264*f*
- cholelithiasis. *See* gallstones
- choleretic agents for cystic fibrosis therapy, 588. *See also* ursodeoxycholic acid
- cholestasis, 179–187, 190–218
 acquired mechanisms of, 30
 adaptation to, 31–32, 32*f*
 and bile secretion in the neonate, 24
 biliary track permeability in neonates, 21
 causes of, treatable, 191*t*
 cholecystokinin and, 196
 conjugated bilirubin flux and, 29
 in cystic fibrosis, 581
 definition of, 29, 179
 differential diagnosis of, in neonates, 179–180, 181*t*
 drug-induced, 31
 etiology of, 183, 242, 247–248
 fatigue in, 202–203
 genetic mechanisms of, 30
 glucocorticoids and, 196
 hepatocellular, 310, 311*t*
 hereditary
 with arthrogryposis multiplex congenital and renal dysfunction, 321
 familial hypercholelanemia, 322
 with lymphedema, 320–321
 in North American Indians, 321–322
- hyperlipidemias in, 203–204
- in infants, 179–187
 differential diagnosis of, 179–180, 181*t*
 evaluation of, 184*f*, 185*t*, 187
 incidence of, 179, 180*t*
 manifestations of, 180–184
- intrahepatic vs. extrahepatic, 242
- malabsorption from reduced delivery of bile, 204–218
- management of, 217–218
 dental hygiene, 218
 family support and, 218
 growth and development in, 217
 immunizations in, 217–218

Cambridge University Press

978-0-521-85657-7 - Liver Disease in Children, Third Edition

Edited by Frederick J. Suchy, Ronald J. Sokol, and William F. Balistreri

Index

[More information](#)

- overview of, 190
- retention of bile constituents, 190–198
- transport of bile constituents into systemic circulation, 198–204
- nonabsorbable ion exchange resins, 199
- nuclear receptor agents and, 196–197
- nutritional assessment in, 205, 206*t*
- nutritional therapy for, 205–216
 - energy and, 205
 - essential fatty acids and, 207–208
 - fat and, 204*f*, 205–207
 - fat soluble vitamins and, 204*f*, 208*f*, 208–215, 209*f*, 210*t*
 - minerals and trace elements, 210*t*
 - minerals and trace elements and, 215–217
 - overview of, 190
 - protein and, 207
- overview of, 29–30, 32–33
- phenobarbital and, 196
- pruritis in, 198–202
 - nonabsorbable ion exchange resins, 199
 - pathogenesis of, 198–199
 - presentation of, 198
 - therapy for, 199–202
- retention of bile acids and, 30
- with retention of bile constituents, 190–198
 - hepatocellular injury and, 190–193
 - progressive fibrosis and cirrhosis, 197–198
- sepsis-associated, 30–31
- tauroursodeoxycholic acid, effect on, 192–193, 195–196
- tests for, 165–170
- total parenteral nutrition and, 196, 909
- TPN-associated, 31
- treatment of (pharmacological), 192*t*
- ursodeoxycholic acid, effect on, 192–193. *See also* ursodeoxycholic acid
- xanthomas in, 203*f*, 203–204
- cholesterol
 - and bile acid synthesis, 736–744, 737*f*
 - allo-bile acid formation by 5 α reduction and, 742–743
 - alternative pathways for, 742
 - alternative pathways for, via 27-hydroxylation, 740–742, 741*f*
 - conjugation of, 737*f*, 743–744
 - cytochrome P450 hydroxylations, 743
 - formation of secondary bile acids, 744
 - 27-hydroxylated 3-oxo- Δ 4-sterol intermediates, 742
 - 7 α -hydroxylation (neutral pathway), 736, 738*f*
 - 21-hydroxylation pathway, 742
 - involving steroid side-chain, 739–740
 - nuclear reactions in, 737–739, 740*f*
 - rate limiting step for (cholesterol 7 α -hydroxylase), 736–737
 - Yamasaki pathway, 742
 - and cholesterol gallstone formation, 356*f*, 356–357
 - 7 α -hydroxylase deficiency, 749*f*, 750
 - in hyperlipidemias and xanthomas, 203
 - liver synthetic functions tests and, 169–170
 - in Niemann–Pick disease, 722
 - peroxisomal biosynthesis of, 843*f*, 845
 - and sitosterolemia, 28
 - cholesterol gallstones, 352, 353*f*, 356–358
 - clinical features of, 358*f*, 358–359, 359*f*
 - conditions predisposing to formation of, 357–358
 - cystic fibrosis, 357–358
 - enterohepatic circulation interruption, 357
 - obesity, 357
 - pregnancy, 358
 - formation of, 356*f*, 356–357
 - prevalence of, 352*f*, 356–357, 357*f*
 - treatment of, 359–361
 - in Wilson's disease, 634
- cholesterosis of the gallbladder, 351–352
- cholesteryl ester storage disease (CESD), 726–728, 727*f*
- cholestyramine, 199
 - for erythropoietic protoporphyria, 690
 - for hyperlipidemias and xanthomas, 203
 - and pruritis in cholestasis, 199–201
- cholic acid
 - for cerebrotendinous xanthomatosis, 752
 - for 3 β -hydroxy-C27-steroid dehydrogenase/isomerase deficiency, 747, 747*f*
 - for 2-methylacyl Co-A racemase deficiency, 753
 - for Δ 4-3-oxosteroid 5 β -reductase deficiency, 748, 749*f*
 - in peroxisomal bile acid synthesis, 844
 - serum concentrates of conjugates of, 21*f*
 - for Zellweger syndrome, 848
- choline, in total parenteral nutrition
 - associated liver disease, 912
- chronic active hepatitis. *See* autoimmune hepatitis (AIH)
- chronic granulomatous disease (CGD), 515*t*, 524
- chronic hemolytic disease, and pigment gallstones, 354
- chronic liver disease. *See also* acute liver failure; cirrhosis
 - immunological disturbances and, 514
 - neurologic disorders in, 105*t*
- chronic respiratory disease, 899
- Chuen-Lin (Chinese herb), 281
- cilia, in cystogenesis, 54
- ciliated hepatic foregut cyst (CHFC), 58
- cimetidine, for polycystic liver disease, 937
- ciprofloxacin
 - in bacterial cholangitis, 874
 - for cat scratch disease, 874–875
- cirrhin, 322
- cirrhosis and chronic liver failure, 97–120, 127. *See also* Indian childhood cirrhosis
- in Alagille syndrome, 328, 328*f*
- vs.* α ₁-antitrypsin deficiency, 546
- ascites, 108–114
 - β -blockers, 113
 - diuretics, 112–113
 - “overflow” hypothesis, 109, 110*f*
 - overview of, 108–109
 - paracentesis, 113
 - peripheral arterial vasodilation hypothesis, 109–110, 110*f*
 - peritoneovenous shunts, 114
 - presentation of, 110–111
 - testing for, 111–112, 112*f*
 - transjugular intrahepatic portasystemic shunts, 113–114
 - treatment of, 112
 - “underfilling” hypothesis, 109, 110*f*
- AST:ALT ratio in patients with chronic hepatitis C, 164–165
- and autoimmune hepatitis, 449
- cardiac, 97–98
- in cholestasis with bile constituent retention, 197–198
- classification of, 97–99
 - clinical, 98–99
 - grouping of, 98, 98*t*
 - histologic, 97–98, 99*f*, 100*f*
 - morphologic, 97–98, 99*f*
- clinical features of
- extrahepatic manifestations of, 104–106, 105*t*
- overview, 103–104
- physical findings, 104*t*
- coagulopathies, 118–121
 - coagulation proteins, 119
 - disseminated intravascular, 119–121
 - inhibitors of coagulation, 119
- overview of, 118
- platelets, 119
- compensated (silent or latent), 98
 - extrahepatic manifestations of, 103
- vs.* cystic fibrosis, 580, 580*t*, 581
- in cystic fibrosis, 582*f*, 582–583, 583*f*, 586–587
- decompensated (active), 98–99, 103
- definition of, 97, 98*t*
- encephalopathy, 114–118
- evaluation of, 106*t*, 106–108
 - continued assessment, 106–108
 - prognostic factors, 108, 108*t*
 - tests, 106, 171–172
- extrahepatic manifestations of, 104–106, 105*t*
- fibrogenesis and, 100–103
 - biochemical assays for, 101
 - biopsy, 100–101
 - collagens, 101

1004 ■ INDEX

- cirrhosis and chronic liver failure (*cont.*)
 laminin, 101
 treatment of, 101
 gallstones in, 104
 in glycogen storage disease, type IV, 616, 617
 and hepatitis B infection, 392, 401
 and hepatitis C infection, 411, 424, 424*f*
 hepatorenal syndrome in, 123–125
 macronodular cirrhosis, 97, 99*f*
 malnutrition and, 106, 125–126
 micronodular cirrhosis, 97, 99*f*
 nutrition and, 106, 125–126
 pathophysiology of, 98*t*, 99–100
 extracellular matrix and, 99–100
 fibrogenesis and, 100–103
 regeneration and, 101–103, 103*t*
 periportal (biliary), 97, 99*f*
 and pigment gallstone formation, 355
 postnecrotic (irregular), 97, 100*f*
 primary biliary cirrhosis and UDCA, 193
 spontaneous bacterial peritonitis, 121–123
 summary of, 126–127
 in Wilson's disease, 98, 634, 639*f*, 640, 642
 cisplatin, 965–966
 citrin deficiency (citrullinemia II), 859*f*, 860–861, 862
 clarithromycin, for mycobacterium avium complex, 877
 clofibrate, 286, 289
 clonidine, in portal hypertension, 142
 clonorchiasis (liver flukes), 884–885, 885*f*
Clonorchis sinensis, 884–885, 885*f*
Clostridium ramosum, urobilinoid production and, 276
 clotting factors
 in acute liver failure, 85*t*, 85–86
 in cirrhosis and chronic liver failure, 107–108, 118–119
 laboratory assessment of, 168–169
 CMV. *See* cytomegalovirus
 CMV immunoglobulin, 235
 coagulopathies, 901–902
 in cirrhosis, 118–121
 coagulation proteins, 119
 disseminated intravascular coagulopathy, 119–121
 inhibitors of coagulation, 119
 overview of, 118
 platelets, 119
 liver synthetic functions tests and, 168–169
 cocaine, hepatotoxicity of, 74–75, 489–490
Coccidioides immitis, 887*f*, 887–888
 coccidioidomycosis, 887*f*, 887–888
 coenzyme Q₁₀ (ubiquinone), 822
 colchicine, 197–198
 colesevelam hydrochloride, 199, 203
 colestipol, 199
 for hyperlipidemias and xanthomas, 203
 and pruritis in cholestasis, 199–201
 collagen vascular diseases, 904–907
 dermatomyositis, 906
 infantile multisystem inflammatory disease, 906–907
 juvenile rheumatoid arthritis, 904–905
 Kawasaki syndrome, 906
 mixed connective tissue disease, 906
 systemic lupus erythematosus, 905–906, 906*t*
 collagens in cirrhosis, 100–101
 coma, in tyrosinemia, 700
 comfrey, 492
 common variable immunodeficiency (CVI), 520–521
 compensated (silent or latent) cirrhosis, 98, 103
 computed tomography (CT)
 and acalculous cholecystitis, 350*f*
 of amiodarone toxicity, 487*f*
 in cat scratch disease, 874*f*
 and cholestasis, 186
 in cystic fibrosis, 585
 and gallstones, 359, 359*f*
 in nonalcoholic fatty liver disease, 833
 of pyogenic liver abscess, 872*f*
 in tuberculosis, 877
 for tumor diagnosis, 946, 948*f*
 in tyrosinemia, 701
 in Wilson's disease, 641
 concanavalin A induced autoimmune hepatitis, 453
 congenital bile duct cysts, 59
 complications of, 59
 etiology and pathogenesis of, 59
 incidence of, 59
 presentation of, 59
 tests for, 106
 treatment of, 59
 congenital disorders of glycosylation (GSD), 913–914, 914*t*
 congenital erythropoietic porphyria (CEP), 688. *See also* porphyria(s)
 classification of, 680, 680*t*
 clinical features of, 688
 diagnosis of, 688
 treatment of, 688
 congenital heart disease and liver dysfunction, 899
 congenital hepatic fibrosis (CHF), 42, 48–50, 929–931
 associations with other syndromes, 48–49, 54
 and autosomal recessive polycystic kidney disease, 48–49, 929–930. *See also* autosomal recessive polycystic kidney disease
 diagnosis of, 930–931, 931*t*
 histopathology of, 49, 49*f*
 in other hepato-renal syndromes, 49–50
 maturity-onset diabetes mellitus of the young, type 5, 49–50
 nephronophthisis-medullary cystic kidney disease, 50
 pathogenesis of, 49
 and portal hypertension, 48
 presentation of, 49, 931*t*
 therapy for, 931
 types of, 49, 930, 932*f*
 congenital syphilis, 234
 congenital tyrosinosis. *See* tyrosinemia
 congestive hepatopathy, 580, 586
 conjugated hyperbilirubinemia
 disorders of, 288*t*, 293–294
 Dubin–Johnson syndrome, 293–294
 Rotor's syndrome, 293
 as liver test, 170
 and nonsyndromatic PILBD, 46
 conjunctival impression cytology (CIC), 209
 connective tissue disease, mixed, 906
 constitutive androstane receptor (CAR), 18, 196–197
 coombs positive giant cell hepatitis, 242
 copper, 216
 in blood serum, 636
 concentration in brain, 634–635
 in gallstones, concentration of, 634
 histochemical stain for, 640, 640*f*
 in Indian childhood cirrhosis, 650
 in kidneys, 635
 mitochondrial toxicity and, 817–818
 radio-labeled, for testing, 638
 in urine, concentration of, 637*t*, 638, 644
 in Wilson's disease, 817–818
 copper chelation therapy. *See* penicillamine; trientine; zinc
 copper storage diseases, 652
 absorption and metabolism, 626–628, 627*f*
 idiopathic copper toxicosis. *See* idiopathic copper toxicosis
 Indian childhood cirrhosis. *See* Indian childhood cirrhosis
 overview of, 626
 toxicity, mechanism of, 629
 Wilson's disease. *See* Wilson's disease
 coproporphyrin
 in Dubin–Johnson syndrome, 294
 in Rotor's syndrome, 293
 cornstarch, in glycogen storage disease, 613
 corticosteroid therapy. *See also specific drugs*
 for autoimmune hepatitis, 101
 for cat scratch disease, 874–875
 in cholestasis, 196
 for hemangiomas, 966
 for hemophagocytic lymphohistiocytosis, 522
 for liver transplantation, 983, 985
 risks of, 91

- in sarcoidosis, 913
 - for toxocariasis, 883
- COX-2 inhibitors. *See* cyclooxygenase-2
- Coxiella burnetti*, 880
- Coxsackie virus, acute liver failure and, 76
- CPS. *See* carbamylphosphate synthetase
- CPSI. *See* carbamyl phosphate synthetase I
- CREST syndrome (subcutaneous calcinosis, Raynaud's phenomena, esophageal dysfunction, sclerodactyly and telangiectasia), 905
- Crigler–Najjar syndrome, 19, 170, 291–292
 - bile pigment composition of, 290f
 - diagnosis and treatment of, 292
 - kernicterus in, 291
 - in neonatal jaundice, 281
 - and neurotoxicity of bilirubin, 282
 - pathophysiology of, 274f, 291–292
 - types of, 291–292
- Crohn's disease (ileal)
 - and cholesterol gallstone formation, 357
 - and sclerosing cholangitis, 461t, 463
- cryptococcosis, 888
- Cryptococcus neoformans*, 888
- Cryptosporidium* in cryptosporidiosis
 - in human immunodeficiency virus, 519, 520t
- opportunistic infections in sclerosing cholangitis, 516f, 516–517, 517f
 - management of, 516t, 517–518
- parvum* species, 516
- and sclerosing cholangitis, 468
- CSD. *See* cat scratch disease
- CTNBN1* gene, 960–961, 964
- CTX. *See* cerebrotendinous xanthomatosis
- curcumin and CFTR, 588
- cutaneous manifestations. *See* skin manifestations
- cyclins
 - expression of during development, 7
 - and tumors, acquired genetic changes in, 961–962
 - and tumors, prognosis for, 964
- cyclooxygenase-2 (COX-2), 967
- cyclophosphamide
 - acute liver failure and, 74
 - and posttransplant lymphoproliferative disease, 986–987
- cyclosporine
 - for autoimmune hepatitis, 76, 454
 - for graft-versus-host diseases, 904
 - for hemophagocytic lymphohistiocytosis, 522
 - hepatic drug metabolism of, 479
 - hepatotoxicity of, 490
 - for liver transplantation, 707, 983, 985
- cystic duct
 - embryology of, 35
 - obstruction and gallstones, 358f, 358–359
- cystic fibrosis (CF), 194, 572–589
 - and α 1-antitrypsin deficiency, 579
 - and cholesterol gallstone formation, 357–358
 - clinical manifestations of, 580t, 580–583
 - biliary tract disease, 583
 - cholestasis, 581
 - cirrhosis, focal biliary and multilobular, 582f, 582–583, 583f
 - congestive hepatopathy, 580
 - steatosis, 581f, 581–582
 - cystic fibrosis transmembrane conductance regulator, 572–575
 - alternate channels and cholangiocyte secretion, 574f, 575
 - as a channel, 572–573, 573f
 - mutation data base for, 575
 - mutations in, 575–576, 576f
 - as a regulator, 573, 573f, 574f
 - diagnosis of, 583–586
 - biochemical evaluation of, 584, 584f
 - biomarkers, 585–586
 - biopsy, 585
 - endoscopic retrograde cholangiography, 585
 - hepatobiliary scintigraphy
 - iminodiacetic acid (IDA), 585
 - imaging, 585
 - physical exam, 583–584
 - ultrasonography, 584–585
 - future therapies in, 588–589
 - alternate channels, 588
 - antifibrotic agents, 589
 - antioxidants, 589
 - CFTR correctors and potentiators, 588
 - choleretic agents, 588
 - gene therapy, 588
 - history of, 572
 - nutritional management of, 587
 - pathogenesis of injury in, 576–578, 577f
 - antioxidants, 578
 - bile acids and, 577–578
 - mucins, 577
 - steatosis, 578
 - stellate cells, 578
 - portal hypertension and transplantation, 587–588
 - potential genetic modifiers of, 578–579
 - immune system and antioxidant status, 579
 - ion channels and, 579
 - male sex, 578
 - meconium ileus, 578–579
 - other liver diseases, 579
 - prevalence of, 579–580
 - treatment of, 586–587, 978
 - cirrhosis, focal biliary and multilobular, 586–587
 - hepatic congestion, 586
 - hepatic steatosis, 586
- cystic fibrosis transmembrane conductance regulator (CFTR). *See also* cystic fibrosis
 - alternate channels and cholangiocyte secretion, 574f, 575
 - as a channel, 572–573, 573f
 - correctors and potentiators for, 588
 - and development of gallbladder and biliary tree, 583
 - mutation data base for, 575
 - mutations in, 575–576, 576f
 - as a regulator, 573, 573f, 574f
 - role of, in liver function, 574–575
- cystogenesis (renal and hepatic), 54–57
 - overview of, 54
 - renal tubular, 54–56
 - ciliary pathway of, 55
 - pathophysiology of cystic epithelium, 55–56
 - primary cilia of, 54–55
- cysts (renal and hepatic), 936f
 - classification of bile duct, 262t
 - development of
 - genetic influences on, 937–938
 - theories for, 937
 - due to *Echinococcus granulosus*, 882
 - in fibrocystic liver diseases, 928–929
 - in polycystic liver disease, 936–937
 - solitary nonparasitic cysts in, 929, 930f
- CYT. *See* cytochrome P450
- cytochrome C oxidase deficiency, 810
- cytochrome P450. *See also specific drugs and cyclosporine metabolism*, 490
- CYP1A subfamily of enzymes, 18–19, 479
- CYP2B subfamily of enzymes, 479
- CYP2C subfamily of enzymes, 19
- CYP2D subfamily of enzymes, 19, 479
 - in autoimmune hepatitis, 453–454
- CYP2E subfamily of enzymes, 19
- CYP3A subfamily of enzymes, 18, 479
 - and erythromycin metabolism, 490
- development of, 480–481
- hepatic drug metabolism and, 18, 18f, 478–479
- cytokeratins, 36, 37
 - in Alagille syndrome, 45–46
 - immunoreactivity of, 37
- cytokines
 - in acute phase response to infection, 897–898
 - associated with hepatic regeneration, 101–103, 103t
 - and biliary atresia, 252
- cytomegalovirus (CMV)
 - acute liver failure and, 76
 - and biliary atresia, 250
 - hepatitis due to, in neonates, 235, 235f
 - as postoperative complication of transplantation, 986

1006 ■ INDEX

- cytotoxicity
 of erythromycin, 490
 of halothane, 492
 and hepatic drug metabolism, 481
- D-bifunctional protein (DBP), 842
 deficiency in, 846, 849–850
- D-penicillamine, 198, 216
- daclizumab, for liver transplantation, 983
- dactinomycin, hepatotoxicity of, 487–488
- danazol, for α 1-antitrypsin deficiency, 562
- day care centers and hepatitis A virus, 374–375
- DBP. *See* D-bifunctional protein
- decompensated (active) cirrhosis, 98–99, 103
- deferiprone, 669
- deferoxamine, 669, 670*f*
- defibrotide, for veno-occlusive disease, 903
- delta bilirubin, 275–276
- delta hepatitis virus. *See* hepatitis D virus
- dental hygiene in cholestasis, 218
- deoxycholic acid, for cerebrotendinous xanthomatosis, 752
- deoxyguanosine kinase (dGK), 811–812
- deoxymannojirimycin (DMJ), 562
- deoxyribonucleotides (dNTP), 811
- dermatologic manifestations. *See* skin manifestations
- dermatomyositis, 906
- desferrioxamine
 and fulminant hepatic failure, 977
 for neonatal hemochromatosis, 671, 671*t*
- dexoxythymidine triphosphate (dTTP), 815
- DHA. *See* docosahexaenoic acid
- diabetes mellitus (Type 1)
 gallbladder predispositions in, 351
 liver dysfunction in, 907
- diabetes mellitus (Type 2), and screening for nonalcoholic fatty liver disease, 832
- diarrhea, chronic, 814
- dicarbazine, acute liver failure and, 74
- dichloroacetate, 823
- diclofenac, hepatotoxicity of, 495
- didanosine (DDI), and mitochondrial DNA, 818–819
- 2,4-dienoyl-CoA reductase deficiency, 781
- diet. *See also* nutrition
 in 2-methylacyl Co-A racemase deficiency, 753
 caloric intake in, 909
 in chronic liver failure, 126
 copper in, 626, 627*f*
 in cystic fibrosis, 584, 586
 in fatty acid oxidation disorders, 790–791
 in galactosemia, 599–601, 600*t*
 in hereditary fructose intolerance, 606
 for hyperlipidemias and xanthomas, 204
 in nonalcoholic fatty liver disease
 treatment, 835
 and phytanic acid, 843*f*, 844
 for respiratory chain disorders, 823
 in tyrosinemia, non-NTBC treated patients, 705–706
 in urea cycle disorders, 864
 for veno-occlusive disease, 903
- dihydroxycholestanic acid (DHCA), 844, 845, 847
- diltiazem, hepatic drug metabolism of, 479
- dinitrophenylhydrazine (DNPH) test, 532, 534*t*
- diphenylhydantoin. *See* phenytoin
- disorders of bilirubin metabolism. *See* bilirubin metabolism
- disseminated intravascular coagulopathy (DIC), 119–121
- diuretics
 for ascites in cirrhosis, 112–113
 bumetanides, 113
 furosemides, 113
 spironolactones, 112–113
 thiazides, 113
- docosahexaenoic acid (DHA), 844
- dopamine
 in acute liver failure management, 89
 for encephalopathy in cirrhosis, 118
 for hepatorenal syndrome prevention, 125
- Doppler ultrasonography in cystic fibrosis, 584
- double glucagon tolerance test, 615
- Down syndrome, gallbladder predispositions in, 351
- doxorubicin, 965–966
- doxycycline, 234
 for brucellosis, 876
 for leptospirosis, 880
 for Q fever, 880
 for Rocky Mountain Spotted Fever, 880
- DPM. *See* ductal plate malformation (DPM)
- Drisdol, 211–212
- drug hypersensitivity syndrome, 482, 482*t*
- drug-induced cholestasis, 31
- drug-induced liver disease, 478–500, 483*f*.
See also hepatotoxins
 developmental aspects of, 480–481
 hepatic drug metabolism, 478–480, 480*f*, 483*f*
 hepatotoxicity of, 484–500
 acetaminophen, 484–487, 485*f*
 amiodarone, 487, 487*f*
 antineoplastic drugs, 487–488
 aspirin, 488–489
 azathioprine, 489
 carbamazepine, 489
 cocaine, 489–490
 cyclosporine, 490
 ecstasy, 490
 erythromycin (and other macrolides), 490
 estrogens (oral contraceptives), 491
 felbamate, 491
 haloperidol, 491
 halothane, 491*f*, 491–492
 herbal medications, 492
 isoniazid, 492–493
 ketoconazole, 493
 lamotrigine, 493
 methotrexate, 493–494
 minocycline, 494–495
 nonsteroidal anti-inflammatory drugs, 495
 pemoline, 495
 penicillins, 495
 phenobarbital, 495–496
 phenytoin, 496
 propylthiouracil, 496–497
 retinoids, 497
 sulfonamides, 497
 valproic acid, 497–500, 498*f*, 499*f*
- mitochondrial disorders and, 808*t*, 818
- overview of, 478
- patterns of, 481–484, 482*t*
 associated syndromes, 482
 biotransformation and immune reactivity, 483, 483*t*
 classification of chemicals, 483*t*, 483–484, 484*t*
 clinical types, 481–482
 time course of, 481
 treatment principles, 500
- drugs. *See also* drug-induced liver disease; *specific drug names*
 and drug-induced cholestasis, 31
 metabolism of
 stages of, 17–18
 variables that influence, in neonates, 17
- Dubin–Johnson syndrome, 293–294
 clinical presentation of, 293
 diagnosis and treatment of, 294
 and multispecific transporter, 28
 pathophysiology of, 293–294
 and secretion of bilirubin conjugates, 275
- ductal plate malformation (DPM), 39–40.
See also Caroli's disease; ductal plates
 abnormalities associated with, 37*f*, 39–40
 vs. congenital hepatic fibrosis (CHF), 42*f*, 42–43
 definition of, 39
 development of, 928
 in fibrocystic diseases, 47, 47*f*, 48*f*
 hepatic nuclear factors and, 39
 visualization of, 39
- ductal plates. *See also* ductal plate malformation
 in biliary atresia, 41–42

- formation of, 37, 928, 929*f*
- remodeling of, 38
- ductogenesis, 39
- ductopenia
 - BD/PT ratio and, 38
 - due to carbamazepine, 489
 - postoperative complications of liver transplantation, 985–986
- ductular reaction, 41
- Duncan's disease. *See* X-linked lymphoproliferative (XLP) disease
- dyskinesia, in Wilson's disease, 634
- E-Ferol (vitamin E), 900
- early viral response (EVR), in hepatitis C infection, 421, 422
- echinacea, 492
- Echinococcus granulosus* (Echinococcal disease), 881–882
- echovirus, acute liver failure and, 76
- ecstasy (MDMA), 490
- ehrlichioses, 878
- electron transfer flavoprotein (ETF), 781
- electron transport deficiency, and FAO disorders, 816
- EMA. *See* ethylmalonic acid
- embryology of gallbladder, 346, 347*f*
- embryology of liver, 3, 35–36. *See also* liver development
 - of caudal bud, 35
 - of cystic duct, 35
 - of hepatic diverticulum, 35–36
- emphysema, and α 1-antitrypsin deficiency, 545, 547
- treatment of, 562–563
- encephalomyopathies, mitochondrial, 806, 807*t*
- encephalopathy
 - in acute liver failure, 71, 82–84
 - ammonia and, 84
 - definition of, 82–83
 - diet, 84
 - electroencephalogram, 84
 - expected outcomes for, 91
 - and liver transplantation, 977
 - pathophysiology of, 84
 - presentation of, 83
 - scale for grading, 83*t*
 - stages of progression, 83*t*, 83–84
 - ammonia and, 114–115, 172
 - antibiotic treatment for, 117
 - benzodiazepine antagonists for, 118
 - and bilirubin production, 282
 - in cirrhosis and chronic liver failure, 114–118
 - ammonia hypothesis, 114–115
 - blood-brain barrier changes, 114
 - false neurotransmitter hypothesis, 115
 - γ -aminobutyric acid–ergic inhibitory neurotransmitter hypothesis, 105*t*, 115–118, 117*f*
 - overview of, 114
 - portasystemic shunting, 114
 - synergistic neurotoxin hypothesis, 115
 - toxic metabolites, 114
- combination therapy for, 117–118
- dopamine for, 118
- and lactitol therapy, 117
- and lactulose therapy, 117
- and manganese, 216
- in portal hypertension, 144–145
- and protein intake, 116–117
- end-stage renal disease (ESRD)
 - and autosomal dominant polycystic kidney disease, 934
 - in nephronophthisis-medullary cystic kidney disease, 50
- endocrinologic disorders, 907
 - adrenal disorders, 907
 - in cirrhosis, 105
 - diabetes mellitus, 907
 - hypopituitarism, 907
 - myopathy mimicking liver disease, 907
 - of the thyroid, 907
- endoplasmic reticulum (ER)
 - cellular adaptive mechanisms to
 - mutations in α 1-antitrypsin Z, 553–555, 554*f*
- endoscopic retrograde cholangiography (ERCP), 186–187, 585
- endoscopy, and portal hypertension, 146–147, 147*f*, 148, 149
- in emergency variceal hemorrhage therapy, 150*f*, 150–151, 151*f*
- Energix-B, 394*t*
- energy requirements in cholestasis, 205
- Entamoeba histolytica*, 880–881, 881*f*
- entecavir, for hepatitis B treatment, 403, 520
- enteric starvation, 910–911
- Enterobacter spp.*, in bacterial cholangitis, 873
- Enterococcus faecalis* and spontaneous bacterial peritonitis, 121
- Enterococcus spp.*
 - in bacterial cholangitis, 873
 - as postoperative complication of transplantation, 986–987
- enteroviral hepatitis, 239–240
- enzyme immunoassay (EIA), for hepatitis C, 416
- enzymes. *See also specific enzymes*
 - for amino acid metabolism in neonates, 16–17
 - for biotransformation, 18, 18*f*, 19–20
 - for carbohydrate metabolism in fetus vs. neonate, 16
 - hepatic development and, 14
 - of urea cycle, 861–862
- ephedra (ma huang), 492
- Ephynal, 213–214
- epidermal growth factor (EGF), 102, 937–938
- epimerase deficiency galactosemia. *See* galactosemia
- epinephrine, 293
 - in glycogen storage disease test, type III, 615
 - in glycogen storage disease test, type IV, 616
- epipodophyllotoxin etoposide (VP-16), 522
- epoxide hydroxylase (EPHX), 19–20
- EPP. *See* erythropoietic protoporphyria
- Epstein-Barr virus
 - acute liver failure and, 76
 - as postoperative complication of transplantation, 986
 - and X-linked lymphoproliferative (XLP) disease, 523
- ERCP. *See* endoscopic retrograde cholangiography
- erythromycin, 234
 - hepatic drug metabolism of, 479
 - hepatotoxicity of, 490
 - for lyme disease, 879
- erythropoietic protoporphyria (EPP), 688–690. *See also* porphyria(s)
 - autosomal recessive, 690
 - classification of, 680, 680*t*, 684*t*
 - clinical features of, 689
 - diagnosis of, 689*f*, 689–690
 - homozygous dominant, 684*t*
 - treatment of, 690
- erythropoietin, 686
- Escherichia coli*
 - in acalculous cholecystitis, 349
 - in bacterial cholangitis, 873
 - and discovery of hepatitis C virus, 406
 - in hepatitis, neonatal, 235–236
 - and homologous transferase protein, 596
 - in pyogenic liver abscess, 872
 - and sepsis in galactosemia, 597
 - and sepsis in hyperbilirubinemia, 871, 872*f*
 - in spontaneous bacterial peritonitis, 121
 - in urinary tract infection, 234
 - urobilinoid production and, 276
- esophageal variceal hemorrhage (EVH), 259
- esophageal varices, and ultrasound, 139*f*, 146. *See also* variceal hemorrhage, in portal hypertension
- ESRD. *See* end-stage renal disease
- essential fatty acids (EFA)
 - deficiency in, 207–208
 - nutritional therapy in cholestasis, 207–208
- estrogens (oral contraceptives)
 - and cholesterol gallstone formation, 358
 - and hepatocellular adenoma, 955
 - hepatotoxicity of, 491
 - and jaundice, 294

1008 ■ INDEX

- ethambutol, for mycobacterium avium complex, 877
- ethanol
and cocaine hepatotoxicity, 489
toxicity of, and mitochondria, 818
- ether lipid biosynthesis, 843*f*, 845
- ethylmalonic acid (EMA), 780
- etoposide, 965
- EVH. *See* esophageal variceal hemorrhage
- exchange transfusion for neonatal jaundice, 284*f*, 286
- extracellular matrix (ECM)
in cholestasis, 197
in cirrhosis, 99–100
- extrahepatic bile duct atresia. *See* biliary atresia
- extrahepatic bile ducts
abnormal types of, 256
agenesis of, 58–59
in biliary atresia, 58, 249, 249*f*, 255–256
cholangiopathy of, 58–59
- extravascular blood, 279–280
- FAA. *See* fumarylacetoacetate
- facial features in Alagille syndrome, 334–335, 335*f*
- factor VIII in coagulopathies of cirrhosis, 119–120
- FAH. *See* fumarylacetoacetate hydrolase (FAH) deficiency
- false neurotransmitter hypothesis of encephalopathy in cirrhosis, 115
- famciclovir
for hepatitis D infection, 428
for polyarteritis nodosa, 390
- familial adenomatous polyposis (FAP), 944
- familial hypercholanemia, 322
- Fanconi's syndrome, 694, 703–705, 814
- FAO. *See* fatty acid oxidation (FAO) disorders
- FAP. *See* familial adenomatous polyposis
- Farber's disease, 716*t*, 720
- farnesoid-X-activated receptor (FXR), 196–197
and bile acid transport, 23–24
and FIC1 deficiency, 314, 314*f*
- Fas pathway, 962
- Fasciola hepatica*, 885
- fasting, and bilirubin concentration in Gilbert's syndrome, 289–290
- fat malabsorption, in chronic liver disease, 126
- fat requirements in cholestasis, 205–207
- fat soluble vitamins, 126, 204*f*, 208–215.
See also diet; nutrition; *specific vitamins*
in Alagille syndrome, 340
in cystic fibrosis, 587
deficiency in. *See* bile acid synthesis, defects in
vitamin A, 204*f*, 208*f*, 208–210, 209*f*, 210*t*
vitamin D, 204*f*, 210*f*, 210–212
vitamin E, 212–214
vitamin K, 214–215
- fate map of liver progenitors, 3, 4*f*
- fatigue
in cholestasis, 202–203
in primary biliary cirrhosis, 202
- fatty acid oxidation (FAO) disorders, 537–539, 538*t*, 774–776, 775*f*
animal models for, 791–793
CPT-1A deficient mouse, 793
LCAD deficient mouse, 792
MCAD deficient mouse, 792–793
MTP deficient mouse, 790*f*, 791*f*, 791–792, 792*f*, 793*f*
OCTN2 deficient mouse, 793
SCAD deficient mouse, 793
VLCAD deficient mouse, 792
- in carnitine cycle, 775*f*, 776–777
- diagnosis of, 784–787, 788*f*
approach to, 784
molecular genetics of, 787
in newborns, 786*t*, 787, 789*t*
postmortem, 787–789
prenatal, 787
routine laboratory assessment of, 784–785
specialized laboratory assessment of, 785–787, 786*t*
- diagnostic protocol for, 541*f*
- differential diagnosis of, 789
- and electron transport deficiency, 816
- inborn mitochondrial errors of, 767–794
and acyl-CoA dehydrogenases, 769–770, 770*f*, 779*f*
alternative pathways for, 773–774, 774*f*, 775*f*
and 3-hydroxyacyl-CoA dehydrogenase, 770, 770*f*, 816
biochemistry of, 767–768, 768*t*, 769*f*
2,4-dienoyl-CoA reductase deficiency, 781
and enoyl-CoA hydratases, 770, 770*f*
glutaric acidemia type II (GA II), 781
intramitochondrial regulation of, 769, 769*f*
3-ketoacyl thiolase, 770
and mitochondrial trifunctional protein, 770–771, 771*f*
odd-chain fatty acids, 771, 772*f*
overview of, 767
oxidation of unsaturated fatty acids, 771–773, 772*f*, 773*f*, 774*f*
of ketogenesis, 780–781
of long-chain free fatty acids (LCFAs), 777–779
management of, 790–791
and maternal liver disease, 781–784, 782*t*
of medium-chain fatty acid metabolism, 779*f*, 779–780
patient profiles, 538, 538*t*, 539*f*, 540*t*
of short-chain fatty acid metabolism, 780
sudden infant death syndrome (SIDS) and, 784
sudden unexpected death in, 539
types of, 537–538
fatty acid transport protein (FATP), 767–768, 768*t*
- fatty acids
in Alagille syndrome, 339–340
and encephalopathy, 115
in fetus and neonate
oxidation of, 17
support for gluconeogenesis, 17
synthesis of, 17
transport of, 17
laboratory assessment of, 537–539, 538*t*, 785
in peroxisomal β -oxidation, 842
fatty liver of pregnancy, in acute liver failure, 81
- FECH. *See* ferrochelatase (FECH)
- felbamate
acute liver failure and, 74–75
hepatotoxicity of, 491
- Felty's syndrome, 905
- ferritin
in hereditary hemochromatosis, 668
in hereditary hemochromatosis treatment, 668
in porphyria cutanea tarda, 686
in secondary iron overload, 669
- ferrochelatase (FECH), 688–690
- ferroportin and iron regulation, 661, 663*f*
- fetal hematopoiesis, 7
- FGF. *See* fibroblast growth factor (FGF)
- fialuridine (FIAU), 818
- FIAU. *See* fialuridine
- fibrinogen, 119, 168, 169
- fibroblast growth factor (FGF)
and differentiation of bone marrow cells, 9
and Hex expression, 7
liver development and, 4
role in regeneration, 102
- fibrocystic cholangiopathies, 47–58
autosomal dominant polycystic kidney disease (ADPKD), 52–54
autosomal recessive polycystic kidney disease, 47–48, 48*f*
Caroli's disease, 50–51
ciliated hepatic foregut cyst, 58
congenital hepatic fibrosis, 48–50
cystogenesis and, 54–57
isolated polycystic liver disease, 54
mesenchymal hamartoma of the liver, 57
overview of, 47
solitary (nonparasitic) cyst, 57
von Meyenburg complex, 51–52

- fibrocystic liver disease, 928–937, 939
 autosomal dominant polycystic kidney disease. *See* autosomal dominant polycystic kidney disease
 autosomal recessive polycystic kidney disease. *See* autosomal recessive polycystic kidney disease
 Caroli's disease and syndrome. *See* Caroli's disease; Caroli's syndrome
 congenital hepatic fibrosis. *See* congenital hepatic fibrosis
 overview of, 928–929, 929*f*, 929*t*
 pathogenesis and animal models in, 937*t*, 937–939, 939*f*
 polycystic liver disease. *See* polycystic liver disease
 solitary nonparasitic cysts in, 929, 930*f*
 von Meyenburg complexes. *See* von Meyenburg complex
- fibrogenesis in cirrhosis, 100–103
 biochemical assays for, 101
 biopsies and, 100–101
 treatment of, 101
- fibronectin in cirrhosis, 100
- fibrosis
 in biliary atresia, 41
 in cholestasis, 197–198
 herbal therapies for, 198
 pathogenesis of, 197
 treatment of, 197–198
 in glycogen storage disease, 614–615
 in hepatitis C infection, 412
 in peroxisomal disorders, 849*t*
 in PFIC1, 312–313
- FIC1* gene and protein, 310
 evidence as aminophospholipid transporter, 314
 extrahepatic manifestations of, 311
 and farnesoid X receptor activity, 314, 314*f*
 and histopathology of PFIC1, 312–313, 313*f*
 and liver transplantation, 317
- 5'-nucleotidase (5'NT), 167–168
- flavin adenine dinucleotide (FAD), 769–770
- flavin-containing monooxygenases (FMO), 19
- Flaviridae family, 239, 406
- fluconazole
 for *Candida* infection, 887, 986
 for *Cryptococcus neoformans*, 888
- flukes, liver, 884–885, 885*f*
- flumazenil, for encephalopathy in cirrhosis, 118
- 5-fluorocytosine
 for aspergillosis, 889
 for *Candida* infection, 887
 for *Cryptococcus neoformans*, 888
- 5-fluorouracil, 965–966
- FMO. *See* flavin-containing monooxidases
- foodborne illnesses, and hepatitis A virus, 372–374, 374*f*
- Forbes disease. *See* glycogen storage disease, type III
- formula. *See also* breast-feeding; diet; nutrition
 for infants with galactosemia, 600, 606
 for infants with tyrosinemia, 705–706
 and liver injury, 909
- foscarnet, 235
- Foxa transcription factors, 5
- and Gata4 transcription factor, 5
 and Hex expression, 7
- Foxf1* gene, 35
- Foxm1b transcription factors, 6, 37
- fractures in Alagille syndrome, 336
- Francisella tularensis*, 876
- fructose-1,6-diphosphatase deficiency, 602–607
- fructose-1,6-diphosphatase deficiency, definition of, 602
- fructose metabolism. *See* hereditary fructose intolerance
- fructosuria, definition of, 602. *See also* hereditary fructose intolerance
- fucosidosis, 716*t*, 723
- fulminant hepatic failure (FHF). *See also* acute liver failure (ALF) in children
 causes of, 72*t*
 liver transplantation in, 976–977
 in Wilson's disease, 633, 642, 647*t*
- fumarylacetoacetate (FAA), 694
- fumarylacetoacetate hydrolase (FAH) deficiency, 9. *See also* tyrosinemia in tyrosinemia
 as diagnostic test, 696
 gene therapy, 708
 mutations in, 696
 pathophysiology of, 694–696, 695*f*
- functional development of liver, 24
 and energy metabolism, 20
 of amino acids, 17
 of carbohydrates, 16
 of lipids, 17, 20
 enzymatic role in, 14
 hepatic bile formation and, 20–22
- fungal infections of liver, 886–889
 with *Aspergillus sp.*, 888–889
 with *Candida*, 886–887, 986
 with *Coccidioides immitis*, 887*f*, 887–888
 with *Cryptococcus neoformans*, 888
 with *Histoplasma capsulatum*, 888
 with *Penicillium marneffei*, 887
 as postoperative complication of transplantation, 986
 with *Trichosporon cutaneum*, 887
- furosemides, 113
- FXR. *See* farnesoid X receptor
- GAA. *See* acid α -glucosidase
- galactitol. *See* galactosemia
- galactokinase deficiency galactosemia, 596*f*, 602
- galactose, metabolism of, 15, 595–596, 596*f*
- galactosemia, 595–602
 clinical presentation of, 596–597
 diagnosis of, 598–599
 galactokinase-deficiency, 596*f*, 602
 galactose metabolism and physiology and biochemistry of, 595–596, 596*f*
 galactose toxicity, pathogenesis and biochemistry of, 596*f*, 597–598
 in brain, 598
 cellular mechanisms of, 598
 in gonads, 598
 in intestines, 598
 in kidneys, 598
 lenticular changes in, 598
 in liver, 597–598
 genetic screening for, 599
 molecular basis of, 596
 overview of, 595
 subsequent course of, 601–602
 transferase-deficiency, 596, 596*f*
 treatment of, 599–601, 600*t*
 uridine diphosphate
 galactose-4-epimerase deficiency, 596*f*, 602
- galactosialidosis, 716*t*, 724
- β -galactosidofructose (lactulose), for encephalopathy, 117
- gallbladders
 acalculous cholecystitis, 349–350
 clinical features of, 349–350, 350*f*
 etiology and pathogenesis of, 349, 349*t*
 acalculous disease of, 347
 acalculous entities of (dyskinesia), 351
 adenomyosis of, 352
 anomylies of, 59
 and bile flow in neonates, 22
 in biliary atresia, 256
 calculous disease of. *See* gallstones
 and CFTR expression, 574
 cholesterosis of, 351–352
 and chronic cholelithiasis or cholelithiasis, 354*t*, 359
 congenital anomalies of, 346–347, 347*t*
 agenesis, 346
 heterotopia, 346
 hypoplasia, 346
 malposition, 346–347
 multiple, 346
 torsion, 347
 embryology of, 35, 346, 347*f*
 hepatic portocholecystostomy, 258
 hydrops of, 347–349
 clinical features of, 348*f*, 348–349
 etiology and pathogenesis of, 347–348, 348*t*
 inflammatory lesions of, 351
 “milk of calcium,” 351
 opportunistic infections in, 349

1010 ■ INDEX

- gallbladders (*cont.*)
 porcelain, 351
 stasis and gallstone formation, 356
 tumors of, 351, 351*f*
- gallstones, 352–361
 causes of, 353, 354*t*
 cholesterol, 356–358
 conditions predisposing to formation of, 357–358
 formation of, 356*f*, 356–357
 prevalence of, 352*f*, 356–357, 357*f*
 in chronic cholelithiasis or cholelithiasis, 359
 classification of, 352–353, 353*f*
 clinical features of, 358*f*, 358–359, 359*f*
 in cystic fibrosis, 583
 in erythropoietic protoporphyria, 689
 incidence of, 352, 352*f*
 in peroxisomal disorders, 849*t*
 pigment, 353–355
 conditions predisposing to formation of black, 354–355
 conditions predisposing to formation of brown, 355
 formation of, 353–354
 “silent” (asymptomatic), 355, 358, 360–361
 treatment of, 359–361
 in Wilson’s disease, 634
- gallstones in cirrhosis, 104
- γ -aminobutyric acid–ergic inhibitory neurotransmitter hypothesis, 105*t*, 115–118, 117*f*
- γ -glutamyl transpeptidase (γ GT) and hepatic drug metabolism, 481
 in PFIC1, 312
 in PFIC2, 315
 in PFIC3, 318
- γ -glutamyltransferase (GGT), 166–167, 167*t*
 in cholestasis, 186
 in sclerosing cholangitis, 461*t*, 464
 ursodeoxycholic acid therapy, 469
- ganciclovir, 235, 986
- gas chromatography mass spectrometry (GC-MS), 533
- gastrointestinal bleeding in cirrhosis, 120
- gastrointestinal bleeding in portal hypertension, 143
- Gata4 transcription factors, 5, 7
- Gaucher’s disease, 714–719, 716*t*, 717*f*
 diagnosis of, 718
 histopathology of, 718
 treatment of, 718–719
 variants of, 714–717
- Gautier types in biliary atresia, 40
- GB virus C. *See* hepatitis G virus
- gene therapy. *See also* cystic fibrosis
 in α 1-antitrypsin deficiency, 563
 in cystic fibrosis, 588
 for respiratory chain disorders, 823
 in tyrosinemia, 708
- gentamicin
 for cat scratch disease, 874–875
 for listeriosis, 876
- germander, 492
- “Gianotti–Crosti syndrome,” 389–390
- Gilbert’s syndrome, 19, 287–291
 bile pigment composition of, 290*f*
 clinical presentation of, 287–289
 diagnosis and treatment of, 290–291
 four types of, 289
 and hepatic drug metabolism, 479–480
 pathophysiology of, 289–290
 red blood cell abnormalities and, 280
- glucagon and vasodilation, 142
- glucocorticoids, 198
 in cholestasis, 196
 for pruritis, 202
- gluconeogenesis, 15
 fatty acid support for, in neonates, 17
 initiation of, 15–16
- glucose-6-phosphatase, 15
 deficiency of. *See* glycogen storage disease, type 1
- glucose metabolism, in fetus and neonate, 14
- glucosylceramide synthase, in Gaucher’s disease, 718–719
- glutamine
 metabolism of in neonates, 16
 for veno-occlusive disease, 903
- glutamine metabolism, in neonates, 16–17
- glutaric acidemia type II (GA II), 781
- glutathione
 in acetaminophen toxicity, 485, 486
 and cocaine hepatotoxicity, 489
 concentration of, in neonates, 22
 for cystic fibrosis therapy, 589
 and hepatic drug metabolism, 480, 481
- glutathione peroxidase and selenium, 216
- glutathione S-transferase (GST), 19, 272
 in Rotor’s syndrome, 293
- glutethimide, and bilirubin concentration, 289
- glycerol, for α 1-antitrypsin deficiency, 562
- glycogen storage disease (GSD), 607*t*, 607–618
 glycogen metabolism, in liver, 608*f*, 609
 glycogen metabolism, physiology and biochemistry of, 607–609, 608*f*, 609*f*
 type I, 609–614
 classification of, 609
 clinical presentation of, 610*f*, 610–611
 diagnosis of, 612, 613*f*
 growth impairment and hepatocellular changes in, 612
 metabolic consequences of, 611*f*, 611–612
 molecular basis of, 609–610
 subsequent course of, 614
 treatment of, 612–614
- type II (Pompe disease), 724–726, 725*f*
 adult onset, 725–726
 diagnosis of, 726
 juvenile onset, 725
 neonate onset, 725
 treatment of, 726
- type III, 614–616
 biochemical and pathologic characteristics of, 615, 615*f*
 clinical presentation of, 614–615
 diagnosis of, 615
 metabolic consequences of, 615
 molecular basis of, 614
 treatment of, 616
- type IV, 616–618
 biochemical and pathologic characteristics of, 617, 617*f*
 clinical presentation of, 616
 diagnosis of, 617
 metabolic consequences of, 616
 molecular basis of, 616
 subsequent course of, 617–618
 treatment of, 617
- glycogen stores, hepatic, in fetus and neonate, 15
- glycogen synthesis, in fetus and neonate, 15
- glycogenolysis, hepatic, in neonates, 15
- glycoprotein degradation disorders, 723–724
- glycoproteins in cirrhosis, 100, 102
- glypican-3 (GPC3) oncofetal protein, 949, 960
- G_{M1} gangliosidosis, 716*t*, 720–721, 721*t*
- GNPTA gene mutations in mucopolipidosis, 728
- gold therapy in juvenile rheumatoid arthritis, 905
- GPC3. *See* glypican 3 oncofetal protein
- GRACILE syndrome, 670
- graft-versus-host diseases (GVHD), 903–904, 904*f*
 ursodeoxycholic acid, effect on, 195
- group A and C rotavirus. *See* rotavirus infection
- growth failure
 in Alagille syndrome, 338
 in galactosemia, 598–599
 in PFIC1, 311
- GSD. *See* congenital disorders of glycosylation; glycogen storage disease (GSD)
- Günther disease. *See* congenital erythropoietic porphyria
- haloperidol, hepatotoxicity of, 491
- halothane
 acute liver failure and, 74
 hepatotoxicity of, 491*f*, 491–492

- hamartomas. *See* mesenchymal hamartoma of the liver (MHL); tumors
- harderoporphyria, 684*t*, 687
- HAT. *See* hepatic artery thrombosis
- Havrixâ (hepatitis A vaccine), 380, 381, 382
- hawkinsinuria, 697
- HB. *See* hepatoblastomas
- HCC. *See* hepatocellular carcinoma
- HE. *See* hemangioendotheliomas
- heatstroke, 899
- Helicobacter*, in sclerosing cholangitis, 468
- HELLP (hemolysis, elevated liver enzymes, and low platelets) syndrome, 781–782
- and maternal liver disease and LCHAD deficiency, 782*t*, 782–783
- hemangioendotheliomas (HE), 944*t*, 955, 959*f*, 960*f*, 961*f*. *See also* tumors
- hematemesis in portal hypertension, 149*t*
- hematin treatment, in tyrosinemia, 707
- hematologic disorders
- in cirrhosis, 104
- in Wilson’s disease, 635–636
- hematopoiesis
- in early gestation, 14
- fetal, 7
- hematopoietic stem cell transplant (HSCT) for hemophagocytic lymphohistiocytosis, 522–523
- in hepatitis B/primary immunodeficiency patients, 520
- for hyperimmunoglobulin M syndrome, 517, 518
- hematopoietic stem cells
- development of, 3
- and Hlx transcription factor, 6
- and oncostatin M, 7
- heme biosynthesis, 677–679, 678*f*, 679*t*, 685*f*
- heme oxygenase (HO), 270, 286–287
- hemin treatment
- for acute intermittent porphyria, 684
- for ALA-dehydratase porphyria, 682
- in harderoporphyria, 688
- hemochromatosis
- in cystic fibrosis, 579
- type 2. *See* juvenile hemochromatosis
- Yersinia enterocolitica* in, 876
- hemodynamic changes in portal hypertension, 141–143
- hemoglobin, in bilirubin production, 270
- hemoglobinopathies, 280, 901, 901*t*
- hemoperfusion and neonatal jaundice, 287
- hemophagocytic lymphohistiocytosis (HLH), 521*f*, 521–523, 522*t*, 523*t*
- treatment of, 522–523
- with liver transplantation, 977
- vs. X-linked lymphoproliferative (XLP) disease, 523
- Hemophilus influenzae* and spontaneous bacterial peritonitis, 121
- hemorrhaging. *See also* variceal hemorrhage
- in acute liver failure, 86, 91
- in cirrhosis, 120–121
- in portal hypertension, 143
- hemosiderosis. *See* secondary iron overload
- hepadnaviridae. *See* hepatitis B virus
- heparin, for veno-occlusive disease, 903
- hepatic artery thrombosis (HAT), 984–985
- hepatic bile formation, 20–22
- cellular mechanisms of, 22–24
- anion transporters, 23
- bile salt excretory pump, 23
- intracellular transport of, 23
- multidrug resistance protein and, 23
- Na⁺-K⁺ ATPase, 22
- nuclear receptors, 23–24
- transport across basolateral plasma membrane, 22–23
- transport across canalicular plasma membrane, 23
- concentration of acids, 20
- excretion of bile, 20*t*, 20–21, 21*f*
- flow of bile, 21–22
- and gallbladder role, 22
- secretion of bile, 21
- synthesis of bile, 20
- transport of organic anions, 21
- hepatic blood flow
- altered systemic circulation of, 898–899
- in portal vein, 138
- hepatic diverticulum, embryology of, 35–36
- hepatic drug metabolism, 478–480
- hepatic encephalopathy. *See* encephalopathy
- hepatic fructokinase deficiency. *See* fructosuria; hereditary fructose intolerance
- hepatic galactokinase, in carbohydrate metabolism of neonates, 15
- hepatic growth factor (HGF), 6, 7*f*
- and hepatocyte lineage, 7
- as a promotor for hematocyte lineage, 8
- role in regeneration, 102
- hepatic hypoperfusion and neonatal jaundice, 282
- hepatic hypoplasia, and Hlx transcription factor, 6
- hepatic metabolism, in fetus and neonate, 20
- of amino acids, 17
- of carbohydrates, 16
- of lipids, 17, 20
- hepatic nuclear factors (HNFs), and ductal plate malformation, 39
- hepatic portoenterostomy, for biliary atresia, 40, 41
- complications of, 42
- follow up biopsies, 42, 42*f*
- liver lesions from, 42–43
- hepatic steatosis. *See* nonalcoholic fatty liver disease; steatosis
- hepatic stellate cells (HSC), 101
- hepatic transplantation. *See* liver transplantation
- hepatic tumors. *See* tumors
- hepatic venous outflow obstruction. *See* Budd–Chiari syndrome
- hepatic venous pressure gradient (HVPG), 147, 148
- hepatitis
- acute, in Wilson’s disease, 633, 641
- and alkaline phosphatase levels, 166
- and aminotransferases, 165
- autoimmune. *See* autoimmune hepatitis (AIH)
- autoimmune and acute liver failure, 76, 77*f*
- from carbamazepine, 495–496
- chronic, in Wilson’s disease, 633–634, 642
- coombs positive giant cell, 242
- enteroviral, in neonates, 239–240
- herpes, 235–236, 236*f*
- immunodeficiencies in chronic viral, 518
- neonatal. *See* neonatal hepatitis
- nonviral and acute liver failure, 76
- parvovirus, in neonates, 240
- perihepatitis, 875
- in peroxisomal disorders, 849*t*
- from phenytoin, 496
- and sickle cell disease, 901
- Trichosporon, 887
- typhoid, 875
- ursodeoxycholic acid, effect on, 195
- viral. *See specific types of*; viral hepatitis
- hepatitis A vaccine
- adverse effects of, 381
- efficacy of, 380–381
- epidemiologic risk factors, 371
- long term protection of, 381
- recommended use for, 375*f*, 376*f*, 376*t*, 381*t*, 381–382, 587
- hepatitis A virus (HAV), 369–382
- acute liver failure and, 75
- clinical features and pathogenesis of, 375–377, 378*f*, 378*t*, 379*t*
- diagnosis of, 370*t*, 377
- epidemiology of, 371–375, 372*f*, 372*t*, 373*f*, 374*f*, 375*f*, 376*t*
- expected outcomes for, 91
- historical background of, 369, 371*t*
- incidence of in US, 375, 375*f*, 376*f*, 377*f*
- management of, 237, 377–378
- acute illness, 377–378
- in neonates, 237
- prevention of, 378–382
- active immunization, 380
- efficacy of vaccine, 380–381
- passive immunization, 378–380, 379*t*, 380*t*

1012 ■ INDEX

- hepatitis A virus (HAV) (*cont.*)
 - tests for, 237
 - vaccine for, 217–218, 237
 - viral characteristics of, 369–371, 371*f*
- hepatitis B immune globulin (HBIG), 379*t*, 392, 393*t*
- hepatitis B vaccine
 - adverse effects of, 396–397
 - characteristics of, 395–396
 - in hemophiliacs, 901–902
 - long term protection of, 394*t*, 395–396
 - prior to liver transplantation, 978
 - recommended use for, 394*t*, 395*t*, 396–397, 587
- hepatitis B virus (HBV), 382–405
 - acute liver failure and, 75
 - chronic, 387*f*, 387–388
 - diagnosis of, 391
 - infection, 385
 - clinical features of, 389–390, 390*f*, 390*t*
 - coinfection with autoimmune hepatitis, 449–450
 - coinfection with hepatitis D, 237–238, 426, 427*f*, 428*t*
 - diagnosis of, 390*f*, 390–391, 391*t*, 400*t*
 - epidemiology of, 386–389, 387*f*
 - geographic variability and, 387–388
 - pediatric infection, 388, 388*t*
 - perinatal transmission of, 387*f*
 - expected outcomes for, 91
 - future treatments for, 405
 - genotypes of, 385–386
 - geographic variability and, 385
 - mutations in, 385–386
 - geographic variability and, 385
 - and hepatocarcinogenesis in α 1-antitrypsin deficiency, 560
 - historical background of, 369, 371*t*
 - and HIV coinfection, 520
 - incidence of, 387*f*, 387–388
 - interferon therapy, 398–401, 399*t*
 - adverse effects of, 400–401
 - for children, 399
 - parameters of response to, 399–400
 - for patients with cirrhosis, 401
 - long term protection of, 394*t*, 395–396
 - management of, 386*t*, 397*t*, 397–398, 398*t*
 - in neonates, 237–238
 - new treatments for, 401–403
 - adefovir dipivoxil, 402*t*, 402–403
 - lamivudine, 401–402
 - novel treatments for, 403–404
 - entecavir, 403
 - nucleotide/nucleoside analogues, 403, 404
 - peginterferon, 403–404
 - telbivudine, 403
 - tenofovir, 403
 - outcome, 391–392
 - pathogenesis of, 384*f*, 384–386
 - prevention of, 392–397
 - active immunization, 388*t*, 392–393
 - adolescent immunization, 394*t*, 395
 - groups with poor response to vaccination, 395
 - passive immunization, 379*t*, 392, 393*t*
 - perinatal transmission of, 393*t*, 393–394, 394*t*
 - universal vaccination, 393*t*, 394*t*, 394–395
 - and primary immunodeficiency, 520
 - terminology of, 386*t*
 - tests for, 238, 400*t*
 - therapy for transplant patients, 404–405
 - treatment of, 238
 - and tumors, 943
 - vaccine for, 217–218, 237–238
 - viral characteristics of, 382*f*, 382–383, 383*f*, 384*f*, 386*t*
- hepatitis C virus (HCV), 405–424
 - acute liver failure and, 75
 - AST:ALT ratio and cirrhosis, 164–165
 - clinical features of, 409–410, 410*f*, 410*t*
 - coinfection with autoimmune hepatitis, 449–450
 - coinfection with hepatitis B, 415
 - coinfection with human immunodeficiency virus, 415, 901–902
 - diagnosis of, 415*t*, 415–417
 - enzyme immunoassay, 416
 - genotyping, 417
 - nucleic acid based tests, 416, 416*t*
 - quantitation of viral genomes, 416–417, 417*f*
 - epidemiology of, 406–409, 407*f*, 408*t*, 409*f*
 - perinatal transmission of, 408–409
 - extrahepatic manifestations of, 408*t*, 411–412
 - fatigue in, 202
 - genotypes and quasispecies of, 406
 - histology of, 412, 413*f*
 - historical background of, 406
 - and HIV coinfection, 520
 - management of, 418*t*, 418–422, 419*f*, 420*f*
 - with combination therapy, 419–422, 420*f*, 421*f*, 422*f*
 - early viral response to, 421, 422
 - emerging therapies, 425*t*
 - with pegylated interferon, 418–419
 - with ribavirin, 419
 - in neonates, 238
 - “occult” (silent) infection, 412
 - outcome, 410–411
 - in adults, 411
 - in children, 410–411
 - in perinatal transmission, 411
 - pathogenesis of, 413–415, 414*f*
 - prevalence of, 405*f*
 - prevention of, 417–418, 418*t*
 - and primary immunodeficiency, 520–521
 - replication mechanism of, 406, 413–414
 - tests for, 238
 - treatment of, 418–424
 - acute infections, 423–424
 - chronic infections, 422–423
 - in cirrhosis, 424, 424*f*
 - future of, 424
 - in persons with normal ALT levels, 423
 - trreatment of, 238
 - ursodeoxycholic acid, effect on, 195
 - viral characteristics of, 406
- hepatitis D virus (HDV), 424–428
 - acute liver failure and, 75
 - clinical features of, 426–427
 - in children, 427
 - coinfection with hepatitis B, 426*t*, 426–427, 427*f*
 - superinfection, 427, 427*f*
 - coinfection with hepatitis B, 237–238
 - diagnosis of, 427–428, 428*t*
 - epidemiology of, 425–426
 - history of, 424–425
 - in neonates, 238–239
 - prognosis for, 428
 - tests for, 239
 - treatment of, 239, 428
 - in children, 428
 - with interferon, 428
 - viral characteristics of, 425, 425*f*
- hepatitis E virus (HEV), 429–431
 - acute liver failure and, 75
 - clinical features of, 430, 430*f*, 430*t*
 - epidemiology of, 429–430
 - management and prevention of, 430–431
 - in neonates, 239
 - pathogenesis of, 430, 430*f*, 430*t*
 - viral characteristics of, 429, 429*f*
- hepatitis G virus (HGV)
 - acute liver failure and, 75–76
 - in neonates, 239
- hepatobiliary scintigraphy, 186
- hepatoblastomas (HB). *See also* tumors
 - acquired genetic changes in, 958–960, 963*f*
 - classification of, 952*t*
 - clinical presentation of, 945
 - diagnosis of, 948–949, 950*t*
 - epidemiology of, 943
 - etiology of, 944, 946*f*
 - and liver transplantation, 977–978
 - pathology of, 951–953, 952*f*, 953*f*, 954*f*, 954*t*, 955*f*, 956*f*
 - prognosis of, 964*t*
- hepatoblasts
 - and cytokeratin expression, 36
 - differentiated from bone marrow, 9
 - differentiation of, 8
 - growth of, 7, 7*f*
 - and hepatocyte nuclear factor, 8

- and Hex knock out studies, 6
- phenotypic change to cholangiocyte, 37–38
- and vps33b ortholog, 8
- hepatocanalicular jaundice, 481–482, 482*t*
- hepatocellular carcinomas (HCC). *See also* tumors
 - diagnosis of, 948–949, 950*t*
 - epidemiology of, 943
 - etiology of, 944–945, 947*f*
 - and hepatitis B infection, 385, 392
 - and liver transplantation, 977–978, 979*t*
 - and neoplasia, 947*f*
 - pathology of, 947*f*, 953–955, 956*f*, 957*f*, 958*f*
 - risk in tyrosinemia, 698–699, 699*t*, 700*f*, 709
- hepatocellular mass and liver transplantation, 979–980
- hepatocyte nuclear factors (HNFs)
 - in α 1-antitrypsin deficiency, 551
 - functions of, 8
 - and gene regulation in hepatocytes, 8
 - and hepatoblasts, 8
- hepatocytes. *See also* cytochrome 450
 - in acid sphingomyelinase deficiency, 719*f*
 - adaptation to cholestasis, 31–32, 32*f*
 - bilirubin uptake, 272, 273*f*, 275
 - from bone marrow cells differentiated, 9
 - clotting factors of, 85*t*, 85–86
 - development of, 8
 - and drug toxicity, 481
 - gene regulation in, 8
 - and hepatic growth factor signaling pathway, 6, 7*f*
 - in hepatitis B virus, response, 384
 - immune response role of, 513
 - impairment of, 81
 - mitochondria in, 810–811
 - necrosis of, 81
 - primitive, 14
 - regeneration in, 101–102, 559
 - and retained bile acids, 30
 - transplantation of, in tyrosinemia, 708
 - and tumor pathology, 950–951, 952*t*, 953*f*
- hepatoerythropoietic porphyria (HEP), 686. *See* porphyria cutanea tarda
- hepatomegaly
 - in collagen vascular diseases, 904. *See also* collagen vascular diseases
 - in cystic fibrosis, 584
 - in Gaucher's disease, 717
 - in nonalcoholic fatty liver disease, 831
 - in peroxisomal disorders, 849*t*
- hepatopuertoenterostomy. *See* Kasai hepatopuertoenterostomy
- hepatopulmonary syndrome (HPS)
 - in biliary atresia, 259
 - in portal hypertension, 144
- hepatorenal syndrome (HRS)
 - definition of, 123
- differential diagnosis, 124
- etiology of, 123–124
- forms of, 123
- histologic findings in, 123
- management of, 124–125
 - drug therapy, 125
 - liver transplantation, 125
 - portavalen/peritoneovenous shunts, 125
 - principles of, 124–125
 - volume expansion, 125
- and portal hypertension, 144
- predisposing factors, 124
- presentation of, 124, 124*t*
- hepatorenal tyrosinemia. *See* tyrosinemia
- hepatosplenomegaly, in galactosialidosis, 724
- hepatotoxins, 484*t*. *See also*
 - biotransformation; drug-induced liver disease; *specific hepatotoxins*
 - acute liver failure and, 74
 - and bile acids, 190–193
 - and biliary atresia, 252
 - classification of chemicals, 483*t*, 483–484
 - copper, 626, 629
- hepcidin and iron regulation, 661, 663*f*
- Hepeviridae family, 429
- herbal medications, hepatotoxicity of, 492
- hereditary cholestasis with lymphedema, 320–321
- hereditary coproporphyria (HCP), 686–687. *See also* porphyria(s)
 - classification of, 680, 680*t*
 - clinical features of, 687
 - diagnosis of, 687
 - homozygous dominant and harderoporphyria, 684*t*, 687
 - treatment of, 687
- hereditary fructose intolerance (HFI), 602–607
 - clinical presentation of, 604, 604*t*
 - definition of, 602–603
 - diagnosis of, 606
 - fructose metabolism and, 603, 603*f*
 - fructose toxicity, biochemical and pathogenesis of, 604–605, 605*f*, 606*t*
 - history of, 603–604
 - molecular basis of, 604
 - subsequent course of, 606–607
 - treatment of, 606
- hereditary hemochromatosis (HHC)
 - approach to child with parent with, 666, 667*f*
 - in children with liver dysfunction, 666–668, 670*f*
 - classification of, 662*t*
 - clinical features of, 664–665, 665*f*, 665*t*, 666*f*
 - diagnosis and screening of, 664*f*, 665–666
- epidemiology of, 664
- genetics of, 662–664, 664*f*
- physiology and pathophysiology of iron overload, 661–662, 663*f*
- treatment of, 668, 668*t*
- hereditary tyrosinemia type 1 and hepatocellular carcinomas, 944–945, 947*f*
- herpes viruses
 - acute liver failure and, 76
 - hepatitis due to, in neonates, 235–236, 236*f*
 - as postoperative complication of transplantation, 986
- Hes 1 protein and gene, 36
- Hex homeodomain transcription factor, 7, 7*f*
- HFE* gene, in hereditary hemochromatosis, 662–664
- HFI. *See* hereditary fructose intolerance
- HHC. *See* hereditary hemochromatosis
- HHH syndrome. *See* hyperomithinemia, hyperammonemia and homocitrullinuria (HHH) syndrome
- high performance liquid chromatography (HPLC), 277
- high pressure liquid chromatography (HPLC), 292
- highly active anti-retroviral therapy (HAART), 518–519, 520*t*
 - hepatotoxicity of, 519–520
- Histoplasma capsulatum*, 888
- histoplasmosis, 888
- HIV. *See* human immunodeficiency virus
- HLH. *See* hemophagocytic lymphohistiocytosis
- Hlx transcription factor, 6
- HMG-CoA. *See*
 - 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA)
- HNF1 β* gene
 - and ciliary pathway of cystogenesis, 55
 - and MODY5, 49–50
- Hodgkin's disease, hepatic involvement in, 902
- hormones, and appearance of
 - developmental enzymes, 14
- HPA. *See* hyperpepicolic acidemia
- HPE. *See* Kasai hepatopuertoenterostomy
- HPLC. *See* high performance liquid chromatography
- HPS. *See* hepatopulmonary syndrome
- HRS. *See* hepatorenal syndrome
- human chorionic gonatropin (HCG), 945
- human herpesvirus 6 infection, 240
- human immunodeficiency virus (HIV), 240–241, 518–519
 - coinfection with hepatotropic viruses, 520
 - and hepatitis B infection, 388

1014 ■ INDEX

- human immunodeficiency virus (HIV) (*cont.*)
 and hepatitis C infection, 409, 415, 901–902
 and mycobacterium avium complex, 877
 opportunistic infections in
 cholangiopathy, 519–520, 520*t*
 fungal, 887
 sclerosing cholangitis, 516*f*, 516*t*, 516–518, 517*f*
 human leukocyte antigen (HLA)
 in autoimmune hepatitis, 449, 451
 and biliary atresia, 251–252
 in sclerosing cholangitis, 467–468
 ursodeoxycholic acid, effect on, 193
 human papillomavirus (HPV), and biliary atresia, 250
 HVPg. *See* hepatic venous pressure gradient
 hydrops of the gallbladder, 347–349, 906
 clinical features of, 348*f*, 348–349
 etiology and pathogenesis of, 347–348, 348*t*
 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA) lyase deficiency, 780
 hydroxychloroquine, 686
 4-hydroxyphenylpyruvate dioxygenase (4HPPD), in tyrosinemia, 697
 3 β -hydroxysteroid dehydrogenase isomerase deficiency, 195
 hygiene
 and hepatitis A virus, 371–374, 378
 and hepatitis B virus, 386–387
 hyperammonemia, 858. *See* ammonia
 hyperbilirubinemia, 19
 associated with sepsis, 871, 872*f*
 causes of, 278*t*
 conjugated, disorders of, 288*t*, 293–294
 Dubin–Johnson syndrome, 293–294
 Rotor’s syndrome, 293
 extravascular blood and, 279–280
 incidence of, 289*f*
 isoimmunization and, 279
 in neonates after early hospital discharge, 278
 polycythemia and, 280
 tests for, 107
 unconjugated, disorders of, 287*t*, 287–292
 Crigler–Najjar syndrome. *See* Crigler–Najjar syndrome
 Gilbert’s syndrome. *See* Gilbert’s syndrome
 hypercarotenemia, 277
 hypercholanemia, familial, 322
 hypercholesteremia, 203
 hyperimmunoglobulin M (IgM) syndrome, 517
 hyperlactacidemia, 533*t*, 534
 hyperlipidemias, 203–204
 cholesterol synthesis blocking agents, 204
 diet and, 204
 in glycogen storage disease, 612
 nonabsorbable ion exchange resins for, 203
 ursodeoxycholic acid for, 203–204
 hypernatremia, in acute liver failure, 87
 hyperomithinemia, hyperammonemia and homocitrullinuria (HHH) syndrome, 860
 hyperpipecolic acidemia (HPA), 845–847, 849
 hyperpyrexia (heatstroke), 899
 hypertonic saline, 85
 hypertyrosinemia. *See* tyrosinemia
 hyperuricemia, in glycogen storage disease, 611, 611*f*
 hypoalbuminemia
 in cirrhosis and chronic liver failure, 107
 as test for liver disease, 168
 hypobetalipoproteinemia, and gallstone formation, 358
 hypoglycemia
 in acute liver failure, 86
 in glycogen storage disease, 611
 hypokalemia, in acute liver failure, 87
 hypomagnesium, 215
 hyponatremia, in acute liver failure, 87
 hypophosphatemia
 in acute liver failure, 87
 in glycogen storage disease, 611
 hypoprothrombinemia, 253
 hypotension, in acute liver failure, 88
 hypothyroidism, 907
 hytatid disease. *See* *Echinococcus granulosus*
 I-cell disease. *See* mucopolipidosis
 IBD. *See* inflammatory bowel disease
 ibuprofen
 as bilirubin displacer, 283
 hepatotoxicity of, 495
 ICC. *See* Indian childhood cirrhosis
 ICT. *See* idiopathic copper toxicosis
 icterus. *See* jaundice; neonatal jaundice
 idiopathic copper toxicosis (ICT), 650–652.
 See also Indian childhood cirrhosis;
 Wilson’s disease
 clinical features of, 651
 diagnostic evaluation of, 651
 etiopathogenesis of, 651
 histopathology of, 651
 overview of, 647–648, 650–651
 treatment of, 651–652
 ifosfamide, 966
 IGF2 gene, 958–960
 IL 6, 102–103
 ileal exclusion, 317
 and cholesterol gallstone formation, 357
 for pruritis, 202
 illicit drug use. *See also* cocaine; drugs
 acute liver failure and, 74–75
 and hepatitis A virus, 372, 374*f*
 and hepatitis C infection, 407, 409*f*, 417
 Imatinib, 967
 immune function, in cirrhosis, 105
 immune response
 and biliary atresia, 251–252
 to hepatitis B virus, 384, 384*f*
 innate vs. adaptive, 513
 role of liver in, 513–514
 immune serum globulin (ISG)
 and hepatitis A virus, 378–380, 379*t*, 380*t*, 381
 and hepatitis B virus, 392
 immune theory of liver injury in
 α 1-antitrypsin deficiency, 555–556
 immunizations. *See also* hepatitis
 in cholestasis, 217–218. *See also* hepatitis
 and hepatocellular carcinoma, 392
 prior to liver transplantation, 978
 immunodeficiency, 513–524. *See also*
 α 1-antitrypsin deficiency
 and chronic granulomatous disease, 524
 chronic viral hepatitis in, 518
 and hemophagocytic
 lymphohistiocytosis, 521*f*, 521–523, 522*t*, 523*t*
 treatment of, 522–523
 and hepatitis B virus, 520
 and hepatitis C virus, 520–521
 in human immunodeficiency virus, 518–519
 cholangiopathy, 519–520, 520*t*
 coinfection with hepatotropic viruses, 520
 hyperimmunoglobulin M syndrome, 517
 liver complications in, 514–516
 liver disease and, 518
 liver’s role in immune response, 513–514
 opportunistic infections in sclerosing cholangitis, 516*f*, 516*t*, 516–517, 517*f*
 management of, 516*t*, 517–518
 primary, 514, 515*t*
 primary vs. secondary, 514
 and X-linked lymphoproliferative (XLP) disease, 523–524
 immunoglobulin G (IgG)
 in autoimmune hepatitis, 449
 and autoimmune hepatitis treatment, 454
 in autoimmune sclerosing cholangitis, 455, 462, 462*f*
 for CMV, post liver transplantation, 986
 for hemophagocytic
 lymphohistiocytosis, 522
 immunomodulatory agents, for liver transplantation, 983
 inborn errors of metabolism, 531–541, 532*t*. *See also* fatty acid oxidation (FAO) disorders; tyrosinemia; urea cycle disorders

- of bile acid, 186
- of carbohydrates. *See* carbohydrate metabolism
- misconceptions in, 531, 531*t*
- routine laboratory assessment of, 532, 533*t*, 534*t*
- signs and symptoms of, 531–532
- specialized laboratory assessment of, 532–541
 - amino acid disorders, 532*t*, 534*t*, 540–541
 - fatty acid transport and oxidation disorders, 537–539, 538*t*, 539*f*, 540*t*, 541*f*
 - lactic acidemias, 533*t*, 534–537, 536*t*
 - organic acidurias, 533–534, 535*t*
 - urea cycle disorders, 534*t*, 539–540
- Indian childhood cirrhosis (ICC), 647–650. *See also* idiopathic copper toxicosis; Wilson's disease
 - clinical features of, 648
 - diagnosis and treatment of, 650
 - epidemiology and genetics of, 648
 - histopathology of, 648–649, 649*f*
 - overview of, 647–648
 - pathogenesis of, 649–650
- Indians, North American cholestasis in, 321–322
- Indinavir, 290–291
- infantile hemangiomas, 944*t*, 955, 959*f*. *See also* tumors
- infantile multisystem inflammatory disease, 906–907
- infantile polycystic disease. *See* autosomal recessive polycystic kidney disease
- infantile Refsum disease (IRD), 844, 849. *See also* peroxisomal disorders
- infants. *See also* neonates
 - biliary atresia in, 183
 - cholestasis in, 179–187
 - differential diagnosis of, 179–180, 181*t*
 - evaluation of, 184*f*, 185*t*, 187
 - incidence of, 179, 180*t*
 - manifestations of, 180–184
- infection, liver, 897–898. *See also* nosocomial infections
 - acute phase response in, 897
 - acute phase response to, 31
 - jaundice as sign of, 897
 - laboratory assessment of, 897
 - in neonatal hepatitis, routes of, 232
 - as postoperative complication of transplantation, 986–987
 - and TPN-associated cholestasis, 31
- inflammatory bowel disease (IBD). *See also* sclerosing cholangitis
 - association with primary sclerosing cholangitis, 459, 461, 461*t*
 - lymphocyte homing, 468
 - and CFTR mutation, 583
- Ingram icterometer, 277
- injection drug use. *See* illicit drug use
- inotropes, for acute liver failure management, 89
- INR. *See* international normalized ratio
- insertional mutation (*inv*), murine, 251
- insulin-like growth factors and proteins, 103, 204–205
- insulin-resistance, and screening for nonalcoholic fatty liver disease, 832
- intelligence in galactosemia, 601
- interferons (IFN), 238
 - for hemangioma therapy, 966
 - in hepatitis B treatment, 398–401
 - adverse effects of, 400–401
 - for children, 399
 - parameters of response to, 399–400
 - for patients with cirrhosis, 401
 - and primary immunodeficiency, 520
 - for hepatitis C infection, 414–415
 - acute, 423
 - drug resistance in, 406
 - for hepatitis D infection, 428
 - in children, 428
 - for tumor therapy, 967
- internal ileal exclusion. *See* ileal exclusion
- international normalized ratio (INR), 979
- intracranial bleeding, in Alagille syndrome, 336
- intrahepatic bile ducts
 - cholangiopathies of
 - biliary atresia, 40–44
 - sclerosing cholangitis, 464
 - cholangiography of, 331–332
 - development of, 36*f*, 36–39
 - and cytokeratin expression, 36–37
 - portal vein role, 38
 - postnatal, 38–39
 - stages of, 37–38
 - theories concerning, 36
 - ductal plate malformation and, 39–40
 - morphogenesis defects and biliary atresia, 251
 - paucity in Alagille syndrome, 326–327, 327*f*, 327*t*
 - paucity, syndromic vs. nonsyndromic, 326–327
- intrahepatic cholestasis of pregnancy (ICP), 318
- intrahepatic fistula, in TIPS, 113
- intrahepatic vs. extrahepatic cholestasis, 242
- Intralipid, for urea cycle disorders, 864
- iodoquino, for *Entamoeba histolytica*, 881
- ion channels and cystic fibrosis, 579
- IRD. *See* infantile Refsum disease
- irinotecan, 290–291, 965
- iron, 216
 - absorption of, 661, 663*f*
 - vs. ferritin tests, 669
 - and hepcidin, 661, 663*f*
 - in porphyria cutanea tarda, 686
- iron storage diseases, 661–672, 667*f*
 - classification of, 662*t*
 - hereditary hemochromatosis
 - approach to child with parent with, 666, 667*f*
 - in children with liver dysfunction, 666–668, 670*f*
 - clinical features of, 664–665, 665*f*, 665*t*, 666*f*
 - diagnosis and screening of, 664*f*, 665–666
 - epidemiology of, 664
 - genetics of, 662–664, 664*f*
 - treatment of, 668, 668*t*
 - juvenile hemochromatosis, 668–669
 - neonatal hemochromatosis, 669–672
 - clinical manifestations of, 670–671
 - treatment of, 671*f*, 671–672, 672*t*
 - overview of, 661
 - physiology and pathophysiology of iron overload, 661–662, 663*f*
 - hepcidin and ferroportin, 661, 663*f*
 - transferrin and, 661–662, 666
 - secondary iron overload, 669
 - treatment of, 669, 670*f*
- irregular (postnecrotic) cirrhosis, 97, 100*f*
- ischemic hepatopathy, 898–899
- ISG. *See* immune serum globulin
- isoimmunization, 279
- isolated polycystic liver disease (PCLD), 54
 - presentation and management of, 54
 - PRKCSH* gene, 54
 - SEC63* gene, 54
- isoniazid (INH)
 - acute liver failure and, 74
 - and carbamazepine hepatotoxicity, 493
 - hepatotoxicity of, 492–493
 - postnecrotic (irregular) cirrhosis and, 97
 - and rifampicin hepatotoxicity, 492–493
 - for tuberculosis, 877
- isoprenoid biosynthesis, 843*f*, 845
- itraconazole
 - for aspergillosis, 889
 - for histoplasmosis, 888
 - for *Penicillium marneffei*, 887
- JAG1* gene
 - in Alagille syndrome, 45, 326, 340–342
 - arterial involvement in Alagille syndrome and, 337–338
 - genetic risk of carrying, 329, 330*t*
 - Notch signaling pathway and, 340–341
- Jarcho-Levin syndrome, 336
- jaundice
 - assessment of, 277
 - and azathioprine treatment, 454
 - and biliary atresia, 252–253
 - breast-feeding and, 183
 - and cholestasis, 179–183
 - in the critically ill child, 897, 898*f*, 898*t*

1016 ■ INDEX

- jaundice (*cont.*)
 γ -glutamyltransferase levels and, 167
 and Gilbert's syndrome, 288–289
 neonatal. *See* neonatal jaundice
 in peroxisomal disorders, 849*t*
 in PFIC1, 312
 as sign of infection, 897
 jejunoileal bypass, and cholesterol gallstone formation, 357
 Jendrassik–Grof procedure, 277
 JHC. *See* juvenile hemochromatosis
 jin bu huan, 492
 JRA. *See* juvenile rheumatoid arthritis
 juvenile hemochromatosis (JHC), 668–669
 classification of, 662*t*
 physiology and pathophysiology of iron overload, 661–662, 663*f*
 juvenile rheumatoid arthritis (JRA), 493–494, 904–905
- Kala-azar (*Leishmania donovani*), 885–886
- Kasai hepatopuertoenterostomy (HPE), 261
 in bacterial cholangitis, 874
 in biliary atresia, 255–256, 257*f*, 258–259, 260*f*, 975–976
 prognosis for, 258
 reoperation, role of, 258–259
- kava-kava, 492
- Kawasaki syndrome, and hydrops of the gallbladder, 347–348, 348*t*, 906
- Kayser–Fleischer (K-F) rings. *See also* cataracts; ocular features
 asymptomatic, in Wilson's disease, 642
 in autoimmune hepatitis, 450
 in fulminant hepatic failure with Wilson's disease, 642
 and penicillamine therapy, 644
 in Wilson's disease, 632*f*, 632–633, 641
- Kearns–Sayre syndrome (KSS), 814
- kernicterus, 278, 281–282
 in Crigler–Najjar syndrome, 291
- ketanserin, in portal hypertension, 142
- ketoconazole, hepatotoxicity of, 493
- ketogenesis
 disorders of, 780–781
 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA) lyase deficiency, 780
 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA) synthase deficiency, 780
 β -ketothiolase deficiency, 781
 succinyl-CoA:3-oxoacid CoA transferase (SCOT) deficiency, 781
 and fatty acid oxidation, 767
- ketone bodies
 formation and metabolism of, 771–773, 773*f*
 formation of, in fetus and neonate, 17
- ketonuria, 533–534, 537
- kidney transplantation
 in primary hyperoxaluria type 1, 850
 in tyrosinemia, 702*t*, 707–708
- kifunensine (KIF), 562
- Klebsiella*
 in bacterial cholangitis, 873
 in pyogenic liver abscess, 872
 and spontaneous bacterial peritonitis, 121
- Kreb's cycle intermediates, in lactic acidemias, 537
- KSS. *See* Kearns–Sayre syndrome
- Kupffer cells
 in acid sphingomyelinase deficiency, 719*f*
 in acute liver failure, 81–82
 in acute phase response to infection, 897
 and biliary atresia, 252
 in histoplasmosis, 888
 and IL 6, 102–103
 immune response role of, 513
 in malaria infection, 886
 in mucopolysaccharidoses, 728
 in neonatal hepatitis, 243
 and reduced bile formation, 30–31
- kwashiorkor, 908–909
- L*-asparaginase, hepatotoxicity of, 488
- L*-aspartic acid, 281
- L*-pipecolic acid, 845–846
- laboratory assessment, 163–173. *See also* *specific tests and conditions*
 in acute liver failure management, 89
 in altered systemic circulation disorders, 899
 for ascariasis, 882–883
 of autoimmune hepatitis, 448–449
 of autosomal dominant polycystic kidney disease, 935
 in autosomal recessive polycystic kidney disease, 931–933
 in biliary atresia diagnosis, 252–255
 blood and urine samples, collection of, 532–533
 of Budd–Chiari syndrome, 899–900
 for *Candida* infection, 886–887
 of cholangitis, bacterial, 873, 873*f*
 in cholestasis, 184*f*, 185*t*, 187
 in cirrhosis and chronic liver failure, 106–108, 108*t*
 of *Coccidioides immitis*, 887*f*, 888
 of congenital disorders of glycosylation, 914, 914*t*
 of congenital hepatic fibrosis, 930–931
 for cytomegalovirus, 235, 235*f*
 for *Echinococcus granulosus* (Echinococcal disease), 882
 of *Entamoeba histolytica* (hemolytic abscess), 881
 for *Fasciola hepatica*, 885
 of fatty acid oxidation (FAO) disorders
 routine, 784–785
 specialized, 785–787, 786*t*
- of hemoglobinopathies, 901
- of hepatic excretory function, 170–171
 bile acids, 171
 bilirubin, 170–171
 urobilinogen, 171
- of hepatic metabolic function, 171–172
 ammonia, 171–172
 quantitative or dynamic, 172
- of hepatitis C infection, 416–417, 417*f*
- of hepatitis D infection, 427–428, 428*t*
- in hepatitis, neonatal, 233–234, 242–243, 243*f*
- in hepatopulmonary syndrome, 144
- for human immunodeficiency virus, 241
- of impaired bile flow or cholestasis, 165–170
 5'-nucleotidase, 167–168
 alkaline phosphatase, 165–166
 γ -glutamyltransferase, 166–167, 167*t*
 leucine aminopeptidase, 168–170
- of inborn errors of metabolism, 532–541, 533*t*, 534*t*
 amino acid disorders, 532*t*, 534*t*, 540–541
 fatty acid transport and oxidation disorders, 537–539, 538*t*, 539*f*, 540*t*, 541*f*
 lactic acidemias, 534–537, 536*t*
 organic acidurias, 533–534, 535*t*
 urea cycle disorders, 534*t*, 539–540
- of infection, general liver, 897
- of jaundice, 277
- of leishmaniasis, 886
- of liver disease, miscellaneous tests, 172–173
 amino acids, 173
 serum globulins, 172–173
- for liver flukes (*Clonorchis sinensis*), 885
- of liver injury, 164–165
 aminotransferases, 164–165
 lactate dehydrogenase, 165
- of liver synthetic function, 168–170
 albumin, 168
 coagulation disorders, 168–169, 169*t*
 lipids and lipoproteins, 169–170
- overview of liver tests, 163–164, 173
- in patients with cirrhosis and ascites, 111–112, 112*f*
- of peroxisomal metabolism, 846
- for portal hypertension, 146–147
- respiratory chain disorders, screening tests for, 819–820, 820*t*, 821
- for schistosomiasis, 884
- in sclerosing cholangitis, 461*t*, 464
- in syphilis, congenital, 234
- for toxocariasis, 883
- in tyrosinemia, liver crises in, 698
- for urea cycle disorders, 859*f*, 862–863, 863*f*

- for vitamin A deficiency, 208–210
- for vitamin D deficiency, 211
- for vitamin E deficiency, 213
- for vitamin K deficiency, 214
- of Wilson’s disease, 636–637
- lactate, as metabolic fuel in neonates, 15
- lactate dehydrogenase (LDH), 165
- lactate:pyruvate (L:P) ratio, 534, 820
- lactic acidosis in glycogen storage disease, 611
- lactitol (β -galactoside sorbitol), for encephalopathy, 117
- Lactobacillus* and lactulose, 117
- lactose intolerance, 597. *See also* galactosemia
- lactulose and ammonia levels, 84
- lactulose (β -galactosidofructose), for encephalopathy, 117
- laminin in cirrhosis, 100–101
- lamivudine, 238
 - vs. entecavir, 403
 - and hepatitis B treatment, 401–402
 - adverse effects and monitoring, 402
 - use in children, 402
 - and hepatitis B virus
 - therapy for transplant patients, 404
 - for hepatitis D infection, 428
 - for HIV hepatitis coinfection, 520
 - and mitochondrial DNA, 818–819
 - vs. peginterferon, 404
 - for polyarteritis nodosa, 390
 - vs. telbivudine, 403
- lamotrigine, hepatotoxicity of, 493
- LAP. *See* leucine aminopeptidase
- laparotomy, staging, 902
- LCAD. *See* long-chain acyl-CoA dehydrogenase (LCAD) deficiency
- LCHAD. *See* long-chain 3-hydroxyacyl-CoA dehydrogenase
- LDH. *See* lactate dehydrogenase
- Leishmania donovani*, 885–886
- leishmaniasis, 885–886
- Leptospira interrogans*, 879f, 879–880
- leptospirosis, 879f, 879–880
- lesser omentum and aortic diameter (LO:AD) ratio, 146
- leucine aminopeptidase (LAP), 168–170
- leukemia, 902
- levodopa, for encephalopathy in cirrhosis, 118
- Lhx2 (LIM homeobox gene), 6
- lidocaine, and paracentesis, 113
- ligandin. *See* glutathione S-transferase B
- ligation therapy for variceal hemorrhage, 150f, 151f, 153–154, 154t
- limit dextrinosis. *See* glycogen storage disease, type III
- linolenic acid, 207
- lipid metabolism, in fetus and neonate, 17
 - gluconeogenesis and, 17
 - oxidation of fatty acids, 17
 - synthesis of fatty acids, 17
 - transport of fatty acids, 17
- lipid tests, 169–170
- lipofuscin, 293
- lipoprotein tests, 169–170
- lipoprotein X (LPX)
 - in hyperlipidemias and xanthomas, 203
 - in PFIC3, 318
- Liqui-E, 213
- Listeria monocytogenes*
 - in hepatitis, neonatal, 235–236
 - in spontaneous bacterial peritonitis, 121
- listeriosis, 876
- lithotripsy, for gallstone treatment, 360
- liver bud. *See* hepatic diverticulum
- liver crisis, 698, 706
- liver development. *See also* bile duct cells
 - and bone morphogenetic proteins, 5
 - cardiac mesoderm, 4
 - and cyclin expression, 7
 - and drug metabolism, 480–481
 - fetal hematopoiesis, 7
 - fibroblast growth factors and, 4
 - gene regulation in, 8
 - and hematopoietic stem cells, 3
 - hepatoblasts, 7, 7f
 - and hepatic growth factor, 6
 - markers, liver specific, 3, 9
 - mass/growth of, 38–39
 - metabolic changes during, 15t
 - morphogenesis defects and biliary atresia, 249f, 251
 - progenitor domains, 3, 4f
 - septum transversum mesenchyme, 4f, 5
 - transcription factors in, 6, 7f
 - Foxa, 5
 - Foxm1b, 6
 - Gata4, 5
 - Hex, 7
 - Hlx, 6
 - Xbp-1, 6
 - transdifferentiation and, 9
- liver disease
 - and alanine aminotranferase, 165
 - and α_1 -antitrypsin deficiency, 545–547, 546t, 559–560
 - chronic with tyrosinemia, 699t, 703, 704f, 706
 - and congenital heart disease, 899
 - dysplasia in, with tyrosinemia, 703
 - fibrocystic, 928–939
 - clinical entities in, 929–937
 - overview of, 928–929, 929f, 929t
 - pathogenesis and animal models in, 937t, 937–939
 - fulminant with tyrosinemia, 703
 - and immunodeficiency, 518
 - maternal, 781–784
 - and Niemann–Pick disease as cause of, 721–722
- liver failure. *See also* acute liver failure and bile secretion in the neonate, 24
- late onset (Alpers–Huttenlocher syndrome), 812–814, 813f
- neonatal, 809–810, 824t
- and valproic acid hepatotoxicity, 497–499, 498f
- liver flukes, 884–885, 885f
- liver function tests, 163–173, 164t
 - 5'-nucleotidase, 167–168
 - alkaline phosphatase, 165–166
 - aminotransferases, 164–165
 - in autoimmune hepatitis and autoimmune sclerosing cholangitis, 455t
 - in cirrhosis and chronic liver failure, 106–107
 - dynamic, 172
 - γ -glutamyltransferase, 143t, 166–167
 - lactate dehydrogenase, 165
 - leucine aminopeptidase, 168–170
 - in tyrosinemia NTBC (nitisinone) therapy, 708
- liver transplantation, 975–989
 - for acute intermittent porphyria, 684
 - in acute liver failure management, 90–91
 - in Alagille syndrome, 331
 - in α_1 -antitrypsin deficiency, 562
 - aplastic anemia and NANB hepatitis, 78
 - autoimmune hepatitis infection after, 456
 - in biliary atresia, 255–256, 259–261, 260f
 - contraindications to, 978
 - in coombs positive giant cell hepatitis, 242
 - in Crigler–Najjar syndrome, 292
 - donor shortage, consequences of, 90–91, 259–260, 979
 - in erythropoietic protoporphyria, 690
 - in glycogen storage disease, 613, 617
 - for graft-versus-host diseases, 904
 - in hemophagocytic lymphohistiocytosis, 523
 - hepatitis B therapy in, 404–405
 - in hepatopulmonary syndrome, 144
 - in hepatorenal syndrome, 125
 - immunosuppressive management for, 982–984
 - indications for, 975, 976t
 - in liver failure, neonatal, 810
 - in neonatal hemochromatosis, 671–672
 - operative procedures for, 982–984
 - outcome following, 978–979, 987–989, 988f
 - in portal hypertension and cystic fibrosis, 587–588
 - and portosystemic shunting, 155
 - postoperative complications of, 984f, 984–987

1018 ■ INDEX

- liver transplantation (*cont.*)
 acute cellular rejection, 985
 biliary, 985
 chronic rejection, 985–986
 infection, 986–987
 primary nonfunction, 985
 vascular thrombosis, 984–985
 preoperative preparation for, 978–982
 donor age, 981
 donor stability, 980–981, 981*t*
 ethical issues, 981–982
 hepatocellular mass, 979–980
 living donor selection, 980*f*, 981
 in primary hyperoxaluria type 1, 850
 primary liver diseases leading to, 975–978
 and biliary atresia, 975–976
 cystic fibrosis, 978
 fulminant hepatic failure, 976–977
 hepatic-based metabolic diseases, 976, 976*t*
 malignancies, 977–978, 978*t*, 979*t*, 980*t*
 prioritization of, 978–979
 prognostic factors/survival curves for, 108, 108*t*
 for progressive familial intrahepatic cholestasis, 317
 reduced-size, 260
 for respiratory chain disorders, 823
 retransplantation, 987
 for sclerosing cholangitis, 470–471
 selection process for, 975, 980*f*
 for tumor therapy, 966
 in tyrosinemia, 699*t*, 706
 and kidney transplant, 702*t*
 for urea cycle disorders, 866
 ursodeoxycholic acid, effect on orthotopic, 195
 and variceal hemorrhage, 145–146
 in Wilson's disease, 646–647, 647*t*
- liver tumors. *See* tumors
- living-donor transplantation (LD). *See* liver transplantation
- LO:AD ratio, 146
- long-chain 3-hydroxyacyl-CoA dehydrogenase (LCHAD) deficiency
 and maternal liver disease, 778*f*, 782*t*, 782–783
 maternal liver disease and FAO disorder association, 783
 and respiratory chain disorders, 816
- long-chain acyl-CoA dehydrogenase (LCAD) deficiency, 779, 779*f*, 792
- long-chain free fatty acids (LCFAs), 769–770
 cellular uptake of, 767–768
 metabolic disorders of, 777–779
 and mitochondrial function, 806
 in peroxisomal β -oxidation, 843–844
 transporting/binding defects, 776
- loop diuretics, 113
- lorazepam, 290
- lovastatin, 204
- Lucey–Driscoll syndrome, 282
- lumirubin, 284
- lupoid hepatitis. *See* autoimmune hepatitis (AIH)
- lupus erythematosus
 neonatal, 241
 systemic, 905–906, 906*t*
- lyme disease, 878–879
- lymphedema, with hereditary cholestasis, 320–321
- lymphocytes
 and biliary atresia, 252
 immune response role of, 513
 and phenytoin hepatotoxicity, 496
 and sclerosing cholangitis, 468
- lymphomas, 902
- lysosomal acid lipase deficiency, 716*t*, 726–728, 727*f*
- lysosomal storage diseases, 714–730
 glycogen storage disease type II (Pompe disease), 724–726, 725*f*
 glycoprotein degradation disorders, 723–724
 α -mannosidosis, 723–724
 fucosidosis, 723
 galactosialidosis, 724
 sialidosis, 724
 lysosomal acid lipase deficiency, 716*t*, 726–728, 727*f*
 mucopolipidosis, types II and III, 728–730
 mucopolysaccharidoses, 728, 729*t*
 multiple sulfatase deficiency, 730
 overview of, 714, 715*f*, 716*t*
 sphingolipidoses, 714–721
 acid sphingomyelinase deficiency (NPA and NPB) and, 719*f*, 719–720
 Farber's disease, 720
 Gaucher's disease and, 714–719, 717*f*
 G_{M1} gangliosidosis, 720–721, 721*t*
 Niemann–Pick disease C, 721–722
- M/SCHAD. *See* medium short-chain 3-hydroxyacyl-CoA dehydrogenase (M/SCHAD) deficiency
- ma huang (ephedra), 492
- MAC. *See* mycobacterium avium complex
- macronodular cirrhosis, 97, 99*f*
- MAD. *See* multiple acyl-CoA dehydrogenation (MAD) deficiency
- magnesium, 215
- magnetic resonance cholangiography (MRC), and cholestasis, 186
- magnetic resonance imaging (MRI)
 in cystic fibrosis, 585
 in neonatal hemochromatosis, 671, 671*f*
 in nonalcoholic fatty liver disease, 833
 for tumor diagnosis, 946, 948*f*
 in tyrosinemia, 701–703
 in Wilson's disease, 641
- magnetic resonance spectroscopy (MRS),
 in nonalcoholic fatty liver disease, 833
- MAI. *See* maleylacetoacetate isomerase
- major histocompatibility complex (MHC),
 in autoimmune hepatitis, 451
- malabsorption from reduced delivery of bile, 204–218
- malaria, 886
- maleylacetoacetate isomerase (MAI), 697
- malignancies
 in choledochal cysts, 263
 and liver transplantation, 977–978, 978*t*, 979*t*, 980*t*
- malnutrition, 908–909
 in Alagille syndrome, 339–340
 in cirrhosis, 106, 125–126
 in cystic fibrosis, 586
 and diet in chronic liver failure, 126
 fat malabsorption, 126
 in galactosemia, 599–601, 600*t*
 in Indian childhood cirrhosis, 650
 iron deficiency, 216
 magnesium deficiency, 210*t*, 215
 selenium deficiency, 216
 and steatosis, 582, 586
 vitamin A deficiency, 208
 vitamin D deficiency, 210–211
 vitamin E deficiency, 212–213, 213*f*
 zinc deficiency, 215
- manganese, 216–217, 912
- mannitol, 85, 89–90
- maple syrup urine disease (MSUD), 540–541
- markers, liver specific, 3, 9
- MARS. *See* molecular adsorbent recirculating system
- mass of liver, 38–39
- mass spectrometry, for FAO disorder screening, 786*t*, 787, 788*f*
- maternal autoantibodies, 241
- maternal liver disease, 781–784
- matrix metalloproteinase-2 in cirrhosis, 100
- maturity-onset diabetes mellitus of the young, type 5 (MODY5), 49–50
- MCAD. *See* medium-chain acyl-CoA dehydrogenase (MCAD) deficiency
- MCKAT. *See* medium-chain 3-ketoacyl-CoA thiolase (MCKAT) deficiency
- MDR1 gene and protein, 20
 cellular mechanisms of, 23
 in PFIC3, 318, 319*f*, 320, 320*f*
 and sclerosing cholangitis (in animal models), 469
 and tumor therapy, 967

- MDS. *See* mitochondrial DNA depletion syndrome
- mebendazole
for ascariasis, 883
for capillariasis, 883
for toxocariasis, 883
- medium-chain 3-ketoacyl-CoA thiolase (MCKAT) deficiency, 780
- medium-chain acyl-CoA dehydrogenase (MCAD) deficiency, 779f, 779–780, 788f, 792, 793
- medium-chain fatty acid metabolism disorders, 779f, 779–780
- medium chain triglycerides (MCT), 205–207, 816
- medium short-chain 3-hydroxyacyl-CoA dehydrogenase (M/SCHAD) deficiency, 780
- medullary sponge kidney. *See* Cacchi–Ricci disease
- meglumine antimonite, for leishmaniasis, 886
- melanin, 293
- melenia in portal hypertension, 149t
- Menkes' disease gene, 630
- menodione, menaquinone. *See* vitamin K
- mental retardation in galactosemia, 601
- meperidine and pruritis, 199
- mephenytoin, hepatic drug metabolism of, 479
- Mephyton, 214
- mercaptans and encephalopathy, 115
- 6-mercaptopurine, hepatotoxicity of, 489
- mesenchymal hamartoma of the liver (MHL), 57. *See also* tumors
histology of, 57, 57f
pathogenesis of, 57
pathology of, 962f
presentation of, 57
treatment for, 57
undifferentiated embryonal sarcoma, association with, 57
- mesentericoportal bypass (meso Rex bypass), 145, 155, 155f
- mesoderm
cardiac, 4
septum transversum mesenchyme, 4f, 5
- metabolic liver disease. *See also* bile acid synthesis
bile acid synthesis defects that cause, 744–756
- metabolism of drugs, 478–480
- metformin, for nonalcoholic fatty liver disease treatment, 836, 836t
- methionine, 706
- methotrexate
hepatotoxicity of, 493–494
in juvenile rheumatoid arthritis, 905
liver biopsy for monitoring, 494
toxicity of, 905
- methyl prednisolone, 196, 202
- 2-methylacyl Co-A racemase deficiency, 745f, 752f, 752–753
- methyldopa, and postnecrotic (irregular) cirrhosis, 97
- methylenedioxamphetamine (ecstasy), 74–75
- 3,4-methylenedioxymetamphetamine (MDMA), 490
- methylphenidate, hepatotoxicity of, 495
- metronidazole
for *Entamoeba histolytica*, 881
in total parenteral nutrition, 911
- mevalonic aciduria (mevalonate kinase deficiency), 846–847, 850
- mezlocillin, in bacterial cholangitis, 874
- MFE2. *See* multifunctional enzyme 2
- MHL. *See* mesenchymal hamartoma of the liver
- MICA gene, in sclerosing cholangitis, 468
- micronodular cirrhosis, 97, 99f, 706
- microsomal oxidation, 774, 775f
- midodrine and hepatorenal syndrome, 125
- miliary tuberculosis, 876–877, 877f
- “milk of calcium” gallbladder, 351
- minerals and trace elements, nutritional therapy for cholestasis, 215–217
- minocycline, hepatotoxicity of, 494–495
- mitochondria
autophagy of, in $\alpha 1$ -antitrypsin deficiency, 558
copper toxicity in, 629
functions of, 805f, 805–806
injury to via $\alpha 1$ -antitrypsin Z accumulation, 555
mutations in DNA, 804
structure and genetics of, 803–804, 804t
in Wilson's disease diagnosis, 640f, 640–641
- mitochondrial disorders, 803–824
classification of, 807–809, 808t
epidemiology of, 806t, 807
and fulminant hepatic failure, 977
neuromuscular, 806–807, 807t, 808t
overview of, 803, 804t, 824
functions of, 805f, 805–806
mitochondria structure and genetics of, 803–804, 804t
- primary, 808t, 809–816, 824t
fatty acid oxidation and electron transport deficiency, 816
mtDNA depletion syndrome, 810–816, 811f, 812f, 813f
neonatal liver failure, 809–810
- respiratory chain disorders, 819–821
clinical features of, 804t, 819
definitive diagnostic tests for, 820–821
prenatal diagnosis of, 823–824
screening tests for, 819–820, 820t
treatment of, 820t, 821–824, 822t
- secondary, 806, 807t, 816–819
drugs and toxins, 808t, 818–819
hydrophilic bile acid toxicity, 819
and nonalcoholic steatohepatitis, 819
Reye's syndrome, 816–817, 817f
Wilson's disease, 817–818
websites on, 824
- mitochondrial DNA depletion syndrome (MDS), 810–816, 812f, 824t
- mitochondrial encephalomyopathy, lactic acidosis and stroke-like episodes (MELAS) syndrome, 807
- mitochondrial fatty acid oxidation, inborn errors of, 767–794, 775f
acyl-CoA dehydrogenases and, 769–770, 770f
alternative pathways for, 773–774, 774f, 775f
 β -ketothiolase deficiency, 781
biochemistry of, 767–768
fatty acid uptake, 768, 769f
lipid mobilization and cellular uptake, 767–768, 768t
and enoyl-CoA hydratases, 770, 770f
and 3-hydroxyacyl-CoA dehydrogenase, 770, 770f
3-ketoacyl thiolase, 770
and mitochondrial trifunctional protein, 770–771, 771f
odd-chain fatty acids, 771
overview of, 767
oxidation of unsaturated fatty acids, 771–773, 772f
and electron transfer flavoprotein, 773
ketone body formation, 771–773, 773f
regulation of, 769
 β -oxidation, 769, 769f
- mitochondrial neurogastrointestinal encephalomyopathy (MNGIE), 814–815
- mitochondrial trifunctional protein (MTP), 770–771, 771f, 782t
animal models for, 790f, 791f, 791–792, 792f, 793f
defects in, 778f, 778–779
 α -subunit, 778–779
 β -subunit, 779
- mixed connective tissue disease, 906
- MNGIE. *See* mitochondrial neurogastrointestinal encephalomyopathy
- MODY5. *See* maturity-onset diabetes mellitus of the young
- molecular adsorbent recirculating system (MARS), 90
- monoclonal antibodies, for liver transplantation, 983
- monoethylglycineylidide (MEGX) test, 172
- morphine and pruritis, 199

1020 ■ INDEX

- morphogenesis, defects in as cause of
 biliary atresia, 249*f*, 251
 and bile flow, 251
 insertional mutation (*inv*), murine, 251
 intrahepatic bile ducts, 251
 moxalactam, 281
 moyamoya disease, 336, 338*f*
 MTP. *See* mitochondrial trifunctional protein
 mucin
 and gallstone formation, 354, 356
 and pathogenesis of injury in cystic fibrosis, 577
 mucopolipidosis, types II and III, 716*t*, 728–730
 mucopolysaccharidoses (MPS), 716*t*, 728, 729*t*
 multidrug resistance gene and protein. *See* *MDR1* gene and protein
 multifunctional enzyme 2 (MFE2), 842
 deficiency in, 846, 849–850
 multilayered slide technology, 277
 multiple acyl-CoA dehydrogenation (MAD) deficiency, 781
 multiple intestinal atresia (MIA), 518
 multiple sclerosis and vaccination, 396
 multiple sulfatase deficiency, 716*t*, 730
 multipotent adult progenitor cells (MAPCs), 10
MURR1 gene and product, 628
 musculoskeletal features of Alagille syndrome, 335–336, 336*f*, 337*f*
 mushroom ingestion and acute liver failure, 74, 81
 mutations. *See also* gene therapy
 in acid ceramidase, 720
 in acute intermittent porphyria, 683–684
 in adolase gene and fructose intolerance, 604
 in α -mannosidosis, 723–724
 in α_1 -antitrypsin deficiency, 547–549, 550*t*, 551*t*, 553, 557*f*. *See also* α_1 -antitrypsin deficiency
 in CFTR in cystic fibrosis, 575–576, 576*f*
 in chronic granulomatous disease, 524
 in ferrochelatase (FECH), 689
 in fumarylacetoacetate hydrolase, 696
 in galactose-1-phosphate uridyl transferase, 596
 in galactosialidosis, 724
 in Gaucher's disease, 714
 in glucose-6-phosphatase gene, 609–610
 in glycogen debranching enzyme gene, 614, 616
 in G_{M1} gangliosidosis, 720
 in the *GNPTA* gene, 728
 in harderoporphyria, 687
 in hepatitis B viral genes, 385–386
 in hepatitis C viral genes, 406
 in hereditary hemochromatosis, 662–664
 in *HSD3B7* gene, 747
 in juvenile hemochromatosis, 668
 in mitochondrial DNA, 804, 806*t*, 807, 809
 in mitochondrial trifunctional protein, 778–779
 in *NPC1* and *NPC2* genes, 721–722
 in PFIC2 genes, 316
 in PFIC3 genes, 318–319
 in *POLG* gene, 813–814
 in porphyria, 682
 in sclerosing cholangitis, 467–468
 in sialidosis (lysosomal neuraminidase), 724
 in tumors, 957–964
 website for, 682
 in Wilson's disease genes, 630
 in X-linked lymphoproliferative (XLP) disease, 523
 in *YMDD* locus, 401–402
Mycobacterium avium, 241
 mycobacterium avium complex (MAC), 877
Mycobacterium tuberculosis, 241
 mycophenolate mofetil
 for autoimmune hepatitis, 454
 for liver transplantation, 983
 myoclonic epilepsy with ragged red fibers (MERFF), in neuromuscular mitochondrial disorders, 807
 myopathy mimicking liver disease, 907
 Na⁺-K⁺ ATPase, activity of in bile formation, 22
 NAC. *See* N-acetylcysteine
 NAFLD. *See* nonalcoholic fatty liver disease
 NAGS. *See* N-acetyl glutamate synthetase
 nalmefene and pruritis, 199, 201
 naloxone and pruritis, 199, 201–202
 naltrexone and pruritis, 201
 naproxen, hepatotoxicity of, 495
 NASH. *See* nonalcoholic fatty liver disease
 Navajo neurohepatopathy (NNH), 815–816, 824*t*
Neisseria gonorrhoeae, in perihepatitis, 875
Neisseria meningitidis and spontaneous bacterial peritonitis, 121
 neomycin and ammonia levels, 84
 neomycin, in encephalopathy therapy, 117
 neonatal adrenoleukodystrophy, 848–849
 neonatal cholestasis
 differential diagnosis of, 179–180, 181*t*
 most common cause of, 721–722
 neonatal hemochromatosis (NH), 669–672
 classification of, 662*t*
 clinical manifestations of, 670–671
 treatment of, 671*f*, 671–672, 672*t*
 neonatal hepatitis, 232–243, 233*f*. *See also* *specific types of hepatitis*
 and cholestasis, 242
 clinical presentation of, 242
 differential diagnosis of, 180, 242, 255*f*
 etiology of, 232–234
 bacterial, 232–234
 chromosomal, 241
 toxoplasmosis in, 234–235
 viral, 235*f*, 235–240, 236*f*, 237*f*
 in HBsAg positive mother, 393
 histopathology of, 242–243, 243*f*
 infection, routes of, 232
 meaning of term, 180, 232
 prognosis of, 243
 neonatal jaundice, 277–287. *See also*
 bilirubin metabolism; jaundice
 assessment of, 277, 278*t*, 279*f*, 280*f*
 decreased bilirubin production, 278*t*, 280–282
 Crigler–Najjar syndrome and, 281
 diabetic mothers and, 281–282
 drugs and, 281
 hepatic hypoperfusion and, 282
 hormones and, 281
 increased enterohepatic circulation and, 280–281
 Lucy–Driscoll syndrome and, 282
 prematurity and, 282
 epidemiologic risk factors for, 278–279
 and Gilbert's syndrome, 288–289
 increased bilirubin production, 278*t*, 279–280
 extravascular blood and, 279–280
 isoimmunization and, 279
 oxytocin-induced labor and bilirubin production, 280
 polycythemia and, 280
 red blood cell abnormalities and, 280
 increased production and decreased excretion of bilirubin, 282
 and kernicterus, 278
 management of, 283*f*, 283–287, 284*f*
 breast-feeding and, 286
 exchange transfusion and, 284*f*, 286
 heme oxygenase and, 286–287
 hemoperfusion and, 287
 pharmacologic and, 286
 phototherapy and, 283–286, 285*f*
 toxicity of, 282–283
 neonatal lupus erythematosus, 241
 neonatal sclerosing cholangitis, 461–462
 neonates
 biliary atresia in, 183
 cholestasis in
 differential diagnosis of, 179–180, 181*t*
 evaluation of, 184*f*, 185*t*, 187
 pediatric liver disease, 581
 and drug metabolism, development of, 480–481
 hepatitis in. *See* neonatal hepatitis
 jaundice in, 277–279. *See also* neonatal jaundice
 sclerosing cholangitis in, 461–462

- tyrosinemia in, 705–706
urea cycle disorders, clinical presentation of, 859–860, 860*t*
- neoplasia, hepatotoxicity of drugs for, 487–488
- neoplasms. *See* tumors
- nephronophtisis-medullary cystic kidney disease (NPH-MCKD), 50
- neuraminidase, 724
- neuroleptics, and acute liver failure, 74–75
- neurologic disorders. *See also specific neurologic disorders*
in Alagille syndrome, 338
in chronic liver disease, 105*t*
in cirrhosis, 105, 105*t*
in galactosemia, 601
in tyrosinemia, 695–696, 699–701, 706–707
and vitamin E deficiency, 212–213
in Wilson's disease, 630*t*, 634–635, 635*t*, 641
and penicillamine therapy, 645
- neutropenia
as acute liver failure complication, 88–89
in glycogen storage disease, 612
- N^G-monomethyl-L-arginine (L-NMMA), 142
- NH. *See* neonatal hemochromatosis
- niacin (nicotinic acid) test, 290
- nicotinamide adenine dinucleotide (NAD), 599
- nicotinic acid (niacin) test, 290
- Niemann–Pick disease A and B (NPA and NPB), 716*t*, 719*f*, 719–720
- Niemann–Pick disease C (NPC), 716*t*, 721–722
clinical presentation of, 721–722
diagnosis of, 722
genetics of, 721
histopathology of, 722
treatment of, 722
- nifedipine, hepatic drug metabolism of, 479
- nimesulide, hepatotoxicity of, 495
- Nisseria meningitidis*, and acute liver failure, 76
- nitisinone, 694, 695*f*, 708–709
- nitric oxide (NO)
and blood flow regulation, 899
and urea cycle disorders, 859*f*, 866
and vasodilation, 110, 142
- 2-(2-nitro-4-trifluoromethylbenzoyl) cyclohexane-1,3-dione (NTBC), 694
and tyrosinemia, diet in patients not treated with, 705–706
and tyrosinemia, pathophysiology of, 695, 695*f*
and tyrosinemia, therapy, 695*f*, 708–709, 976
complications of, 709
results of, 708–709, 709*f*
treatment protocols for, 708
- nitroblue-tetrazolium (NBT) test, 524
- nitrofurantoin, and acute liver failure, 74
- nitrogen metabolism, 858, 859*t*
- nitroglycerin, 149
- NNH. *See* Navajo neurohepatopathy
- NO. *See* nitric oxide
- non-A, non-B (NANB) hepatitis. *See also* hepatitis C virus (HCV)
acute liver failure and, 76, 78*f*, 78–79
aplastic anemia after liver transplant, 78
and hepatitis C virus, 406
- nonalcoholic steatohepatitis (NASH).
See nonalcoholic fatty liver disease
- non-Hodgkin's lymphoma, 902
- nonalcoholic fatty liver disease (NAFLD), 819, 830–836
diagnosis of, 831–833, 834*t*
differential diagnosis of, 832*t*
epidemiology of, 830–831, 831*t*
imaging in, 833
liver biopsy and histology in, 833–834, 834*t*, 835*f*
natural history of, 834
overview of, 830, 836
terminology of, 830
treatment of, 834–836
lifestyle, 835
pharmacologic, 835–836, 836*t*
- nonalcoholic steatohepatitis (NASH), 101
- nonketotic hyperglycinemia (NKHG), 541
- nonsteroidal anti-inflammatory drugs (NSAIDs), 495, 905
- norepinephrine, in patients with cirrhosis and ascites, 110
- norfloxacin, prophylaxis in spontaneous bacterial peritonitis, 123
- North American Indian cholestasis, 321–322
- nosocomial infections
and hepatitis A virus, 375
and hepatitis B virus, 386–387, 396
and hepatitis C virus, 407
- Notch signaling, 8
in Alagille syndrome, 45, 326, 340–342
arterial involvement in Alagille syndrome and, 337–338
in bile duct growth, 36–37, 39
pathway in Alagille syndrome, 340–341
- NPC1* and *NPC2* genes, 721–722
- NPH-MCKD. *See* nephronophtisis-medullary cystic kidney disease
- NPHP* genes, 50
- NSAIDs, 905. *See* nonsteroidal anti-inflammatory drugs
- NTBC. *See* 2-(2-nitro-4-trifluoromethylbenzoyl) cyclohexane-1,3-dione
- NTCP. *See* sodium-dependent bile acid transporter (NTCP)
- nuclear receptors
agents and cholestasis, 196–197
bile acids as activators of, 30
- nucleoside analogues, 808*t*, 818–819
- nursing. *See* breast-feeding
- nutrition
in Alagille syndrome, 339–340
in cholestasis, 205–216, 210*t*
assessment of, 205, 206*t*
energy and, 205
essential fatty acids and, 207–208
fat and, 204*f*, 205–207
fat soluble vitamins and, 204*f*, 208*f*, 208–215, 209*f*, 210*t*
minerals and trace elements and, 215–217
overview of, 190
protein and, 207
in cirrhosis, 106, 125–126
in cystic fibrosis, 584, 586–587
and diet in chronic liver failure, 126
fat malabsorption, 126
in fatty acid oxidation disorders, 790–791
in galactosemia, 599–601, 600*t*
in glycogen storage disease, 613
in hereditary fructose intolerance, 606
and hyperlipidemia, 204
in Indian childhood cirrhosis, 650
in progressive familial intrahepatic cholestasis, Type 2, 316
and steatosis, 582, 586
and xanthomas, 204
- nutritional disorders, 908–913
Celiac disease, 908
malnutrition, 908–909. *See also* malnutrition
overview of, 908
total parenteral nutrition, 909*t*, 909–913, 910*t*
- N^w-nitro-L-arginine, 142
- obesity
and cholesterol gallstone formation, 357
and nonalcoholic fatty liver disease, 831–833
- OCTN2, 793
- octopamine and encephalopathy, 115
- octreotide
and hepatorenal syndrome, 125
and variceal hemorrhage, 149–150
- ocular features. *See also* cataracts;
Kayser–Fleischer rings
in Alagille syndrome, 333–334, 334*f*
in hypopituitarism, 907
in tyrosinemia NTBC (nitisinone) therapy, 709
- oculocutaneous tyrosinemia.
See tyrosinemia, type II

1022 ■ INDEX

- OKT-3, monoclonal antibody, 983, 985
oliguria, in acute liver failure, 87
oncostatin M (OSM), 7, 9
ondansetron, 202
opioid antagonists, and pruritis in
cholestasis, 198–199, 201
opportunistic infections
in HIV-cholangiopathy patients,
519–520, 520*t*
in sclerosing cholangitis, 516*f*, 516*t*,
516–517, 517*f*
oral contraceptives
and cholesterol gallstone formation, 358
and hepatocellular adenoma, 955
hepatotoxicity of, 491
and jaundice, 294
Orfadin, 694
organic acidurias, laboratory testing of,
533–534
organic cation transporter (OCTN2), 768,
793
ornithine transcarbamylase (OTC), 540,
861–862
ornithine translocase deficiency. *See*
hyperomithinemia,
hyperammonemia, and
homocitrullinuria (HHH)
syndrome
ornithine transporter mitochondrial 1
(ORNT1), 862
ORNT1. *See* ornithine transporter
mitochondrial 1 (ORNT1)
osteoporosis in galactosemia, 602
OTC. *See* ornithine transcarbamylase
ovarian disorders in galactosemia,
601–602
oxacillin, and acute liver failure, 74
oxaliplatin, 967
oxamniquine, for schistosomiasis, 884
 Δ -3-oxosteroid-5 β -reductase deficiency,
195
 Δ 4-3-oxosteroid 5 β -reductase deficiency,
745*f*, 747–748, 749*f*
oxysterol 7 α -hydroxylase deficiency, 745*f*,
748–750, 749*f*
oxytocin-induced labor and bilirubin
production, 280

P3P. *See* procollagen III peptide
p57KIP2 gene, 958
pancreatic enzyme replacement therapy
(PERT), 587
pancreatitis, in acute liver failure, 87
papular acrodermatitis of childhood
(PAC), 389–390
para-aminobenzoic acid (PABA) test,
172
paracentesis
for ascites in cirrhosis, 113
and spontaneous bacterial peritonitis,
121*t*, 121–122, 122*t*

paramyxovirus infection
acute liver failure and, 76
neonatal hepatitis and, 240
parasitic infections of liver, 880–886
with *Ascaris lumbricoides*, 882–883,
883*f*
with *Capillaria hepatica*, 883
with *Clonorchis sinensis*, 884–885, 885*f*
with *Echinococcus granulosus*, 881–882
with *Entamoeba histolytica*, 880–881,
881*f*
with *Fasciola hepatica*, 885
with *Leishmania donovani*, 885–886
with *Plasmodium* sp., 886
with *Schistosoma* sp., 883–884, 884*f*
with *Toxocara canis*, 883
parathyroid hormone (PTH), 215
parathyroid hormone related peptide
(PTHrP), 38
parenteral nutrition. *See* total parenteral
nutrition
paromomycin, 518–519, 881
partial biliary diversion and pruritis, 202
partial cutaneous external biliary diversion,
316–317
parvovirus B19
acute liver failure and, 76
in neonates, 240
paucity of interlobular bile ducts (PILBD),
44*f*, 44–45
biliary atresia with, 46–47
definition of, 44
diagnosis of, 44
neonatal cholestasis with, 180
nonsyndromic, 46
syndromic (Alagille syndrome), 45–46
PCLD. *See* isolated polycystic liver disease
PCR. *See* polymerase chain reaction
Pearson’s marrow-pancreas syndrome, 814,
818, 824*t*
Pediatric Acute Liver Failure Study Group
(PALF), 71
final diagnosis in children with ALF, 73*t*
initial findings from, 91
pegylated interferon, 238
for chronic hepatitis C infection, 423
for hepatitis B treatment, 403–404
for hepatitis C infection, 418–419
combination therapy, 419–422, 420*f*,
421*f*, 422*f*
for HIV hepatitis coinfection, 520
pemoline, hepatotoxicity of, 495
D-penicillamine, 198, 216
penicillamine
in Indian childhood cirrhosis, 650
in juvenile rheumatoid arthritis, 905
and noncompliance with medication
regime, 633
and urinary copper test, 638
in Wilson’s disease, 629, 644*t*, 644–645
dosing, 644
monitoring of, 644–645
neuro-psychiatric monitoring, 645
during pregnancy, 647
side-effects of, 645
surgery and, 647
penicillins
for actinomycosis, 877–878
in bacterial cholangitis, 874
hepatotoxicity of, 495
for leptospirosis, 880
for lyme disease, 879
for syphilis, 878
for syphilis, congenital, 234
*Penicillium marneffe*i, 887
pentamidine
for leishmaniasis, 886
for pneumocystis infection, 987
percutaneous transhepatic
cholangiography, 186
perforin, in hemophagocytic
lymphohistiocytosis, 521
pericholangitis. *See* small-duct primary
sclerosing cholangitis
perihepatitis, 875
peripheral arterial vasodilation and ascite
formation, 109–110, 110*f*
peripheral nerve, in tyrosinemia, 705
periportal (biliary) cirrhosis, histologic
findings in, 97, 99*f*
peritoneovenous shunts
for ascites in cirrhosis, 114
in hepatorenal syndrome, 125
peritonitis, bacterial, in cirrhosis, 121–123
peroxins, 841
peroxisomal disorders, 846–852
in bile acid synthesis, 745*f*, 753–754
biochemical, 846–847
assays of peroxisomal metabolism in,
846
enzyme deficiencies, 846–847
of peroxisome biogenesis, 846, 847*t*
clinical manifestations of, 847*t*, 847–848,
848*t*, 849*t*
in α -methylacyl-CoA racemase
deficiency, 850–851
in acyl-CoA oxidase deficiency, 850
in D-bifunctional protein deficiency,
849–850
in hyperpipecolic acidemia, 849
in infantile Refsum disease, 849
in mevalonic aciduria, 850
in neonatal adrenoleukodystrophy,
848–849
in primary hyperoxaluria type 1, 850
in Zellweger syndrome, 848
diagnosis of, 847*t*, 851
presentation of patients with, 851
putative mechanisms for hepatic
abnormalities, 843*f*, 851
treatment of, 851–852
peroxisomal fatty acid oxidation, 773, 774*f*

- peroxisome proliferator activated receptors (PPARs), 841–842
 peroxisome targeting signal 1 (PTS1), 840.
 See also peroxisome(s)
 peroxisome(s), 840–846
 biogenesis of, 840–841
 metabolic pathways of, 842–846
 α -methylacyl-CoA racemase, 844–845
 α -oxidation, 843*f*, 844
 amino acid metabolism and, 843*f*, 845–846
 β -oxidation, 842–844, 843*f*
 bile acid synthesis, 844
 catalase, 843*f*, 846
 cholesterol and isoprenoid biosynthesis, 843*f*, 845
 ether lipid biosynthesis, 843*f*, 845
 overview of, 840, 841*f*
 proliferation of, 841–842
 PERT. *See* pancreatic enzyme replacement therapy
 PEX genes, 846, 848–849
 PFIC. *See* Byler's disease
 phenobarbital
 and BGT induction, 289
 and bile flow, 192–193
 and bilirubin production, 286
 in cholestasis, 196
 and constitutive androstane receptor, 197
 in Crigler–Najjar syndrome, 291–292
 in Dubin–Johnson syndrome, 294
 and excretion of bilirubin conjugates, 275
 γ -glutamyltransferase levels and, 167
 and hepatobiliary scintigraphy, 253
 hepatotoxicity of, 495–496
 for hyperlipidemias and xanthomas, 204
 and pruritis in cholestasis, 199–201
 and vitamin D deficiency, 211
 phenothiazines, for porphyria, 684
 phenylacetate (Ammonul, Ucyclid Pharma), 864, 865*t*
 phenylacetate (Buphenyl), 865
 phenylalanine, in tyrosinemia, 697, 705–706
 phenylbutyrate (Buphenyl), 865
 4-phenylbutyric acid (PBA), 562
 phenytoin
 and acetaminophen toxicity, 486
 acute liver failure and, 74–75
 and bilirubin production, 286
 and carbamazepine hepatotoxicity, 496
 γ -glutamyltransferase levels and, 167
 hepatotoxicity of, 496
 and phenobarbital, 495–496
 phosphate levels
 in acute liver failure, 87
 in cholestasis, 210*t*, 215–217
 phosphatidylcholine, in PFIC3
 pathophysiology, 319–320
 phosphoenolpyruvate carboxykinase (PEPCK), and gluconeogenesis, 15
 phospholipids
 and cholesterol gallstone formation, 356, 356*f*
 in PFIC3, 318
 photosensitivity in porphyria, 685*f*, 686, 688–690
 phototherapy, 283*f*
 in Crigler–Najjar syndrome, 292
 in neonatal jaundice, 283–286, 285*f*
 phyloquinone. *See* vitamin K
 physiologic jaundice. *See* jaundice;
 neonatal jaundice
 phytanic acid, 843*f*, 844–845
 phytosterols, in total parenteral nutrition, 912
 pigment gallstones, 352–353, 353*f*
 black, 353
 brown, 353
 clinical features of, 358*f*, 358–359, 359*f*
 conditions predisposing to formation of
 black, 354–355
 chronic hemolytic disease, 354
 cirrhosis and chronic cholestasis, 355
 total parenteral nutrition, 354–355
 conditions predisposing to formation of
 brown, 355
 formation of, 353–354
 prevalence of, 352*f*
 treatment of, 359–361
 in Wilson's disease, 634
 PILBD. *See* paucity of interlobular bile ducts
 PIZZ. *See* α 1-antitrypsin deficiency
 PKD genes
 and autosomal dominant polycystic kidney disease, 53, 935–936, 938, 939*f*
 and ciliary pathway of cystogenesis, 55
 PKDH1 gene, 929–931, 938–939
 PLA. *See* pyogenic liver abscess
 plasmalogens, 846
 plasmapheresis, 292
Plasmodium spp. (malaria infection), 886
 platelets
 in cirrhosis, 119
 dysfunction of, in glycogen storage disease, 612
 in emergency variceal hemorrhage therapy, 148
 transfusion in cirrhosis, 120
 PLD. *See* polycystic liver disease
 pleconaril, 240
 POLG gene, 813–814
 polyarteritis nodosa (PAN), 390
 polyclonal antibodies for liver transplantation, 983
 polycystic liver disease (PLD), 936, 936*f*, 937. *See also* autosomal dominant polycystic kidney disease
 polycystin proteins, and autosomal dominant polycystic kidney disease, 53, 938
 polycythemia, 280
 polymerase chain reaction (PCR)
 for hepatitis C diagnosis, 416
 for hepatitis D diagnosis, 428
 Pompe disease (glycogen storage disease, type II), 724–726, 725*f*
 porcelain gallbladder, 351
 porphobilinogen (PBG)
 in acute intermittent porphyria, 683
 urinary tests for, 681
 porphyria cutanea tarda (PCT), 685–686.
 See also porphyria(s)
 classification of, 680, 680*t*, 684*t*
 clinical features of, 685
 diagnosis of, 685–686
 hepatoerythropoietic porphyria subtype, 684*t*, 686
 treatment of, 686
 porphyria(s), 677–691
 animal models of, 690–691
 classification of, 680, 680*t*, 684*t*
 diagnosis of, 680–681
 acute, 681
 cutaneous, 681
 subclinical, 681
 dual, 690
 erythropoietic, 688–690
 congenital erythropoietic porphyria, 688
 erythropoietic protoporphyria, 688–690, 689*f*
 heme biosynthesis and, 677–679, 678*f*, 679*t*, 685*f*
 hepatic, 681–688
 acute intermittent porphyria, 682–684, 683*t*
 ALA-dehydratase porphyria, 681–682
 hereditary coproporphyria, 686–687
 porphyria cutanea tarda, 685–686
 variegate porphyria, 687–688
 overview of, 677
 porphyrin(s), 681, 685–687
 portal hypertension, 138–156. *See also* ascites
 clinical manifestations of, 143–145, 149*t*
 hepatopulmonary syndrome, 144
 renal and brain, 144–145
 splenomegaly in portal hypertension, 143
 variceal hemorrhage, 143
 vascular markings, 143–144
 definition of, 138, 139*t*

1024 ■ INDEX

- portal hypertension (*cont.*)
 diagnostic evaluation of, 146–147
 additional tests, 147
 endoscopy, 146–147, 147*f*
 ultrasonography, 139*f*, 146
 experimental models of, 138–139
 extrahepatic portal vein obstruction in, 140
 intrahepatic portal vein obstruction in, 140–141
 natural history of, 145–146
 extrahepatic biliary atresia, 145–146
 extrahepatic portal vein obstruction, 145
 overview of, 138, 139*f*, 139*t*, 143*t*, 155–156
 pathophysiology of, 139–143
 and fluid mechanics, 139–140
 hemodynamic changes in, 141–143
 increased vascular resistance and, 140–141
 in patients with ARPKD and CHF, 48
 therapy for, 147–155
 emergency, 148–149
 endoscopy (emergency), 150*f*, 151*f*
 and liver transplantation, 587–588
 mechanical (emergency), 151, 151*f*
 pharmacologic (emergency), 149–150
 portosystemic shunting, 154*f*, 154–155, 155*f*, 155*t*
 pre-primary prophylaxis, 147–148
 primary prophylaxis, 148
 sclerotherapy and ligation, 150*f*, 151*f*, 153*t*, 153–154, 154*t*
 secondary prophylaxis, 153–155
 surgical (emergency), 151–153, 152*f*
- portal vein. *See also* ascites; portal hypertension
 anatomy of, 138, 139*f*
 in biliary atresia, 42, 252
 blood flow in, 138
 development, role in, 38
 developmental abnormalities in, 252
 extrahepatic obstruction in, 145
 immune response role of, 513
 normal branching pattern of, 39*f*
 obstruction of, 140
 pressure and ascite formation, 108–109
 pressure and propranolol, 113
- portopulmonary hypertension (PPHTN), in biliary atresia, 144, 259
- portosystemic shunting
 for glycogen storage disease, 613
 for hepatic encephalopathy in cirrhosis, 114
 in portal hypertension, 142–144
 for variceal hemorrhage in portal hypertension, 154*f*, 154–155, 155*t*
- positron emission tomography (PET)
 scanning, for tumor diagnosis, 946, 949*f*
- posterior embryotoxon in Alagille syndrome, 333–334, 334*f*
- postnecrotic (irregular) cirrhosis, 97, 100*f*
- posttransfusion hepatitis (PTH), 411
- posttransplant lymphoproliferative disease (PTLD), 986–987
- potassium levels
 in acute liver failure management, 89
 laboratory assessment of, 168–169
- PPAR. *See* peroxisome proliferator activated receptors (PPARs)
- praziquantel
 for liver flukes (*Clonorchis sinensis*), 885
 for schistosomiasis, 884
- prednisolone
 for autoimmune hepatitis, 454, 456
 for sclerosing cholangitis, 469*t*, 470
- prednisone
 for graft-versus-host diseases, 904
 and posttransplant lymphoproliferative disease, 986–987
- Pregestimil, 205–208
- pregnancy
 in acute intermittent porphyria, 682
 and cholesterol gallstone formation, 358
 and therapy for Wilson's disease, 647
- pregnane X receptor (PXR), 18, 196–197, 200
- prematurity and tumor risk, 943–944
- primary biliary cirrhosis (PBA), fatigue in, 202
- primary biliary cirrhosis (PBC)
 and phenobarbital for cholestasis-associated pruritus, 201
 ursodeoxycholic acid, effect on, 193
- primary hyperoxaluria type I (AGT deficiency), 846, 850
- primary immunodeficiencies (PIDs), 514
 and chronic granulomatous disease, 524
 classification of, 515*t*
 and hemophagocytic lymphohistiocytosis, 521*f*, 521–523, 522*t*, 523*t*
 treatment of, 522–523
 and hepatitis B virus, 520
 and hepatitis C virus, 520–521
 hyperimmunoglobulin M syndrome, 517
 liver complications in, 514–516, 516*f*
 opportunistic infections in sclerosing cholangitis, 516*f*, 516–517, 517*f*
 management of, 516*t*, 517–518
 and X-linked lymphoproliferative (XLP) disease, 523–524
- primary nonfunction (PNF), as liver transplantation complication, 985
- primary sclerosing cholangitis (PSC), 193–194.
See also sclerosing cholangitis
 and biliary atresia, 252
 and CFTR mutation, 583
 definition of, 459, 460*t*
 vs. secondary sclerosing cholangitis, 459
- PRKCSH* gene, in polycystic liver disease, 54, 936–937
- procollagen III peptide (P3P), in fibrogenesis, 101
- progenitor domains, 3
 fate map of, 3, 4*f*
- progressive familial intrahepatic cholestasis. *See* Byler's disease
- progressive familial intrahepatic cholestasis type 1 (PFIC1-FIC1 disease), Needs range, 311*t*, 755*t*. *See also* bile acid synthesis, defects in
 clinical features of, 310–312
 extrahepatic manifestations of, 311
 growth failure in, 311
 jaundice in, 312
 pruritis in, 311
 genetics of, 313
 histopathology of, 312*f*, 312–313, 313*f*
 laboratory assessment of, 312
 γ -glutamyl transpeptidase (γ GT), 312
 total serum bile acid concentrations, 312
 pathophysiology of, 313–314, 314*f*
 and pigment gallstone formation, 355
 type 1 (PFIC1-FIC1 disease), 310–314
- progressive familial intrahepatic cholestasis type 2 (PFIC2-BSEP deficiency), 311*t*, 314–317, 755*t*. *See also* bile acid synthesis, defects in
 clinical features of, 314–315
 genetics of, 315–316
 histopathology of, 315, 315*f*
 history of, 314
 laboratory assessment of, 315
 pathophysiology of, 316
 treatment of, 316–317
 enterohepatic circulation, interruption of, 316–317
 liver transplantation, 317
 nutrition in, 316
 pharmacologic, 317
 pruritis management, 316
 surgical therapies, 317
- progressive familial intrahepatic cholestasis type 3 (PFIC3), 311*t*, 317–320
 clinical features of, 317–318
 description of, 317
 genetics of, 318–319
 histopathology of, 318, 319*f*
 laboratory assessment, 318
 pathophysiology of, 319*f*, 319–320, 320*f*
 treatment of, 320
- propranolol, 113
 and portal hypertension, 147–148
- propylthiouracil (PTU), 496–497
 acute liver failure and, 74
- prostaglandin E-1, and fulminant hepatic failure, 977

- proteins. *See also specific protein names*
 coagulation, 119
 encephalopathy therapy, intake during, 116–117
 nutritional therapy in cholestasis, 207
 serpins, in α_1 -antitrypsin deficiency, 547–548, 548f, 549f, 550t, 551t
 proteoglycans in cirrhosis, 100
 prothrombin
 and factor VII, 85t
 and prothrombin time (PT), 168, 169t
 protoporphyrin(s)
 in bilirubin production, 270, 271f
 in erythropoietic protoporphyria, 689
 tests for, 681
 pruritis
 in progressive familial intrahepatic cholestasis, Type 1, 311
 in progressive familial intrahepatic cholestasis, Type 2, 314–316
 pruritis in cholestasis, 198–202
 nonabsorbable ion exchange resins, 199
 pathogenesis of, 198–199
 presentation of, 198
 therapy for
 additional, 198–202
 pharmacologic, 199–201
 surgical, 202
 PSC. *See* primary sclerosing cholangitis
 pseudo-Hurler polydystrophy. *See* mucopolidosis
 pseudo-TORCH syndrome, 241–242
Pseudomonas spp.
 in acalculous cholecystitis, 349
 in bacterial cholangitis, 873
 pseudoparkinsonian, in Wilson's disease, 634
 pseudosclerosis, in Wilson's disease, 634
 psychiatric disorders/symptoms, in Wilson's disease, 634–635, 635t, 641
 and penicillamine therapy, 645
 PTLD. *See* posttransplant lymphoproliferative disease
 PTS. *See* peroxisome targeting signal
 pulmonary arteriovenous shunting, in portal hypertension, 144
 pulmonary disorders
 in Alagille syndrome, 336–338
 in α_1 -antitrypsin deficiency, 547, 562–563
 in cirrhosis, 104
 in cystic fibrosis, mucin secretion in, 577
 pulmonary edema, in acute liver failure, 88
 pulmonary infection, in acute liver failure, 88
 purinergic signaling, 575
 PXR. *See* pregnane X receptor
 pyogenic liver abscess (PLA), 871–873, 872f
 pyrantel pamoate, for ascariasis, 883
 pyrazinamide, for tuberculosis, 877
 pyridoxine, 850
 pyrrolizidine alkaloids, hepatotoxicity of, 492
 pyruvate, 15, 806
 Q fever, 880
 quinidine hydrochloride, for malaria, 886
 radiation therapy for tumors, 966
 rapamycin, for liver transplantation, 983
 RCDP. *See* rhizomelic chondrodysplasia punctata
 RdRp protein, in hepatitis C virus, 406
 Rebetrone, 419f, 423
 recessive spondylocostal dysostosis, 336
 recombinant immunoblot assays (RIBA), 416
 Recombivax HB, 394t
 red blood cell abnormalities, 280
 reduced-size transplantation (RSLTx), 979.
 See also liver transplantation
 reducing substances test, 532
 regeneration in cirrhosis, 101–103, 103t
 cytokine role in, 102
 epidermal growth factor, 102
 epidermal growth factor and, 102
 fibroblast growth factor, 102
 hepatic growth factor and, 102
 hepatocyte division, 101–102
 hormones that influence, 102
 IL 6, 102–103
 insulin-like growth factor, 103
 TGF- α and TGF- β , 102
 relative dose response (RDR), for vitamin A, 208–209, 209f, 210t
 renal dysfunction
 in acute liver failure, 87
 in Alagille syndrome, 333, 334f
 cystic disorders in, 929t
 and kidney development, 928–929
 in tyrosinemia, 701, 702t, 703–705, 707–708
 in Wilson's disease, 635
 renal tubular cystogenesis, 54–56
 ciliary pathway of, 55
 pathophysiology of cystic epithelium, 55–56
 primary cilia of, 54–55
 reovirus 3 infection, 240
 and biliary atresia, 250
 and sclerosing cholangitis, 468
 respiratory chain defects
 clinical features of, 804t, 819
 definitive diagnostic tests for, 820–821
 enzymatic activity, 820–821
 histopathological, 821
 molecular analyses, 821
 and fulminant hepatic failure, 977
 in neonates with liver failure, 810
 screening tests for, 819–820, 820t
 treatment of, 821–824, 822t
 dietary, 823
 gene therapy, 823
 liver transplantation, 823
 pharmacologic, 820t, 821–823
 prenatal diagnosis of, 823–824
 respiratory disease, chronic, 899
 retinoids, hepatotoxicity of, 497
 retinol binding protein (RBP), 208
 retinol, retinoic acid, retinyl esters, 204f, 208, 208f. *See* vitamin A
 reverse transcriptase inhibitors, 808t, 818–819
 reverse transcription polymerase chain reaction (RT-PCR), 428
 Reye's syndrome, 816–817, 817f. *See also* fatty acid oxidation (FAO) disorders
 vs. fatty acid oxidation disorders, 789
 vs. valproic acid hepatotoxicity, 497–499, 499f
 Rh incompatibility, bilirubin production and, 279
 rhabdomyolysis, 899
 Rhett syndrome, and pigment gallstone formation, 355
 rheumatoid diseases, and aspirin hepatotoxicity, 488
 rhizomelic chondrodysplasia punctata (RCDP), 845
 ribavirin, 238
 for chronic hepatitis C infection, 423
 for hepatitis C infection, 419
 combination therapy, 419–422, 420f, 421f, 422f
 for hepatitis D infection, 428
 for HIV hepatitis coinfection, 520
 riboflavin, in fatty acid oxidation disorders, 791
 rickets
 in tyrosinemia, 707
 and vitamin D deficiency, 211, 211f, 215
Rickettsia rickettsii, 880
 Rickettsial disease, 880
 Q fever, 880
 Rocky Mountain Spotted Fever, 880
 Rieger anomaly, 334
 rifampin (rifampicin)
 for cat scratch disease, 874–875
 and isoniazid hepatotoxicity, 492–493
 and pruritis in cholestasis, 199–201
 and pruritis management, 316
 for tuberculosis, 877
 ritanserin, in portal hypertension, 142
 rituximab, 986–987
 RMSF. *See* Rocky Mountain Spotted Fever
 Rocaltrol, 211–212
 Rocky Mountain Spotted Fever (RMSF), 880
 rotavirus infection, and biliary atresia, 250–251

1026 ■ INDEX

- Rotor's syndrome, 293
 clinical presentation of, 293
 diagnosis and treatment of, 293
 pathophysiology of, 293
- Roux-en-Y loop procedure. *See* Kasai
 hepatoportoenterostomy
- roxithromycin, and acute liver failure, 74
- RSLTx. *See* reduced-size transplantation
- RT-PCR. *See* reverse transcription
 polymerase chain reaction
- rubella, hepatitis due to, in neonates,
 236–237, 237f
- Saccharomyces cerevisiae*, and tranferase
 homologs, 596
- salicylates, and mitochondrial function,
 816–817
- saline, hypertonic, 85
- Salmonella spp.*, 875
- sarcoidosis, 913
- SBP. *See* spontaneous bacterial peritonitis
- Schistosoma spp.*, 883–884, 884f
- schistosomiasis, 883–884, 884f
- Schistosomiasis mansoni*, 139
- scintigraphy
 and acalculous cholecystitis, 350–351
 and cystic fibrosis, 585
 and gallstones, 359
 hepatobiliary, 186
- scleroderma, 905
- sclerosants, 150, 150f
- sclerosing cholangitis (SC), 459–472
 and CFTR mutation, 583
 clinical features of, 463t, 463–464
 in children vs. adults, 463t, 463–464
 laboratory findings, 461t, 464
 diagnosis of, 464–467
 biopsy, 462f, 465, 465f
 histologic classification (Ludwig's)
 and small duct, 466t, 466–467, 467f
 imaging, 464f, 464–465
 serologic markers, 465
 epidemiology of, 461t, 462–463
 incidence of, 461t, 462–463
 opportunistic infections in, 516f, 516t,
 516–517, 517f
 management of, 516t, 517–518
 pathogenesis of, 467–469
 in animal models, 468–469
 autoimmunity, 467
 biliary epithelial cells, 467
 genetics, 467–468
 infection, 468
 lymphocyte homing, 468
 and primary immunodeficiencies,
 514–516, 516f
 primary vs. secondary, 459, 471
 prognosis for, 470–471
 factors, 471
 post-transplantation, 471
 survival/progression rates, 470–471
- spectrum of, 459–462, 460f, 460t, 461t
 in autoimmune hepatitis (overlap),
 462, 462f
 neonatal, 461–462
 treatment of, 469t, 469–470
 pharmacologic, 469t, 469–470
 surgical, 469t, 470
- sclerotherapy for variceal hemorrhage,
 153t, 153–154, 154t
- SEC63 gene, in polycystic liver disease, 54,
 936–937
- secondary iron overload, 669
 classification of, 662t
 treatment of, 669, 670f
- selenium, 216
 and fulminant hepatic failure, 977
 and malnutrition, 908
- Sengstaken–Blakemore tube (SSBT), 151,
 151f
- sepsis
 as acute liver failure complication, 88
 in hyperbilirubinemia, 871, 872f
 as postoperative complication of
 transplantation, 986–987
 in total parenteral nutrition associated
 liver disease, 911
- sepsis-associated cholestasis, 30–31
- septum transversum mesenchyme, 4f, 5, 6
- serpin-enzyme complex (SEC) receptors,
 552
- Serratia*, in acalculous cholecystitis, 349
- serum globulins, 172–173
- serum glutamic oxaloacetate transaminase
 (SGOT). *See* aspartate
 aminotransferase
- serum glutamic pyruvic transaminase
 (SGPT). *See* alanine aminotransferase
- sexual contact
 and hepatitis A virus, 372
 and hepatitis C virus, 407–408
- short-chain acyl-CoA dehydrogenase
 (SCAD) deficiency, 780, 793
- shunts, for α 1-antitrypsin deficiency, 562
- sialidosis, 716t, 724
- sickle cell disease, 901, 901t
 and pigment gallstone formation, 354,
 359f
 and pigment gallstone treatment, 361
- SIDS. *See* sudden infant death syndrome
- simvastatin, 204
- sincalide, 196, 913
- sinusoids in cirrhosis, 100, 109
- Sirolimus, rapamycin, 983
- sitosterolemia, 28
- Sjögren's syndrome, 241, 905
- skeletal manifestations in Wilson's disease,
 636
- skin manifestations
 in cirrhosis, 104–105
 in erythropoietic protoporphyria, 689
 in porphyria cutanea tarda, 685
- SLE. *See* systemic lupus erythematosus
- SLTx. *See* split-liver transplantation
- small-duct primary sclerosing cholangitis,
 466–467
- small heterodimer partner (SHP), 24
- Sn-mesoporphyrin (Sn-MP), 286–287
- sodium-dependent bile acid transporter
 (NTCP), 322
- sodium levels
 in acute liver failure management, 89
 and diuretics, 112–113
 imbalances in acute liver failure, 87
 in patients with cirrhosis and ascites,
 109, 111–112, 112f
 and vasodilation, 142
- sodium valproate, acute liver failure and, 74
- solitary nonparasitic cysts, 57, 929, 930f
- somatosensory evoked potentials (SEP),
 282–283
- somatostatin, 149–150
- sorbitol and fructose intolerance, 606
- soy, in infant formulas, 600
- sphingolipidoses, 714–721
 Gaucher's disease and, 714–719, 717f
- spirochetes, 234
- spironolactone, 112–113, 217–218
- splenomegaly
 in collagen vascular diseases, 904
 in portal hypertension, 143
- split-liver transplantation (SLTx), 979, 981,
 981t, 982. *See also* liver
 transplantation
- spontaneous bacterial peritonitis (SBP),
 121–123
 ascites and, 121
 bacterial prophylaxis in, 123
 definition of, 121
 incidence of, 121
 mortality in, 122–123
 oral antibiotics and, 122
 paracentesis and, 121, 121t, 122
 predisposing factors, 121
 species involved in, 121
- spontaneous perforation of common bile
 duct, 263–264, 264f
- SSBT. *See* Sengstaken–Blakemore tube
- staging laparotomy, 902
- stanazolol, for α 1-antitrypsin deficiency,
 562
- stannosporfin, in Crigler–Najjar syndrome,
 292
- Staphylococcus aureus*
 in chronic granulomatous disease, 524
 in hepatitis, neonatal, 235–236
 in immunologic deficiencies, 514
 as postoperative complication of
 transplantation, 986
 in pyogenic liver abscess, 872
- steatorrhea, energy requirements for, 205
- steatosis, 578, 581f, 581–582, 586, 819. *See*
 also nonalcoholic fatty liver disease

- in nonalcoholic fatty liver disease, 834
 - in total parenteral nutrition associated liver disease, 912
- stellate cells, in cystic fibrosis, 578
- stem cells, 10
 - bone marrow cells, 9
 - and endoderm generation, 10
 - and FAH deficiency, 9
 - and MAPC, 10
 - transplantation, 902–904
 - and veno-occlusive disease, 900, 900*t*
- stibogluconate sodium, for leishmaniasis, 886
- Streptococcus spp.*
 - in hepatitis, neonatal, 235–236
 - infection with, 876
 - S. pneumoniae* and spontaneous bacterial peritonitis, 121, 123
 - S. viridans*, in acalculous cholecystitis, 349
 - in sclerosing cholangitis, 468
- succinyl-CoA:3-oxoacid CoA transferase (SCOT) deficiency, 781
- succinylacetone, 695, 695*f*, 696
- sudden infant death syndrome (SIDS), 784
- sulfa-drugs, and acute liver failure, 74
- sulfites in urine, 532
- sulfonamides, 281
 - as bilirubin displacer, 283
 - hepatotoxicity of, 497
- sulfotransferases (SULT), 19
- sulindac, hepatotoxicity of, 495
- sustained virologic response (SVR)
 - in chronic hepatitis C infection, 422–423
 - in hepatitis C infection, 412, 421*f*, 422
- syndromatic cholestasis. *See* Alagille syndrome
- synergistic neurotoxin hypothesis of encephalopathy in cirrhosis, 115
- Synkayvite, 214–215
- syphilis, 234, 878
- systemic diseases, 897–914
 - altered circulation, 898–899
 - amyloidosis, 913
 - Budd–Chiari syndrome (venous outflow obstruction), 899–901
 - collagen vascular diseases, 904–907
 - dermatomyositis, 906
 - infantile multisystem inflammatory disease, 906–907
 - juvenile rheumatoid arthritis, 904–905
 - Kawasaki syndrome, 906
 - lupus erythematosus, 905–906, 906*t*
 - mixed connective tissue disease, 906
 - congenital disorders of glycosylation, 913–914, 914*t*
 - endocrine disorders, 907
 - adrenal, 907
 - diabetes mellitus, 907
 - hypopituitarism, 907
 - myopathy mimicking liver disease, 907
 - of the thyroid, 907
 - hematologic disorders, 901–902
 - coagulation disorders, 901–902
 - hemoglobinopathies, 901, 901*t*
 - leukemia(s), 902
 - lymphomas, 902
 - infections, 897–898
 - jaundice, 897, 898*f*, 898*t*
 - nutritional disorders, 908–913
 - Celiac disease, 908
 - malnutrition, 908–909
 - total parenteral nutrition, 909*t*, 909–913, 910*t*
 - sarcoidosis, 913
 - transplantation, stell cell and allogenic bone marrow, 898*f*, 902–904
 - for graft-versus-host diseases, 903–904, 904*f*
 - for veno-occlusive disease, 903
- systemic lupus erythematosus (SLE), 905–906, 906*t*
- tacrolimus
 - for autoimmune hepatitis, 454
 - for liver transplantation, 707, 983, 985–986
- tandem mass spectrometry (MS/MS), and fatty acid oxidation disorders, 539
- TAS-103, 290–291
- taurine
 - in nonalcoholic fatty liver disease, 835, 836*t*
 - in total parenteral nutrition associated liver disease, 911–912
- tauroursodeoxycholic acid (TUDCA), 192–193, 195–196
 - for total parenteral nutrition-associated cholestasis, 195
 - in total parenteral nutrition associated liver disease, 913
- tegretol, 202
- telbivudine, for hepatitis B treatment, 403
- telomerase, 954*t*, 962, 964
- tenofovir, for hepatitis B treatment, 403
- terlipressin, 149
- tetracycline, 234
 - for actinomycosis, 877–878
 - for brucellosis, 876
 - for ehrlichioses, 878
 - in encephalopathy therapy, 117
 - and minocycline, 494–495
 - in total parenteral nutrition, 911
 - for tularemia, 876
- tetralogy of Fallot (TOF), 332, 332*f*, 333*f*
- Tg737* gene, 938
- TGF. *See* transforming growth factor β and α
- thalidomide, 142
- THCA. *See* trihydroxycholestanic acid
- THI. *See* transient hyperphosphatemia of infancy
- thiazides, 113
- thimerosal, in vaccines, 396–397
- 6-thioguanine, in leukemia, 902
- thrombosis, as liver transplantation complication, 984–985
- thymidine kinase-2 (TK2), 811–812
- thymidine phosphorylase (TP), 815
- thymoglobulin, 983
- thyroid disorders, 907
- tight junction protein 2 (TPJ2), 322
- timolol, for portal hypertension, 147
- tin-mesoporphyrin, in Crigler–Najjar syndrome, 292
- tin-protoporphyrin, in Crigler–Najjar syndrome, 292
- TIPS. *See* transjugular intrahepatic portosystemic shunts
- tissue inhibitor of matrix metalloproteinase (TIMP-1), 586
- tocopherols/tocotrienols. *See* vitamin E
- total parenteral nutrition (TPN), 909*t*, 909–913
 - and associated hepatic steatosis, 912
 - and cholestasis, 30
 - clinical features of, 909–910, 910*t*
 - history of, 909
 - management of, 912–913
 - pathology of, 910, 910*t*
 - pathophysiology of, 910*t*, 910–912
 - and pigment gallstone formation, 354–355
 - tauroursodeoxycholic acid, effect on, 195
 - and TPN-associated cholestasis, 31
 - and tumor risk, 944
 - ursodeoxycholic acid, effect on, 195
- toxic metabolites, for hepatic encephalopathy in cirrhosis, 114
- toxic shock syndrome (TSS), 876
- Toxocara canis*, 872, 883
- toxocariasis, 883
- toxoplasmosis, 234–235
- TPN. *See* total parenteral nutrition
- TPN-associated cholestasis, 31
- TPNAC. *See* TPN-associated cholestasis
- Trace PBG kit, 681
- transaminases. *See* aminotransferases
- transcatheter arterial chemoembolization (TACE), 967
- transcription factors, 6, 7*f*
 - Foxa, 5
 - Foxm1b, 6
 - Gata4, 5
 - Hex, 7
 - Hlx, 6
 - Xbp-1, 6
- transcutaneous bilirubin (TcB), 277
- transcutaneous serum bilirubin (TSB), 277

1028 ■ INDEX

- transdifferentiation, 9
 - definition of, 8
 - of liver cells to pancreatic cells, 9
 - and liver inhibitory protein expression, 9
 - of pancreatic cells to liver cells, 9
 - transferase deficiency galactosemia.
See galactosemia
 - transferrin and iron regulation, 661–662, 666
 - transforming growth factor- α (TGF- α)
 - in renal cyst development, 937
 - role in regeneration, 102
 - and tumors, acquired genetic changes in, 962
 - transforming growth factor β (TGF- β), 7
 - biliary cell differentiation and, 36–37
 - liver disease and, 579
 - role in regeneration, 102
 - transfusion-transmitted virus (TTV), 239, 417
 - transient hyperphosphatemia of infancy (THI), 166
 - transient tyrosinemia, 697
 - transjugular intrahepatic portasystemic shunts (TIPS)
 - for ascites in cirrhosis, 113–114
 - for Budd–Chiari syndrome, 900–901
 - in cystic fibrosis, 587
 - in hepatorenal syndrome, 125
 - in variceal hemorrhage, 152, 152f
 - transplacental infection, 232
 - transplantation. *See* bone marrow
 - transplantation; kidney
 - transplantation; liver
 - transplantation
 - transsulfuration pathway, in neonates, 16
 - travel and hepatitis A virus
 - prevention of, 379
 - transmission of, 372, 374, 374f
 - Treponema pallidum*, in neonatal hepatitis, 234
 - treponemes (in syphilis), 878
 - triangular cord, in ultrasonography, 253
 - Trichosporon cutaneum*, 887
 - triclabendazole, for *Fasciola hepatica*, 885
 - trientine (triethylene tetramine dihydrochloride)
 - vs. penicillamine for Wilson’s disease, 645
 - for Wilson’s disease, 645
 - during pregnancy, 644t, 647
 - triethylene tetramine dihydrochloride (trientine)
 - vs. penicillamine for Wilson’s disease, 645
 - for Wilson’s disease, 645
 - during pregnancy, 644t, 647
 - trihydroxycholestanic acid (THCA), 844–845, 847
 - trimethoprim-sulfamethoxazole
 - in bacterial cholangitis, 874
 - for brucellosis, 876
 - for cat scratch disease, 874–875
 - for pneumocystis infection, 987
 - tryptophan and encephalopathy, 115
 - TSS. *See* toxic shock syndrome
 - TTV. *See* transfusion-transmitted virus
 - tuberculosis, 876–877, 877f
 - TUDCA. *See* tauroursodeoxycholic acid
 - tularemia, 876
 - tumor necrosis factor- α (TNF- α), in non-alcoholic fatty liver disease, 832–833
 - tumors, 943–967
 - acquired genetic changes in, 954t, 957, 963f
 - classification of, 952t
 - clinical presentation of, 945–946, 948t
 - diagnosis of, 946–949, 948f, 949f, 950t
 - epidemiology of, 943
 - etiology of, 943–945, 945t, 947f
 - constitutional genetic and metabolic abnormalities, 944–945, 945t, 946f
 - overview of, 943, 944t, 967
 - pathology of, 949f, 950–955, 957
 - benign vascular, 944t, 955, 959f, 960f, 961f
 - hepatoblastomas, 951–953, 952f, 953f, 954f, 954t, 955f, 956f
 - hepatocellular adenoma, 947f, 955–957, 957f
 - hepatocellular carcinomas, 947f, 957f, 958f
 - mesenchymal hamartomas, 955, 962f
 - posttransplant lymphoproliferative disease, 986–987
 - prognosis for, 964, 964t
 - staging of, 949–950, 950t, 951f
 - treatment of, 964–967
 - chemotherapy, 965–966
 - liver transplantation, 966
 - other therapies, 967
 - radiation therapy, 966
 - surgery, 948f, 954t, 965
 - Twinrix (hepatitis vaccine), 380, 394t
 - typhoid hepatitis, 875
 - tyrosine levels, 695f, 696, 705–706
 - tyrosinemia, 694–710
 - chronic liver disease in, 698
 - clinical manifestations of, 701
 - diagnosis of, 696–697
 - differential diagnosis of, 697
 - genetics and screening for, 696
 - hepatic carcinoma risk in, 698–699, 699t, 700f, 976
 - imaging in, 701–703
 - kidneys, 703
 - liver, 701–703
 - pancreas, 703
 - liver crises in, 698, 706
 - management of, 705–709
 - acute liver crises, 706, 709f
 - chronic liver disease and liver transplantation, 699t, 706, 976
 - diet therapy in non-NTBC treated patients, 705–706
 - gene therapy in, 708
 - neurologic crises, 706–707
 - nitisinone (NTBC), 695f, 708–709
 - renal involvement, 702t, 707–708, 709f
 - neurologic crises in, 699–701
 - in non-NTBC treated patients, 697–698, 700
 - overview of, 694, 709–710
 - pathology of, 703–705
 - in heart, 705
 - in kidneys, 703–705
 - in liver, 700f, 703, 704f
 - in pancreas, 705
 - in peripheral nerve, 705
 - pathophysiology of, 694–696, 695f
 - renal disease in, 701, 702t
 - secondary to hepatic failure, 697
 - type II, 697
 - type III, 697
- ubiquinone (coenzyme Q₁₀), 822
- UCD. *See* urea cycle disorders
- Ucyclyd Pharma, 864, 865t
- UDCA. *See* ursodeoxycholic acid
- UGT. *See* uridine 5′-diphosphate glucuronyl transferase
- UGT1 gene, 273–274, 274f
 - in Crigler–Najjar syndrome, 291
 - in Gilbert’s syndrome, 289
- UGT1A1 gene
 - in Crigler–Najjar syndrome, 274f, 291
 - ethnicity and mutations in, 289
 - genetic testing for, 290
 - in Gilbert’s syndrome, 289
 - and hepatic drug metabolism, 479–480
- ulcerative colitis (UC), in sclerosing cholangitis, 471
- ultrasonography
 - abdominal tests for, 106
 - and acalculous cholecystitis, 350, 350f
 - in autosomal recessive polycystic kidney disease, 933
 - and biliary atresia, 253
 - and choledochal cysts, 262–263
 - and cholestasis, 186
 - in cystic fibrosis, 584–585
 - and gallstones, 351f, 359, 359f
 - and hydrops of the gallbladder, 348f, 348–349
 - in neonatal hepatitis, 242
 - and nonalcoholic fatty liver disease, 833
 - and portal hypertension, 146
 - for tumor diagnosis, 946
 - in tyrosinemia, 701
- unconjugated bilirubin (UCB), in pigment gallstones, 353
- unconjugated hyperbilirubinemia, 170, 274f
 - and cholestasis, 180–183
 - disorders of, 287t, 287–292
 - Crigler–Najjar syndrome. *See* Crigler–Najjar syndrome
 - Gilbert’s syndrome. *See* Gilbert’s syndrome
 - Rotor’s syndrome, 293

- undifferentiated embryonal sarcoma (UES), 57
- unfolded protein response (UPR), and α 1-ATZ accumulation, 555
- urea cycle
 - molecular aspects of, 859*f*, 861–862
 - nitrogen sources for, 858, 859*t*
 - overview of, 858, 859*f*
- urea cycle disorders (UCD), 858–866
 - ammonia in, 539–540
 - clinical presentation of, 858–861, 859*t*
 - in arginase deficiency, 861
 - in citrin deficiency (citrullinemia II), 859*f*, 860–861
 - in delayed-onset, 860, 860*t*
 - in hyperomithinemia, hyperammonemia, and homocitrullinuria (HHH) syndrome, 860
 - in neonates, 859–860, 860*t*
 - diagnosis of, 859*f*, 862–863, 863*f*
 - laboratory assessment of, 534*t*, 539–540
 - molecular aspects of, 859*f*, 861–862
 - overview of, 858, 859*f*
 - treatment of, 864*t*, 864–866, 976
 - emergency management of, 864–865
 - issues in, 865–866
 - long-term management of, 866
 - new and future research in, 866
 - website for, 864
- urea synthesis, in neonates, 16
- uridine 5'-diphosphate glucuronyl transferase (UGT), 19
- uridine diphosphate glucuronic acid (UDPGA), 272
- uridine diphosphate (UDP)
 - galactose-4-epimerase deficiency, 596*f*, 602
- uridine, in galactosemia treatment, 599
- urinary tract infection (UTI), 234
- urobilinogens, 171, 276, 276*f*
- uroporphyrinogen (URO) decarboxylase
 - in heme biosynthesis, 678*f*, 678–679, 679*t*
 - in porphyria cutanea tarda, 685–686
- uroporphyrinogen (URO) synthase, 688
- ursodeoxycholic acid (UDCA), 192–193
 - for Alagille syndrome, 194
 - for autoimmune sclerosing cholangitis, 455–456
 - for bile acid synthesis defects, 195
 - for biliary atresia, 195, 259
 - for Byler's disease, 194
 - for cerebrotendinous xanthomatosis, 752
 - for cholesterol gallstone treatment, 360
 - for chronic viral hepatitis, 195
 - for cirrhosis, 193, 586
 - for cryptosporidiosis, 518
 - for cystic fibrosis, 194, 577, 586, 588
 - for graft-versus-host diseases, 195
 - hepatoprotective benefits of, general, 193
 - for hyperlipidemias and xanthomas, 203–204
 - for nonalcoholic fatty liver disease treatment, 835–836, 836*t*
 - opportunistic infections in sclerosing cholangitis, 518
 - for peroxisomal disorders, 851–852
 - for primary biliary cirrhosis, 193
 - for primary sclerosing cholangitis, 194
 - for progressive familial intrahepatic cholestasis (Byler's disease), 194, 317
 - for progressive familial intrahepatic cholestasis, Type 2, 316–317
 - for progressive familial intrahepatic cholestasis, Type 3, 320
 - and pruritis in cholestasis, 199–201
 - for rejection following orthotopic liver transplantation, 195
 - in sarcoidosis, 913
 - for sclerosing cholangitis, 469*t*, 469–470
 - for total parenteral nutrition-associated cholestasis, 195
 - in total parenteral nutrition associated liver disease, 913
 - for veno-occlusive disease, 195, 903
- UTI. *See* urinary tract infection
- valproic acid
 - acute liver failure and, 74–75, 81
 - ammonia and, 172
 - γ -glutamyltransferase levels and, 167
 - hepatotoxicity of, 497–500, 498*f* and β -oxidation, 499
 - carnitine levels, 500
 - generation of toxic metabolites by, 499, 499*f*
 - histological examination of, 497–499
 - and progressive liver failure, 497–499
 - mitochondrial disorders and, 818
- vancomycin, in sclerosing cholangitis treatment, 469*t*, 470
- VAQTA (hepatitis A vaccine), 380–382
- variceal hemorrhage
 - in biliary atresia, 259
 - in cystic fibrosis, 587
- variceal hemorrhage, in portal hypertension, 143, 146–147
- therapy for, 147–155
 - emergency, 148–149
 - endoscopy (emergency), 150*f*, 151*f*
 - mechanical (emergency), 151, 151*f*
 - pharmacologic (emergency), 149–150
 - portosystemic shunting, 154*f*, 154–155, 155*f*, 155*t*
 - pre-primary prophylaxis, 147–148
 - primary prophylaxis, 148
 - sclerotherapy and ligation, 150*f*, 153, 153*t*, 154, 154*t*
 - secondary prophylaxis, 153–155
 - surgical (emergency), 151–153, 152*f*
- variegate porphyria (VP), 687–688. *See also* porphyria(s)
 - classification of, 680, 680*t*
 - clinical features of, 687
 - diagnosis of, 687–688
 - homozygous dominant, 684*t*, 688
 - treatment of, 688
- vascular resistance, in portal hypertension, 140–141
 - disorders that lead to, 141
 - extrahepatic causes of, 140
 - intrahepatic causes of, 140–141
 - vasoactive substances in, 141–142
- vascular thrombosis, as liver transplantation complication, 984–985
- vasoactive substances in portal hypertension, 141–142
- vasodilation in portal hypertension, 142
- vasopressin, 149
- veno-occlusive disease (VOD), 900, 900*t* and antineoplastic drug hepatotoxicity, 488
 - and pyrrolizidine alkaloids hepatotoxicity, 492
 - and transplantation, 898*f*, 903
 - ursodeoxycholic acid, effect on, 195
- venous outflow obstruction, hepatic. *See* Budd–Chiari syndrome
- ventilation, in acute liver failure, 88
- very long-chain acyl-CoA dehydrogenase (VLCAD), 769–770, 770*f*, 777–778, 792
- very long-chain fatty acids (VLCFA)
 - assays of peroxisomal metabolism, 846
 - and diagnosis of peroxisomal disorders, 847*t*, 851
- VGT patterns, in autoimmune hepatitis, 448–449
- vincristine, 965–966
- viral hepatitis. *See also specific types of (i.e., hepatitis A virus)*
 - autoimmune. *See* autoimmune hepatitis (AIH)
 - historical background of, 369, 371*t*
 - in immunodeficiencies, 518
 - vs.* isoniazid hepatotoxicity, 492
 - terminology of, 370*t*
- virion, in hepatitis B virus, 382
- vitamin A, 204*f*, 208*f*, 208–210
 - deficiency in, 208, 210
 - evaluation of, 208–210, 209*f*, 210*t*
 - function and metabolism of, 208
 - hepatotoxicity and monitoring of, 210, 497
 - and liver injury, 909
 - supplements, 210
- vitamin C, in tyrosinemia, 697
- vitamin D, 204*f*, 210*f*, 210–212
 - deficiency in, 210–211, 211*f*
 - tyrosinemia, 707

1030 ■ INDEX

- vitamin D (*cont.*)
 evaluation of, 211
 function and metabolism of, 210
 in galactosemia therapy, 602
 hepatotoxicity and monitoring of, 212
 supplements, 211–212
- vitamin E, 212–214
 deficiency in, 212–213, 213*f*
 evaluation of, 213
 and fulminant hepatic failure, 977
 function and metabolism of, 204*f*, 212, 212*f*
 hepatotoxicity and monitoring of, 214
 and hydrophilic bile acid toxicity, 819
 for neonatal hemochromatosis, 672*t*
 for nonalcoholic fatty liver disease
 treatment, 835, 836*t*
 and obesity-related NASH, 819
 for respiratory chain disorders, 822
 supplements, 213–214
 and veno-occlusive disease, 900
 for veno-occlusive disease, 903
 and vitamin K-deficient coagulopathy, 214
 for Wilson's disease, 644*t*, 646
- vitamin K
 and biliary atresia, 253
 dependent factors, 119
 dose in cirrhosis, 120
 evaluation of, 214
 function and metabolism of, 204*f*, 214
 hepatotoxicity and monitoring of, 214–215
 and nutritional therapy for cholestasis, 214–215
 for respiratory chain disorders, 822
 supplements, 214–215
 in tyrosinemia, 698
- vitamin K-deficient coagulopathy, 214
- vitamins. *See also specific vitamins*
 in 2-methylacyl Co-A racemase
 deficiency, 753
 in Alagille syndrome, 340
 fat soluble, 204*f*, 208–215
 vitamin A, 204*f*, 208*f*, 208–210, 209*f*, 210*t*
 vitamin D, 204*f*, 210*f*, 210–212, 211*f*, 213*f*
 vitamin E, 204*f*, 212*f*, 212–214
 vitamin K, 204*f*, 214–215
 water soluble, 215
- VLCFA. *See* very long-chain fatty acids
- VMC. *See* von Meyenburg complex
- VOD. *See* veno-occlusive disease
- von Meyenburg complex (VMC), 51–52, 936
 and autosomal dominant polycystic
 kidney disease, 52*f*, 53, 53*f*
 and autosomal recessive polycystic
 kidney disease, 51–52
 composition of, 51, 52*f*
 definition of, 51
 diagnostic tests for, 52
 histology of, 52
 incidence of, 51
- voriconazole, for aspergillosis, 889
- VPS33B gene, 321
- warfarin therapy and vitamin E, 214
- water soluble vitamins, 215
- websites
 for Biliary Atresia Clinical Research
 Consortium (BARC), 261
 for CDC (antibiotics for congenital
 syphilis), 234
 for CFTR Mutation Data Base, 575
 for Drug Database for Acute Porphyrias,
 682
 for gene tests, 863
 for Human Gene Mutation Database
 (HGMD), 682–684
 on mitochondrial disorders, 824
 for Online Mendelian Inheritance in
 Man (OMIM), 294
 for peginterferon and ribavirin in
 children (PEDS-C) study, 423
 for porphyria(s), 677
 for the Urea Cycle Disorders
 Consortium (NIH), 864–865
 for urea cycle disorders, management of,
 864
 for US National Screening Status Report,
 787
 for Wilson Disease Mutation Database,
 630
- whole organ transplantation, 979. *See also*
 liver transplantation
- Wilson's disease, 77, 629–647, 817–818.
See also idiopathic copper toxicosis;
 Indian childhood cirrhosis
 and alkaline phosphatase levels, 166
 vs. autoimmune hepatitis, 449–450
 cirrhosis in, 98
 clinical presentation of, 630*t*, 631, 632*f*
 cardiac, 636
 hematologic, 635–636
 hepatic, 633*t*, 633–634, 639*f*
 other manifestations, 636
 renal, 635
 skeletal, 636
 compensated (silent or latent) phase in,
 98
 diagnosis of, 637*t*, 637–643, 640*f*
 in acute hepatitis patients, 641
 in asymptomatic K-F ring patients,
 642
 in asymptomatic siblings of patients,
 643, 643*f*
 in chronic hepatitis and cirrhosis
 patients, 642
 in chronically elevated
 aminotransferases patients, 642
 in fulminant hepatic failure patients,
 642
 hepatic presentation of, 636*f*, 637*t*,
 637–639
 histopathology of, 639*f*, 639–641, 640*f*
 neuro-psychiatric, 635*t*, 641
 epidemiology of, 629–630, 630*t*
 genetics of, 627*f*, 630
 history of, 629
 laboratory assessment of, 636–637
 and macronodular cirrhosis, 97
 pathogenesis of, 631
 and pigment gallstone formation, 355
 tests for, 106
 treatment of, 643–647, 644*t*
 antioxidant therapy, 646
 copper chelation therapy, 643–646
 liver transplantation, 646–647, 647*t*
 in special circumstances, 647
- Wnt signaling pathway, 6
 and bile duct formation, 201
 and tumor formation, 961–963, 963*f*
- Wolman's disease (lysosomal acid lipase
 deficiency), 716*t*, 726–728, 727*f*
- WT1 gene, 953
- X-linked lymphoproliferative (XLP)
 disease, 515*t*, 523–524
- xanthomas, 203*f*, 203–204
 in Alagille syndrome, 330–331
 cholesterol synthesis blocking agents, 204
 diet and, 204
 in glycogen storage disease, 610
 nonabsorbable ion exchange resins for,
 203
 ursodeoxycholic acid for, 203–204
- Xbp-1 transcription factor, 6
- xenobiotic nuclear receptors, for
 biotransformation in neonates, 18
- XLP disease. *See* X-linked
 lymphoproliferative (XLP) disease
- Yersinia enterocolitica*, 876
- Yin Shi Huang, 197
- YMDD mutation in hepatitis B infection
 and adefovir dipivoxil treatment, 402
 and lamivudine treatment, 401–402
- zalcitabine, and mitochondrial DNA,
 818–819
- Zellweger syndrome (ZS)
 acute liver failure and, 77
 vs. cholestasis, 184
 clinical manifestations of, 848
- zidovudine
 and acetaminophen toxicity, 486
 and mitochondrial DNA, 818–819
- zinc, 215
 and copper absorption, 626
 and malnutrition, 908
 and noncompliance with medication
 regime, 633
 for Wilson's disease, 644*t*, 646
 during pregnancy, 647
- ZS. *See* Zellweger syndrome